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A b s t r a c t
The intestinal epithelium is a monolayer of cells that lines the entire surface of 
the gastrointestinal tract from mouth to anus. A key function of the intestinal 
epithelium is the absorption and secretion of fluids and electrolytes. The 
intestinal epithelium is primarily an absorptive tissue, but under normal 
conditions secretion also occurs. In conditions of disease the delicate balance 
between absorption and secretion can become dysregulated leading to the 
onset of diarrhoea. Chloride (Cl ) secretion, which is the primary driving force 
for intestinal fluid secretion, is highly dependent on the availability of oxygen 
(0 2) for generation of cellular energy. Hypoxia inducible factor (HIF) 
hydroxylases are the primary intracellular sensors of 0 2 availability. While 
recent studies have revealed that hydroxylases are important regulators of 
intestinal epithelial barrier function, there is still little known of their role in 
regulating epithelial fluid and electrolyte transport. This thesis set out to 
address this gap in our knowledge. These studies show that inhibition of 
hydroxylases exerts profound antisecretory effects in vitro  and in vivo. The 
antisecretory effect of hydroxylase inhibition occurs via specific inhibition of the 
activity of epithelial sodium potassium adenosine triphosphatase (Na+/K+- 
ATPase) pumps, the energy-dependent step of the Cl" secretory process. 
Investigations into potential mechanisms involved in the antisécretory actions 
of hydroxylase inhibition led to the identification of Modulator of Na+/K+- 
ATPase (MONaKA), a negative regulator of Na+/K+-ATPase function which, upon 
hydroxylase inhibition, displays increased expression at the basolateral 
membrane and forms part of a multimeric complex with Factor Inhibiting HIF 
(FIH-1) and the Na+/K+-ATPase itself. We propose that this complex acts as a 
molecular switch that, upon hydroxylase inhibition, downregulates epithelial 
secretory function. Our data have important implications for our understanding
'-v
of how epithelial fluid and electrolyte transport can be regulated under 
physiological and pathophysiological conditions and suggest that by virtue of
their ability to alter epithelial transport, hydroxylases may be good targets for 
the development of new drugs to treat diarrhoeal diseases.
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C h a p t e r  1
G e n e r a l  I n t r o d u c t i o n
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1 - 0  S t a t e m e n t  o f  P u r p o s e
Intestinal disorders associated with diarrhoea are common and represent a 
significant social and economic problem globally. However, therapeutic options 
for treatment of diarrhoeal diseases are limited and new, more effective drugs 
for their treatment are constantly being sought. Although the epithelial 
transport processes that drive fluid movement in the intestine represent 
excellent targets for the development of new anti-diarrhoeal drugs, there are 
few therapeutic options that act in this way. This Is largely due to our 
incomplete understanding of the molecular mechanisms by which epithelial 
fluid and electrolyte transport are regulated. This thesis sets out to address this 
area of research by studying the role of a family of enzymes, known as 
hydroxylases, in regulating epithelial transport function and the possibility that 
these enzymes could be targeted for treatment of diarrhoeal diseases. The 
following General Introduction aims to set these studies in context.
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1-1 The Gastrointestinal Tract
1 -1 .1  I n t r o d u c t io n
The gastrointestinal (Gl) tract represents the largest mucosal membrane surface 
in the human body. The Gl tract can also be viewed as a complex system of 
glands, tissues and organs that work in a concerted fashion to  facilitate food 
intake and discharge of waste in a safe manner. It serves four main functions; 
namely mixing and transporting of food, secretion of digestive enzymes, 
electrolytes and fluids, digestion and absorption (Moffett et a/., 1993). Ingested 
food is digested by mechanical, chemical and biological means. Mechanically 
this involves mastication, swallowing, peristalsis and defecation (Reed and 
Wickham, 2009). Biochemically, the digestive process involves the breakdown 
of food into simple building blocks, which can then be absorbed by the 
epithelium. Digestion starts in the mouth where enzymes, such as a  amylase, 
initiate the breakdown of complex to simple carbohydrates (Kaczmarek and 
Rosenmund, 1977). Hydrochloric acid (HCI) secretion by parietal cells of the 
stomach facilitates reduction of food into a broth-like material called chyme. 
HCI also denatures proteins and nucleic acids, transforms the inactive precursor 
forms of secreted enzymes into their active forms and destroys ingested 
bacteria. Digested food is transported mechanically through the intestine by 
the peristaltic motion of the muscularis and as it moves through the small 
intestine and colon, nutrients, electrolytes and fluids are continually absorbed 
and secreted across the epithelial layer. Since it is continuously exposed to a 
wide range of noxious substances and pathogens, the Gl tract also plays an 
important role in immune surveillance and the intestinal immune system is the 
first line of host defence against mucosal microbial pathogens. Mucosal barrier 
function is further enhanced by a biologically active lubricant layer of mucus, 
composed of mucin secretions from goblet cells, which forms a crucial 
physiological barrier between the intestinal mucosa and the luminal contents.
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1-1.2 Gross Anatomy
The anatomy of the Gl tract is shown in Figure 1-1.
Salivary Glands
Parotid
Submandibular 
Sublingual
Pharynx
Tongue
Liver
Gallbladder
Duodenum
Common 
bile duct
Colon
Transverse colon 
Ascending colon 
Descending colon-
Cecum —  
Appendix
Stomach
Pancreatic
duct
Ileum 
(small intestine)
Anus
Figure 1-1 Anatom y o f the gastrointestinal tract. The Gl tract is comprised o f the 
mouth, pharynx, salivary glands, oesophagus, stomach, pancreas, liver, gall bladder, 
small intestine, colon, rectum and the anus and intrinsic to  its function is the splanchnic 
circulation and the enteric nervous system. This figure was downloaded from  
W ikimedia.org w ithou t any conditions from  the author.
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The first fluid with which ingested food comes into contact is saliva. 
Components of saliva include enzymes for digestion, growth factors, vasoactive 
serine proteases and regulatory peptides, to name but a few. Salivary secretion 
is promoted by neurohormonal agonists, such as acetylcholine (ACh), vasoactive 
intestinal polypeptide (VIP), norepinephrine, substance P, neurotensin and 
epidermal growth factor (EGF), to name but a few (He et al., 1989; Ship et al., 
1990; Buck and Burcher, 1985; Turner and Yu, 1991; Jaeger and Lamar, 1992). 
These mediators increase second messengers within the cells and activate 
mechanisms responsible for protein exocytosis and fluid secretion. These 
secretions are mixed with food and masticated in the oral cavity and are then 
transported to the stomach via the oesophagus (Johnson, 1994).
1-1.2.2  S tom ach
The stomach lies below the diaphragm and is surrounded by several layers of 
smooth muscle. Goblet cells of the mucosa secrete mucus which helps form a 
protective layer over the mucosa, whereas parietal cells secrete HCI. Other 
cells, such as chief cells produce lipases which help digest dietary fats and which 
also require an acid environment for activity (Gargouri et a l,  1989). The 
activation of the gastric pump or parietal H+/K+-ATPase is regulated by gastrin, 
ACh and histamine. Gastrin is released by G cells in the antrum upon the 
presence of food and amino acids and both gastrin and ACh then stimulate the 
release of histamine from enterochromaffin-like (ECL) cells in the fundic wall to 
stimulate activation of H+/K+-ATPase pumps (Walsh, 1988; Berglindh, 1984; 
Black et a l,  1972). When food exits the stomach, somatostatin inhibits acid 
secretion by preventing histamine release from ECL cells (Prinz et al., 1993). 
From here, the chyme is released into the duodenum via the pyloric sphincter, a 
structure comprised of concentrated smooth muscle.
1-1.2.1 Mouth
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The liver can be considered an accessory organ of the gastrointestinal tract and 
has numerous functions. It produces bile, it aids in metabolism and storage of 
nutrients, minerals and vitamins and it synthesises and deactivates clotting 
factors, to name but a few functions. Hepatocytes are the primary cell type of 
the liver and they function to secrete lipids, bile acids and cholesterol into the 
canaliculi and ultimately via the bile ducts, into the duodenum. The liver has 2 
blood supplies; the hepatic artery which supplies 0 2 for metabolism and the 
hepatic portal vein which transports nutrient-rich blood from the intestine 
(Reed and Wickham, 2009):
1 -1.2.4  Gall b la d d e r
The gallbladder is essentially a storage unit for bile, where it is kept until it is 
required for digestion. During overnight fasting about half of the bile produced 
by the liver enters the gallbladder (van Berge Henegouwen and Hofmann, 
1978). The sphincter of Oddi regulates the entry and release of bile into the 
gallbladder and is hormonally regulated. Upon ingestion of food, bile exits the 
gallbladder into the duodenum. Bile drains back into the gallbladder during 
fasting (Johnson, 1994).
1-1.2.5 Pancreas
The pancreas is a mixed endocrine-exocrine gland, with the exocrine portion 
accounting for approximately 85 % of the organ. The exocrine pancreas is 
composed of acinar cells which produce alkaline secretions of proteins, 
electrolytes and fluid, which are drained by the main pancreatic duct into the 
duodenum (Scheele, 1980). Proteins produced in the pancreas are important 
for digestion, such as active enteropeptidase, which converts inactive 
trypsinogen to active trypsin which, in turn, activates other digestive zymogens 
in the lumen of the gut (Stevenson et a/., 1986). In fact, the pancreas produces
1-1.2.3 Liver
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more protein per gram of tissue than any other organ, with up to 20 g protein 
and 2.5 litres of fluid being secreted in 24 hours (Johnson, 1994).
1-1.2.6  Sm all In te s tin e
The majority of digestion and absorption occurs in the small intestine. The 
small intestine is over 7 metres long in adults, but the surface area for 
absorption is greatly increased by the abundance of villi. Up to 9 litres of fluid 
cross the intestinal epithelium every day, with up to 78 % of this being absorbed 
by the small intestine (Yamada and Alpers, 2009). The small intestine is 
composed of the duodenum, the jejunum, and the ileum. The duodenum 
receives the highly acidic chyme from the stomach, and secretions from the 
liver and the pancreas which aid in digestion of the chyme. Approximately 10 % 
of the epithelial cells of the duodenum are mucus-secreting goblet cells, and 
similar to the stomach, the surface cells of the duodenal epithelium secrete 
bicarbonate (HCO3 ) into the mucus layer to protect against the acidic chyme 
(Johnson, 1994). The duodenal epithelium also secretes enteropeptidase, a 
protein that cleaves pancreatic enzymes into active forms (Stevenson et al., 
1986). The jejunum which joins the duodenum at the Ligament of Treitz, is the 
next section of the intestine. The lumen of the jejunum has a pH of 7-9, and 
contains very few Peyer's patches or Brunners Glands in comparison to the 
duodenum and ileum, respectively. Absorption of nutrients and fluids is the 
primary function of the jejunum. The ileum follows the jejunum, and here the 
villi absorb the nutrients produced by digestion, and transport them via the 
hepatic portal vein to the liver. The ileum is distinguishable from the jejunum 
by the abundance of Peyer's patches, accumulations of lymphoid follicles. The 
epithelium covering the follicles consists of microfold cells (M cells), which are 
specialised for the uptake and transcytosis of macromolecules and 
microorganisms (Miller et al., 2007; Corr et al., 2008). Following transcytosis, 
antigens are presented to the underlying lymphoid aggregates (Hathaway and 
Kraehenbuhl, 2000). M cells have thus been exploited for the development of
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vaccines, and are of great interest in diseases with an immunological 
component, such as Crohn's disease (Gullberg and Soderholm, 2006). The ileum 
ends at the ileocecal valve, which controls the entry of the small intestinal 
contents into the large intestine.
1-1.2.7 Large In te s tin e
The caecum represents the beginning of the colon and is from where the 
appendix protrudes. The appendix has no digestive function and consists 
mostly of lymphoid tissue. It is thought to be a vestigial organ, but more recent 
research has implicated it as being an important component of mucosal 
immune function that may have become defunct in industrialised societies due 
to better hygiene practices (McCabe, 1912; Darwin, 1871; Zahid, 2004; Laurin et 
al., 2011). The colon can be separated into 4 separate anatomical areas 
namely: the ascending, the transverse, the descending, and the sigmoid colon. 
The main function of the colon is to absorb salt and water from the faeces, and 
it cárries out these functions in a spatially distinct manner, displaying segmental 
heterogeneity in its ion transporting properties. By the time the faeces reaches 
the sigmoid colon it is solid, and then passes into the rectum.
1-1.2.8 S tru c tu re  o f  th e  g a s tro in te s tin a l tra c t
The intestine is composed of 4 main layers: the serosa, muscularis, submucosa,
and mucosa (Figure 1-2). The serosa is the outermost layer of the Gl tract and
is essentially comprised of connective tissue that has a surface of mesothelium.
Adjacent to the serosa is the muscularis externa. In the mouth and pharynx this
layer is composed of striated muscle cells that aid in swallowing, while in the
rest of the Gl tract it consists of circular and longitudinal muscle layers that aid
in peristalsis of food throughout the tract (Reed and Wickham, 2009). The
submucosa lies inside the muscularis externa and is a connective tissue that
contains blood vessels, lymphatic vessels, submucosal glands, and the
Meissner's plexus. Inside the submucosa lies the mucosa, which consists of the
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epithelium, the lamina propria, and the muscularis mucosa. The muscularis 
mucosa is a thin layer of smooth muscle that separates the mucosa from the 
submucosa and serves to keep the mucosal surface and underlying glands in a 
constant state of motion. This layer aids in the expulsion of substances from 
the crypts and in the absorption of nutrients from the lumen. The lamina 
propria is composed of connective tissue and serves several key functions, such 
as providing the epithelium with blood and lymphatic vessels, thereby 
delivering nutrients to, and transporting nutrients from, the lumen. The lamina 
propria is also infiltrated with lymphocytes and lymph nodules, such as the 
Peyer's patches. The intestinal epithelium is described in detail in the following 
section.
SER O SA
Longitudinal muscle 
Circular muscle
SU BM U CO SA  
Muscularis mucosa 
Lamina propria
M U SCU LA R IS EXTER N A
M UCOSA
Blood vessels
Epithelium
Figure 1-2 Cross section of the intestine. The intestine is composed of 4 main layers: 
the serosa, muscularis, submucosa, and mucosa. The innermost layer is the epithelium, 
which performs the barrier and transporting functions of the intestine, and which is of 
primary interest in this thesis.
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1 - 2  I n t e s t i n a l  E p i t h e l i u m
1 -2 .1  I n t r o d u c t io n
Epithelial cells serve to exchange substances between the body and the external 
environment, or between Internal body compartments. They surround organs 
that control fluid homeostasis and thus express a wide variety of proteins that 
enable the transport of nutrients, fluids and electrolytes between 
compartments; Epithelial cells from different parts of the intestine have 
different properties and can be arranged in a "leaky" or "non leaky" fashion. 
They are joined to one another by a dynamic arrangement of extracellular and 
transmembrane spanning proteins, known as the zonula occludens, or tight 
junctions. Epithelial cells have an added structural rigidity in the form of a 
basement membrane (Wills et a i,  1996). The epithelium exists as a monolayer 
of cells lining the entire surface of the gastrointestinal tract from mouth to 
anus. It performs several key functions, including absorption of nutrients, 
acting as a barrier to infection, and absorbing and secreting fluids and 
electrolytes. Given that the Gl tract performs different functions along its 
length, it is not surprising that the epithelial cells in different areas can have 
different characteristics. Such different characteristics arise from differential 
expression of proteins within the cells. Another key distinguishing feature of 
epithelial cells is their ability to specifically target transport proteins to different 
poles of the cell, or in other words, to polarise. This polarisation allows 
epithelial cells to perform vectorial transport of ions and nutrients across the 
barrier to the appropriate compartment.
1 -2 .2  F u n c t io n
The functions of the intestinal epithelium are essentially 3-fold. Firstly, 
absorption of nutrients is a critical function of the epithelium. In order to 
facilitate this, the intestinal epithelium expresses several transport proteins that
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are capable of absorbing carbohydrates, amino acids, peptides and proteins, 
lipids, minerals, and vitamins. Carbohydrates, which account for up to 50 % of 
the caloric intake of Western diets are almost completely hydrolysed by the 
salivary and pancreatic enzyme, a  amylase (Johnson, 1994). Products of 
a  amylase are further degraded by brush border expressed glucosidases, such 
as glucoamylase, isomaltase, and sucrase, into monosaccharides. These 
molecules can then be transported across the cell by transporters, such as SGLT- 
1 in the case of D-glucose (Goodman, 2010). Protein breakdown into amino 
acids is more complicated given that there are 20 amino acids. Proteolysis 
begins in the stomach by pepsin, and is followed by pancreatic enzymatic 
digestion in the duodenum, which results in the production of approximately 40 
% free amino acids and 60 % peptides (Johnson, 1994). The unprocessed 
peptides can be further processed by peptidases, or they can be absorbed intact 
as di-and tri-peptides by active transport systems, such as peptide transporter 1 
(PepTl) (Daniel, 2004). However, given the widely different physicochemical 
properties of the 20 amino acids, and the 8000 chemically distinct combinations 
of tri-peptides that can be formed by protein digestion, a variety of transporters 
are required for their absorption.
The second function of the intestinal epithelium is to act as a barrier to prevent 
the entry of harmful substances and microbial infection. This is a crucial role, 
when one considers that there are approximately 10 times more bacteria in the 
healthy human gut than there are cells in the entire body (Savage, 1977). Given 
that up to 60 % of the dry weight of faeces is composed of bacteria (Guarner 
and Malagelada, 2003), it is evident that the intestinal mucosa is constantly 
exposed to luminal antigens. Being the first layer of defence, the epithelium 
must be able to sense and respond appropriately to these luminal antigens, 
without over-reacting.
The third main function of the intestinal epithelium is to absorb and secrete 
fluids and electrolytes. As already mentioned, absorption occurs primarily in
21
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the small Intestine. Fluid secretion is also a very important function of the 
intestinal epithelium which allows mixing and movement of the luminal 
contents throughout the length of the Glv tract and which lubricates and 
protects the delicate epithelial layer. However, the finely-tuned balance 
between absorption and secretion can become dysregulated in disease, leading 
to the onset of diarrhoea, a primary symptom of several infectious and non- 
infectious Gl disorders such as inflammatory bowel disease (IBD), irritable bowel 
syndrome (IBS), iatrogenic diarrhoeas and bile acid malabsorption.
1 -2 .3  S t r u c tu r e
A key feature of the intestinal epithelium is its ability to form an electrically 
tight monolayer, or a barrier, that is selectively permeable to molecules as small 
as ions and water. As already mentioned, a second key feature of epithelial 
cells is their ability to polarise transport protein expression. This is essential for 
the different functions of the epithelium throughout the Gl tract. A third key 
feature of the structure of epithelial cells is their plasticity. These cells change 
their phenotype from secretory to absorptive cells as they migrate from the 
crypt base to surface in the colon, or the villus in the small intestine (Geibel, 
2005). A fourth key structural feature of the epithelium is its ability to maintain 
its barrier function during the sloughing process. With the entire epithelium 
being replaced approximately every 7 days, a huge amount of cell loss occurs on 
a continuous basis. Despite this, the epithelium remains tight, and recent 
studies suggest that mechanisms underlying this phenomenon involve 
cytoskeletal rearrangements in cells adjacent to apoptotic cells that prevent 
luminal contents breaching the barrier (Watson et al., 2009).
1-2.3.1 T ig h t ju n c tio n s
For the epithelial barrier to remain functional the paracellular, or shunt 
pathway, must be tightly regulated. This is accomplished by the zonula
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occludens, or tight junctions. Tight junction physiology is an area of epithelial 
research that is incredibly dynamic and interesting. Great advances in 
understanding the molecular biology of these structures have been made in the 
recent past and are discussed in depth in numerous reviews (Shen et al., 2011; 
Tsukita et al., 2001; Matter and Baida, 2003). Tight junction formation is a key 
step in the segregation of apical and basolateral compartments in cells. Once 
the endogenous extracellular matrix has been formed, the tight junctions 
become restricted to the apicolateral membrane boundary where they form an 
intramembranous fence to prevent the mixing of domain-specific proteins and 
lipids (Yeaman et al., 1999). Importantly, we now know that aberrant tight 
junction function is implicated in numerous pathophysiological conditions, such 
as breast cancer (Brennan et al., 2010; McSherry et al., 2011) and IBD (Edelblum 
and Turner, 2009).
c
Figure 1-3 The apical junctional complex, a) Transmission electron micrograph of 
apical junctional complexes between two villous enterocytes. The tight junction (TJ) is 
just below the microvilli (Mv), with the adherens junction (AJ) located below this and 
the desmosomes (D) further below, b) Freeze-fracture electron micrograph of a. c) 
Schematic representation of interactions between the cytoskeleton, zona occludens-1 
(ZO-1), claudins, tight junction-associated marvel proteins (t a m p s ), junctional 
adhesion molecule (JAM), and the coxsackie adenovirus receptor (CAR). This figure is 
adapted from (Shen et al., 2011).
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As seen in Figure 1-3 tight junctions are located within apical junctional 
complexes. The first tight junction associated protein, zonula occludens-1 (ZO- 
1) was identified in 1986, with the second, cingulin, being identified the 
following year (Stevenson et al., 1986; Citi et al., 1988). However, it was the 
discovery of the tetraspanning protein, occludin, in 1993 that confirmed the 
hypothesis that integral membrane proteins are present in tight junctions 
(Furuse et a!., 1993). Somewhat surprisingly however, occludin knockout 
animals were found to have normal intestinal epithelial physiology, thus leading 
the authors to conclude that occludin is not required for the formation of tight 
junction strands (Saitou et al., 2000). Since these early discoveries, other 
trans'membrane spanning proteins have been discovered in tight junctions. 
Importantly, a large family of claudin proteins has been identified and have 
subsequently been associated with ion transport across the tight junction 
(Anderson and Van Itallie, 2009; Weber et al., 2010). Research has shown that 
expression of different claudins change the electrical properties of epithelial 
monolayers, therefore, it has been suggested that claudins determine the tight 
junction barrier properties (Van Itallie and Anderson, 2004). Other research has 
more directly demonstrated that expression of specific claudin family members 
confers specific ion selectivity to epithelial monolayers (Van Itallie et al., 2001). 
In summary, tight junctions are highly dynamic areas of cell-to-cell contact that 
maintain adhesion of epithelial cells to each other and which regulate the 
passage of molecules, ions and fluid across the epithelial layer.
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1 - 3  E p i t h e l i a l  i o n  t r a n s p o r t
1 -3 .1  In t r o d u c t io n
One of the primary functions of the intestinal epithelium is to transport 
electrolytes and fluids to and from the lumen. Intestinal fluid movement is 
driven by osmotic gradients that are, in turn, established by active ion transport 
across the epithelium. Fluid absorption normally predominates and is 
promoted by Na+ absorption, while fluid secretion is driven predominantly by Cl‘ 
and HC03" secretion. In normal circumstances, a fine balance exists between 
fluid absorption and secretion which favours absorption of the 9 litres of fluid 
that enters the intestine every day (Yamada and Alpers, 2009). However, this 
balance can become disrupted in conditions of disease and can result in the 
clinical manifestation of diarrhoea. Chronic diarrhoea is a primary symptom of 
several gastrointestinal disorders, including IBD, diarrhoea-predominant IBS, 
iatrogenic diarrhoeas, such as those induced by chemotherapy, microscopic 
colitis and bile acid mal-absorption (Carter et al., 2004; Maroun et al., 2007; 
Oelkers et al., 1997; Hofmann, 2009). Often, one of the main therapeutic goals 
of treating patients with these intestinal disorders is to treat the primary 
symptoms, including diarrhoea (Sohrabpour et al., 2010). Ion transport in the 
colon is facilitated by several transport proteins that display considerable 
intrinsic segmental heterogeneity (Sandle et al., 1986; Sandle, 1989). Transport 
is stimulated by multiple factors, including luminal and systemic influences, such 
as hormones and neuro-immune agonists, which can act as either 
secretagogues or absorptagogues. Secretagogues, such as ACh and VIP, 
typically act by binding to their cognate receptors on intestinal epithelial cells to 
stimulate the production of intracellular second messengers, such as Ca2+ and 
cAMP, respectively. In turn, second messenger generation drives Cl* secretion 
from the cell, through the concerted action of several ion transport proteins on 
the cell membrane. The extracellular accumulation of Cl' then promotes 
paracellular Na+ transport and fluid movement by osmosis (Murek et al., 2010).
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Similarly, Na+ absorption across the intestinal epithelium is facilitated by several 
transport proteins that also show considerable intrinsic segmental 
heterogeneity (Sandle et a/., 1986; Sandle, 1989). Luminal influences on 
epithelial ion transport processes are diverse and range from paracrine 
stimulation, such as the release of gastrin by G cells in the stomach causing the 
release of histamine from ECL cells and activation of H+/K+-ATPase pumps, to 
effects of the intestinal micro-flora and their by-products(Walsh, 1988; 
Berglindh, 1984; Black et al., 1972). A good example of luminal factors that 
regulate transport are bile acids. These molecules enter the lumen of the 
duodenum after ingestion of food where they emulsify fats and aid in their 
digestion. Most bile acids are recycled from the small intestine back to the liver, 
but with each cycle of the enterohepatic circulation, a small percentage enters 
into the colon. Here, the bile acids can alter intestinal epithelial transport 
processes (Keating et a/., 2009; Keating and Keely, 2009). However, they can 
also be metabolised by the intestinal micro-flora, with the resulting secondary 
bile acids having distinct effects on ion transport (Edenharder and Knaflic, 1981; 
Lepercq et al., 2004; Kelly et al., 2009b).
The epithelial transport proteins that facilitate the movement of ions across 
epithelial cells comprise a diverse array of protein families. These proteins can 
be classified according to certain characteristics. ATPases, as their name 
suggests, cleave ATP to pump ions across membranes, ion channels allow 
passive movement of ions down electrochemical gradients, and exchangers 
transport ions of equal charge in opposite directions across the membrane. The 
diversity of ion transport proteins can be simplified by their organisation into 
categories, as outlined in the next section.
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1 - 4  E p i t h e l i a l  t r a n s p o r t  p r o t e i n s
Ion transport proteins in the intestinal epithelium perform many tasks from pH 
regulation, to volume regulation, to  vectorial fluid absorption and secretion.
1 -4 .1  A T P a s e s
ATPases are membrane-bound ion transport proteins that utilise a molecule of 
ATP during the transport process. There are many different forms of ATPases 
that have been classified as F-, V-, A-, P- and E-ATPases based on functional 
differences. ATPases generate membrane potentials and are thus critical for all 
ion transport processes across the intestinal epithelium.
1-4.1.1 Na+/K +-ATPase
The Na+/K+-ATPase is known as a P-type ATPase because it catalyses auto- 
Phosphorylation of a conserved aspartate residue within the pump. The 
importance of the Na+/K+-ATPase is such that it is expressed on the membrane 
of every mammalian cell where it creates a separation of charge across the 
membrane (Kaplan, 2002). The P-type ATPases all interconvert between El and 
E2 conformations, which are essentially conformations at which the pump has 
greater affinities for different ions (Morth et al., 2011). This P-type ATPase 
drives both K+ and Na+ against their electrochemical gradients, and cleaves ATP 
in the process. Three Na+ ions are extruded from the cell, while 2 K+ ions are 
imported by the pump for each ATP molecule cleaved. This non-equivalent 
transport is electrogenic and leads to the generation of a transmembrane 
electrical potential of approximately -70 mV, at which point the extrusion of K+ 
and the influx of Na+ are at equal rates.
The Na+/K+-ATPase provides the driving force for intestinal Cl secretion and Na+ 
absorption and is basolaterally located (Skou, 1998; Kaplan, 2002). With
Irespect to the Cl' secretory pathway, the extrusion of Na+ from the cell creates 
an electrochemical driving force for entry of Na+ through the basolateral 
Na+/K+/ 2Cr co-transporter (NKCC1), while in absorptive cells, the pump creates 
the driving force for apical Na+ entry through ENaC and SGLT1. Na+/K+-ATPase 
pumps exist as heterodimers in the plasma membrane, with one a  and one P 
subunit (Craig and Kyte, 1980; Horowitz et a i,  1990). There are several 
isoforms of the Na+/K+-ATPase which are comprised of different a  and 
P subunits. 4 a  and 3 p subunits are known to exist and in the intestine the 
heterodimer formed is an a ip i heterodimer (Morth et a/., 2011). Resolution of 
the crystal structure of the Na+/K+-ATPase in the recent past however, also 
revealed the presence of Na+/K+-ATPase y subunits in renal extracts (Morth et 
a/., 2007). The catalytic a  subunit contains 10 transmembrane domains that 
contain binding sites for ATP, Na+, K+, cardiac glycosides and the 
phosphorylation site for catalytic activity (Lutsenko and Kaplan, 1995). The p 
subunit has a single membrane spanning domain and interacts with the a 
subunit via the p ectodomain (Fambrough et ai., 1994). Much research over the 
years has shown that there are multiple mechanisms by which the pump can be 
regulated, for example by protein kinases, such as PKA and PKC (Begum et a/., 
1994; Feraille et a/., 2000). Its regulation under hypoxic conditions has also 
been well documented and is discussed in more detail in ' Chapter 4. 
Furthermore, additional studies show that Na+/K+-ATPase pumps can exist in a 
complex of multiple proteins, allowing for tissue-specific regulation (Garty and , 
Karlish, 2006; Yoon et a i,  2006). Again, this is discussed in greater detail in 
Chapter 5. Thus, our knowledge of the structure of the IMa+/K+-ATPase is 
constantly evolving, but remains incompletely understood. Na+/K+-ATPase 
regulation is multifaceted, and thus has potential to be exploited for 
therapeutic intervention.
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Ion channels are pore-forming proteins that exist in the plasma membrane and 
help to create and maintain voltage gradients created by ATPases. Ion channels 
allow for the passive transport of ions down their electrochemical gradients, but 
they may still require ATP for functionality, or for gating. Ion channels may be 
voltage, ligand, or ATP-gated.
1-4.2.1 ENaC
The epithelial sodium channel (ENaC) is a hetero-multimeric protein consisting 
of at least 3 subunits, namely a, p and y, which together form an active channel 
with a stoichiometry of 2a : P : y (Rossier et a l,  2002; Firsov et a l,  1998). ENaC 
is expressed in aldosterone-responsive epithelia and is highly expressed in the 
distal colon (Due et a l,  1994; Bubien, 2010; Garty and Palmer, 1997). ENaC is 
reported to be the rate-limiting step of electrogenic Na+ absorption and 
prevents Na+ loss in the stool. The channel has heightened importance in 
conditions of disease, or when dietary sodium intake is low and aldosterone 
levels are high (Rossier et a l,  2002; Schultheis et a l,  1998; Kunzelmann and 
Mall, 2002; Sandle, 1998). ENaC is also important in the kidney where it plays 
an important role in the regulation of blood pressure and fluid homeostasis 
(Takahashi et a l,  2011; Bubien, 2010; Garty and Palmer, 1997). Some 
researchers have queried the, role that ENaC plays in the intestine, suggesting 
that there is redundancy of its function due to the presence of other Na+ 
absorbing proteins, such as NHEs and SGLTs (Hummler and Horisberger, 1999). 
The activity of ENaC is regulated in a tissue-specific manner, and in the colon it 
is regulated by mineralocorticoid and glucocorticoid-induced upregulation of p 
and y ENaC (Epple et a l,  2000). Regulation of ENaC activity is complex and 
involves serine proteases, protein kinases, and cytokines, amongst others 
(Rossier and Stutts, 2009; Diakov and Korbmacher, 2004; Amasheh et a l,  2004). 
More recent research has shown the existence of a 8 subunit of the human
1-4.2 Channels
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ENaC, which when over expressed, dramatically increases ENaC activity 
(Haerteis et al., 2009).
1-4.2.2 A p ica l Cl“ channe ls
Cl" secretion in the colon requires the concerted activities of all the transport 
proteins that comprise the Cl" secretory pathway. Cl" enters epithelial cells 
through basolateral NKCC1 co-transporters, and exits to the lumen through 
apical Cl' channels. There are several types of apical Cl' channels present on the 
apical membrane of intestinal epithelial cells. Second messengers, such as Ca2+ 
and cAMP, can orchestrate apical Cl" secretion through different Cl" channels, 
however there does appear to be some redundancy with regard to Ca2+- 
stimulated activation of the cAMP-regulated cystic fibrosis transmembrane 
conductance regulator (CFTR) (Namkung et al., 2010).
CFTR
CFTR is a cAMP activated Cl" channel and belongs to the family of ATP-binding
cassette (ABC) transporters (Riordan et a l,  1989). While CFTR functions as an
ion transport protein on the apical membrane of epithelia, it has also been
proposed to play roles in vesicular trafficking and acidification of organelles
(Bradbury, 1999). It is composed of five domains: two membrane-spanning
domains, two nucleotide-binding domains that bind ATP and regulate gating of
the channel, and a regulatory (R) domain, the phosphorylation of which
determines channel activity (Sheppard and Welsh, 1999). Stimulation of CFTR
by cAMP occurs by at least 2 mechanisms. Firstly, it is regulated by
phosphorylation. For example, cAMP stimulates cAMP-dependent protein
kinase (PKA)-mediated phosphorylation and activation of CFTR channels in the
plasma membrane (Cheng et a l,  1991; Tabcharani et al., 1991). It is also known
that PKC and phosphatases can regulate channel activity/and can modulate
PKA-dependent binding of the R domains (Berger et al., 1993; Chappe et al.,
2005; Seavilleklein et al., 2008). Secondly, cAMP has been shown by some
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groups to stimulate trafficking of CFTR from an intracellular pool to the plasma 
membrane, while also inhibiting the rapid clathrin-dependent endocytosis of 
CFTR into endocytic pools (Lehrich et al., 1998; Prince et al., 1994; Lukács et al., 
1997). However, the regulation of CFTR by intracellular trafficking is not a view 
shared by all and some studies in T84 cells indicate no alteration in CFTR at the 
apical membrane following cAMP elevation (Huflejt et al., 1994).
Ca2+-activated Cl“ channels (CaCC)
Ca2+-activated Cl" currents in the intestinal epithelium are short lived upon 
stimulation by agonists such as ACh, purines, or histamine. These agonists serve 
to increase intracellular Ca2+ by either releasing it from intracellular stores, or by 
causing an influx from the extracellular space (Hartzell et al., 2005). Ca2+ may 
activate the CaCCs by either binding directly to the channel, or by binding to 
Ca2+-dependent enzymes such as Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) (Worrell and Frizzell, 1991). Other second messengers, such as inositol 
3,4,5,6-tetrakisphosphate (IP4), can inhibit the activity of Ca2+ activated Cl" 
channels (CaCC) by inhibiting activation by CaMKII (Xie et al., 1996). However, 
the physiological relevance of these channels in the intestine has remained 
questionable over the years. For example, a study in 1988 showed that the 
intestinal tissue of patients with CF does not demonstrate secretory responses 
to Ca2+-dependent agonists, suggesting such agonists may normally elicit their 
secretory effects through CFTR (Berschneider et a/., 1988). The identity of 
intestinal Ca2+-activated Cl" channels remained elusive until recent studies 
identified the transmembrane (TMEM) family of proteins. TMEM16A has been 
shown to mediate Ca2+-activated Cl" currents in neonatal mouse colon 
(Ousingsawat et al., 2009). However, this is in contrast to work by the Verkman 
group, who recently showed that Ca2+-dependent Cl" secretion also occurs via 
CFTR (Namkung et al., 2010). Further research is required to resolve these 
discrepancies, although recent w ork by the  Kunzelman group has added new 
weight to the potential physiological significance of TMEM16A. This study
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suggested that rotavirus-induced diarrhoea is caused by activation of 
TMEM16A, coupled to inhibition of Na+ absorption by SGLT-1 and ENaC 
(Ousingsawat et al., 2011). Since it has only recently been discovered, 
regulation of this channel is poorly understood compared to CFTR. However, a 
recent study has shown that the Ca2+-binding protein, calmodulin, is necessary 
for activation of TMEM16A (Tian et al., 2011a). Finally, the precise 
identification of Cl’ channels that mediate responses to Ca2+-dependent 
secretagogues is further complicated by recent findings that CFTR can interact 
with CaCCs, thereby modulating their activity, while Ca2+-dependent agonists 
can also cause CFTR activation through activation of PKA (Wei et o/., 2001; 
Namkung et al., 2010).
1-4.2.3 B aso la te ra l K* channe ls
K+ channels constitute the largest family of ion channels in humans. There are 
several types of K+ channel, which are regulated by diverse stimuli, such as 
changes in membrane voltage, Ca2+i; phosphorylation, cAMP levels, pH, hypoxia 
and cell swelling, to name but a few. K+ that enters the cell through NKCC1, the 
H+/K+-ATPase, and the Na+/K+-ATPase can be recycled through 2 types of 
basolateral K+ channel; the cAMP-activated K+ channel, KCNQ1, and the Ca2+- 
activated basolateral intermediate K+ conductance channel, KCNN4 (Schroeder 
et al., 2000; Flores et al., 2007). Basolateral K+ transport in colonic epithelia is 
essential to maintain a membrane potential that sustains apical anion and fluid 
secretion, and it has been shown that inhibition of basolateral KCNN4 with 
clotrimazole (CLT) inhibits apical Ca2+-dependent Cl' secretion (Rufo et al., 
1997). More recent work has demonstrated that there are several isoforms of 
KCNN4 in the colon (Barmeyer et al., 2010) and that apical KCNN4 may also be 
involved in anion secretion (Nanda Kumar et al., 2010). KCNN4 is regulated by 
calmodulin, which is tightly coupled to the channel and activated by changes in 
intracellular Ca2* levels (Fanger et al., 1999). The K* channel that supports 
cAMP-activated Cl“ secretion is a complex formed by KCNQ1 and its p subunit,
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KCNE3 (Kunzelmann et a l,  2001; Schroeder et a l, 2000). In the intestine both 
proteins co-localise in crypt epithelial cells. Interaction of KCNQ1 with its P 
subunit converts the voltage-dependent KCNQ1 into a voltage-independent, 
constitutively open, channel complex (Schroeder et al., 2000).
1 -4 .3  E x c h a n g e rs  
1-4.3.1 C I'/H C O j' exchangers
Cr/HCCV exchange in the colon acts in conjunction with NHEs to mediate NaCI 
absorption across the epithelium. Apical CI7HC03' exchangers are present in 
the colonic epithelium, and probably the best known of these is SLC26A3, or 
down regulated in adenoma (DRA), mutations of which cause congenital 
chloride diarrhoea (Hoglund et al., 1996; Makela et al., 2002; Wedenoja et al., 
2011; Worrell e ta l,  2005).
1-4.3.2 Na+/H + exchangers
There are 9 members in the mammalian Na+/H+ exchanger family (SLC9 family) 
which can be subdivided into 2 groups based on their cellular expression (Brett 
et a l,  2005). NHEs 1-5 are expressed in the plasma membrane, 6, 7 and 9 are 
expressed on intracellular organelles, whereas the expression profile of NHE8 
has not yet been fully elucidated. The main NHE responsible for Na+ absorption 
from the intestinal lumen is NHE3, with NHE2 being involved to a lesser degree 
(Ikuma et a l,  1999; Zachos et a l,  2005). NHE1 and 4 are basolaterally located 
where they contribute to regulation of cellular pH (Pizzonia et a l, 1998; Beltran 
et a l,  2008). Individual NHEs have different physiological roles and 
interestingly, studies show that the expression of NHE3 can be altered in 
intestinal diseases such as IBD (Khan and Ali, 1999; Larmonier et a l,  2011; 
Sullivan et a l,  2009). Regulation of NHE3 is highly complex and involves a 
variety of signalling proteins, including sodium hydrogen exchanger regulatory
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factors (NHERF)s, ezrin, and other PDZ domain-containing proteins (Donowitz et 
al., 2009).
1 -4 .4  C o - t r a n s p o r te r s
Co-transport, or secondary active transport, refers to the simultaneous 
movement of molecules or ions across the plasma membrane. The molecules 
or ions can be transported in the same (symport) or opposite (antiport) 
directions so long as the charge balance is equal. For this process to occur at 
least one of the molecules being transported must be passively travelling down 
its concentration gradient.
1-4.4.1 NKCC1
NKCC, of which there are 2 isoforms, facilitates the entry of Na+, K+, and 2 Cl’ 
into epithelial cells. NKCC1 has been identified as the isoform expressed in the 
intestinal epithelium and its function has been well characterised (Matthews et 
al., 1992; Matthews et al., 1994; D'Andrea et al., 1996; Haas and Forbush, 2000; 
Del Castillo et al., 2005; Payne et al., 1995). The initial identification of the 
human NKCC was made in T84 cells by Payne et al in 1995 (Payne et al., 1995). 
Following the initial identification, its localisation to the basolateral membrane 
of intestinal epithelial cells was characterised, and its association with the 
cytoskeleton was initially proposed (D'Andrea et a/., 1996). NKCC1 is known to 
be regulated by both low intracellular [Cl ] and by cell shrinkage, indicating that 
the co-transporter plays an important role in maintaining cell volume. NKCC1 is 
also regulated by protein phosphatase 1 (PP1), PKC, Ste20-related proline- 
alanine-rich kinase (SPAK), PKA, and through its interaction with the 
cytoskeleton (Darman et al., 2001; Matthews et al., 1994; Piechotta et al., 2003; 
Dowd and Forbush, 2003; Bachmann et al., 2003; Haas and Forbush, 2000). 
More recent studies have also implicated PKC isoforms as regulators of NKCC1 
trafficking to the basolateral membrane (Del Castillo et al., 2005).
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Secretagogue-induced regulation of NKCC1 was nicely described by Reynolds 
and co-workers, where they showed that Ca2+ -dependent agonists sequentially 
caused the activation, internalisation and degradation of NKCC1 (Reynolds et 
al., 2007). This was followed by re-expression of the co-transporter several 
hours later, thereby completing the cycle of regulation by such agonists. The 
authors also showed that cAMP-dependent secretagogues caused sustained 
activation of the co-transporter, but that this could be curtailed by co­
stimulation by Ca2+-dependent agonists that activate PKC.
1-4.4.2  SGLT-1
Sugars are transported across the brush boarder membrane from the lumen by 
two different transporters, sodium glucose transporters (SGLTs) and glucose 
transporters (GLUTs). There are several SGLT isoforms expressed in human, 
with SGLT1 being the primary co-transporter expressed in the intestine (Wright 
et al., 2011). SGLT-1 transports glucose or galactose from the gut lumen into 
epithelial cells along with Na+, in a ratio of 1 : 2. The sugar moieties can then be 
transported from the cell via the basolateral transporter GLUT2, whereas Na+ is 
transported basolaterally via Na+/K+-ATPase pumps. In order to maintain 
osmolarity, Cl' and HC03" are also absorbed across the epithelium, followed by 
water. This process forms the basis of oral rehydration therapy (ORT) (Wright et 
al., 2011). The pathway by which water is transported across the epithelium 
has been the subject of much investigation and it is likely that several pathways 
exist including, passive diffusion across the phospholipid bilayer, solvent drag 
through the tight junctions and transport through water channels, such as 
aquaporins (Madara and Pappenheimer, 1987; Agre et al., 1993). Other studies 
have proposed SGLT1 as a water transporter itself (Wright and Loo, 2000; 
Meinild et al., 1998). The capacity for SGLT-1 to move water is large, with one 
study suggesting that 210 water molecules are transported across the 
epithelium with each cycle of transport activity.
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1 - 5  H y p o x i a
Hypoxia is defined as the state when cellular oxygen demand exceeds supply. 
This is such a common occurrence that every cell in the body is equipped to deal 
with it, and to mount an appropriate hypoxic response. Such is the 
sophistication of physiological responses to hypoxia that changes can occur 
from the molecular to the whole-body level. For example, reduced arterial 
oxygen is sensed by carotid bodies, highly vascularised organs located at 
bifurcations of the carotid arteries. These carotid bodies contain polarised cells 
that have 02-sensitive K+ channels located on their plasma membranes. 
Conditions of low 0 2 inhibit the K+ channels leading to Ca2+ influx, membrane 
depolarisation, subsequent neurotransmitter release, and changes in 
respiration rate and cardiac output (Peers and Kemp, 2001).
Among the most important molecular elements of hypoxic responses is hypoxia 
inducible factor (HIF). The identification HIF by Semenza et al led to the 
discovery of an extremely well-conserved signalling pathway that allows 
organisms to appropriately respond to changes in the amount of oxygen 
available to them (Semenza and Wang, 1992). However, the precise mechanism 
of how HIF itself detected oxygen eluded researchers for a further 10 years until 
the discovery of the HIF hydroxylases by two groups in 2001 (Epstein et al., 
2001; Bruick and McKnight, 2001). These proteins are the molecular 'oxygen 
sensors' that determine the fate of HIF.
1 -5 .1  H IF
HIF is a transcription factor that functionally exists as a heterodimer comprised 
of the constitutively expressed HIF-lp, or aryl hydrocarbon receptor 
translocator (ARNT), with a labile HIF-a subunit. There are 3 HIF-a subunits, 
with HIF-la being the most extensively studied. HIF-a is an oxygen-dependent 
protein that is post-translationally regulated by HIF hydroxylases. During
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conditions of normal oxygen tension, HIF-a subunits are hydroxylated at specific 
proline and asparagine residues by HIF hydroxylases. This proline hydroxylation 
targets HIF-a for ubiquitination by the von Hippel-Lindau tumour suppressor 
protein (pVHL) and ultimately, degradation via the proteasomal pathway. As a 
consequence of the action of the HIF hydroxylases, in normoxic conditions HIF- 
la  is turned over at a very high rate, thus keeping steady-state levels low 
(Huang eta/., 1998).
1 -5 .2  H IF  h y d r o x y la s e s
Studies published by several research groups in 2001 identified proline 
hydroxylation of HIF-la as the mechanism by which HIF is recognised and 
targeted for destruction by an E3 ubiquitin ligase containing pVHL (Ivan et a i,  
2001; Jaakkola et a i,  2001; Masson et a i,  2001). However, these initial studies 
did not identify the enzymes responsible for HIF hydroxylation until later the 
same year, when 2 groups independently published articles identifying an 
evolutionary conserved family of proteins known as HIF prolyl hydroxylases 
(PHD1-3) (Epstein et a i,  2001; Bruick and McKnight, 2001). An asparaginyl 
hydroxylase of HIF-la, factor inhibiting HIF (FIH-1), was later identified in 2002 
(Lando et a i,  2002a). It was initially thought that the PHDs hydroxylated a 
consensus motif within substrate proteins, until subsequent studies 
demonstrated that the only obligatory residue for proline hydroxylation is the 
proline residue itself (Huang et a i,  2002). Since their discovery in 2001 there 
has been an increasing growth in research interest in these proteins and their 
roles in regulating cellular function in health and disease (Figure 1-4).
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Figure 1-4 The number of published articles relating to HIF prolyl hydroxylases since 
2000. More than 500 articles were found using the search term "HIF prolyl 
hydroxylase" since the year 2000.
The PHDs trans-4-hydroxylate Pro564 and Pro402 of HIF-la thus targeting it for 
recognition by pVHL (Ivan et al., 2001; Jaakkola et al., 2001; Masson et al., 
2001). In contrast, FIH-1 p-hydroxylates asparagine 803 on HIF-la to prevent 
its interaction with the co-activator p300/CBP, thereby inhibiting its 
transactivation domain and keeping it transcriptionally silent (Lando et al., 
2002a; Lando et al., 2002b). The activity of PHDs is dependent on binding of a- 
ketoglutarate and Fell and mutational studies have identified the locations of 
their, binding sites on the hydroxylases (McNeill et al., 2002). Intracellular 
expression patterns of hydroxylases appear to vary greatly among different 
tissues, with PHD1 being present exclusively in the nucleus of osteocarcinoma 
cells and COS-1 monkey kidney cells, but being present in both the cytoplasm 
and nucleus of other cells (Metzen et al., 2003; Huang et al., 2002; Berchner- 
Pfannschmidt et al., 2008). Interestingly, studies have shown that different 
PHDs have different preferences for the HIF-a isoform they hydroxylate, with 
PHD2 being more specific for HIF-la and PHD3 preferentially hydroxylating HIF- 
2a (Appelhoff et al., 2004). Several studies have attempted to identify the 
isoforms involved in particular conditions or phenomena, and reports suggest it 
is PHD2 that is the primary 0 2 sensor involved in HIF-la hydroxylation in 
normoxia (Berra et al., 2003).
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The great potential for modulating HIF hydroxylases in therapeutic settings did 
not go unnoticed, and prolyl hydroxylase inhibitors (PHIs) were rapidly adopted 
by pharmaceutical companies for the treatment of anaemia, and are currently 
in Phase 2 clinical trials (Mole et al., 2003; Fraisl et a l,  2009; Provenzano et a l,  
2011) (http://www.fibrogen.com/press/release/pr_1304365050).
Of the PHIs so far developed, and the most widely used for molecular biology 
has been dimethyloxalylglycine (DMOG) (Baader et a l,  1994). This is a non-
selective inhibitor of HIF hydroxylases, collagen 4-hydroxylase and other a-
i
ketoglutarate-dependent dioxygenases (Elvidge et a l,  2006). It was initially 
developed as a fibrosuppressive agent to inhibit prolyl-4 hydroxylase-regulated 
collagen synthesis (Baader et a l,  1994). Interestingly, DMOG itself is a poor 
inhibitor of proline hydroxylation in purified extracts, but intracellularly it is a 
potent inhibitor. This is thought to be due to enzymatic processing of DMOG in 
a manner similar to the processing of diethyl 2-4 pyridine-2,4-dicarboxylic acid 
(2,4-PDCA) (Tschank et a l,  1991). Other PHIs have been developed by 
biotechnology companies such as FibroGen Inc. and have been described in 
detail elsewhere (Salnikow et al., 2004; Fraisl et al., 2009; Tian et a!., 2011b).
The specificity of the HIF hydroxylases is not confined to HIF and it is now 
known that they hydroxylate residues on many other proteins, with FIH-1 being 
the least specific. An important non-HIF target of proline hydroxylases is IKK(3, 
with the consequent inhibition of NFkB under normoxic conditions (Cummins et 
al., 2006). FIH-1 has been discovered to hydroxylate ankyrin repeat domains 
(Cockman et a l 2006), and in fact its affinity for hydroxylation of the 
intracellular domain of Notch is greater than that its effects on HIF-la (Zheng et 
al., 2008). Given the plethora of ankyrin repeat domain-containing proteins, 
researchers have been keen to attribute a physiological purpose to this 
phenomenon. A proposed function for hydroxylation of ankyrin substrates is 
that they sequester FIH-1 away from HIF-la, and thus increase HIF-la 
transcriptional activity by reducing its asparagine hydroxylation (Coleman et al.,
39
2007). Other more recent studies have suggested that ankyrin hydroxylation by 
FIH-1 is more common than previously thought, and that it serves to stabilise 
ankyrin repeat domain folds, which facilitate protein-protein interactions (Kelly 
et al., 2009a). Finally, the cytoskeletal ankyrin domain-containing family has 
also been shown to be hydroxylated by FIH-1 leading to alterations in protein- 
protein interactions (Yang et al., 2011). HIF hydroxylases are not just oxygen 
sensors, they are also sensitive to the levels of the cofactors and substrates that 
they require for activity (Pan et al., 2007). Thus, some researchers have also 
dubbed them "metabolic sensors". This feature is highlighted in FIH-l'^ mice, 
which exhibit reduced body weight, increased metabolic rate, and improved 
glucose and lipid homeostasis (Zhang et al., 2010),
A physiological role for hydroxylases in the intestine was initially postulated in 
2004 when a study revealed that HIF-1 exerted protective effects in a hapten- 
based murine model of colitis (Karhausen et ai., 2004). In this study, 
constitutively active HIF-1 ameliorated the onset and severity of colitis, whereas 
constitutive inhibition of HIF-1 led to increased disease severity. Further to this 
study in 2006, Cummins et ai. published an article highlighting a non-HIF-1 
target of the HIF hydroxylases, namely NFkB (Cummins et al., 2006). This line of 
research culminated in 2008 with 2 studies being published back to back in 
Gastroenterology, both of which investigated the effects of hydroxylase 
inhibition in the development and progression of mouse models of colitis 
(Cummins et ai., 2008; Robinson et al., 2008). These studies revealed that 
activation of HIF and NFkB pathways via inhibition of hydroxylase activity was 
protective against the onset of disease, and suggested that hydroxylases 
represented potential new targets for the development of therapies for IBD. Of 
particular relevance to this thesis, hypoxia occurs as a pathophysiological 
response in conditions of intestinal inflammation and can lead to alterations in 
several important aspects of intestinal physiology, including fluid and 
electrolyte transport (Eisenhut, 2006).
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1-6 Hypoxic regulation of intestinal epithelial 
Cl' secretion
1 -6 .1  In t r o d u c t io n
Previous sections have highlighted how epithelial transport function is 
dependent on cellular oxygen and energy supply, and how during conditions of 
hypoxia, epithelial transport can become dysregulated. Under physiological 
conditions the intestinal epithelium is exposed to one of the highest oxygen 
gradients in the body. Although the serosa is supplied by the splanchnic 
circulation with amply oxygenated blood, the epithelium is exposed to the harsh 
anoxic environment of the lumen (Taylor and Colgan, 2007). Add to this the 
highly dynamic nature of the splanchnic circulation, and the result is a hugely 
fluctuating oxygen supply to this tissue. Pathophysiological conditions, such as 
those underlying inflammation, can also result in hypoxia, and consequently the 
epithelial cells must be able to mount an appropriate response in order to 
survive. HIF, as already mentioned, is the master regulator of hypoxia and plays 
a key role in regulating metabolism, but is also known to regulate epithelial 
transport processes in the intestine. Some studies have shown that HIF can 
directly regulate the expression of epithelial ion transport proteins, while others 
have shown that intermediary steps, such as the generation of prosecretory 
second messengers can be altered in hypoxia (Ibla et a i,  2006; Zheng et a i,  
2009; Taylor et al., 1998).
1 -6 .2  H y p o x ia  r e g u la te s  t r a n s p o r t  p r o te in s
One of the many effects of hypoxia on the intestinal epithelial Cl" secretory 
mechanism is its actions on the transport proteins themselves. This topic has 
received a good deal of attention, however is most well-documented with 
respect to hypoxic regulation of the Na+/K+-ATPase. While HIF itself is a 
transcription factor, two recent studies have demonstrated how it can act as a
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transcriptional repressor of both CFTR and NKCC1. In the case of CFTR, initial 
studies demonstrated that hypoxia suppresses CFTR mRNA expression, not only 
in the intestine but also in other tissues, and subsequent investigations revealed 
that this occurs by a HIF-l-dependent mechanism (Guimbellot et a i,  2008; 
Zheng et a i,  2009). In other tissues, such as sinonasal respiratory epithelia, 
both CFTR and TMEM16A activity is attenuated by exposure to chronic hypoxia, 
an effect that is associated with decreased CFTR and TMEM16A mRNA 
expression (Blount et al., 2011). Thus, it is clear that hypoxia has the capacity to 
negatively regulate Cl" channels on the apical membranes of epithelial cells.
NKCC1 is also known to be regulated by hypoxia, and more specifically by HIF-1 
which suppresses co-transporter expression at the transcriptional level (Ibla et 
a i,  2006). However, despite its importance to intestinal secretion, there is still 
a paucity of studies on NKCC function under conditions of hypoxia. Studies 
conducted by Yoo et a i,  using a model of chemically-induced hypoxia in 
cultured epithelia, show that PKC e suppresses Cl" secretion upon activation by 
specific agonists (Yoo et a i,  2001). More recent research by the same group 
demonstrates that NKCC1 is rapidly internalised upon PKC activation, an event 
that was sensitive to PKC e inhibition (Del Castillo et a i,  2005). Studies by other 
groups have shown PKC e can be activated by hypoxia in cardiac myocytes (Ogbi 
and Johnson, 2006). Taken together these data suggest that hypoxia may 
activate signalling mechanisms, whereby PKC e activation induces NKCC1 
internalisation to downregulate epithelial secretion.
\ 1
Na+/K+-ATPase pumps provide the driving force for all epithelial electrolyte 
transport processes, and this transporter has been demonstrated in numerous 
studies to be regulated under hypoxic conditions (Skou, 1998; Kaplan, 2002; 
Planes et a i,  1996; Mairbaurl et a!., 2002; Carpenter et a i,  2003; Dada et a i , 
2003; Gusarova et a i,  2011). Initial studies indicated that hypoxia attenuated 
the activity of lung epithelia) Na+/K+-ATPase, without altering its expression 
(Planes et a i,  1996; Carpenter et a i,  2003). The mechanisms involved are
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complex and involve mitochondrial ROS, which is produced during hypoxia, 
which activate Ca2+/calmodulin-dependent kinase kinase P (CaMKKP). Activated 
CaMKKp eventually results in the phosphorylation of Ser-18 on Na+/K+-ATPase 
a i7 culminating in clathrin-dependent pump endocytosis (Dada et al., 2003; 
Chen et al., 2006). This process was shown to require the ubiquitin-conjugating 
system and to be pVHL-dependent, but interestingly was HIF-independent 
(Cornelias et al., 2006; Dada et a i,  2007; Zhou e t al., 2008).
K+ channels play a critical role in 0 2 sensing in the carotid bodies, however there 
is a paucity of information on their regulation by hypoxia in the Gl tract (Wyatt 
et al., 2007; Patel and Honoré, 2001; Ross et al., 2011). The regulation by AMPK 
of KCNQ1 has been demonstrated under conditions of metabolic stress in 
kidney cells, and while it is possible that such effects may also occur in hypoxia, 
this has not been demonstrated in intestinal epithelial cells (Alzamora et al., 
2010). Research by other groups has shown that serum and glucocorticoid- 
responsive kinase-1 (SGK1) regulates KCNQ1/KCNE3 endocytosis (Seebohm et 
al., 2007). Interestingly, SGK1 is known to be regulated by hypoxia in other 
systems, suggesting that KCNQ1 may be regulated under conditions of hypoxia, 
or by hydroxylase inhibitors, through activation of SGK1 (Aoyama et al., 2005; 
Rusai et al., 2009). Studies on the role of hypoxia in regulating Ca2+-activated K+ 
channels are limited to those in the carotid body (Ross et al., 2011).
Thus, by virtue of their ability to regulate epithelial transport proteins through a 
variety of different transcriptional and post-transcriptional mechanisms, 
hypoxia-dependent signalling pathways represent good targets for the 
development of drugs to treat intestinal disorders associated with dysregulated 
fluid and electrolyte transport.
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1-7 Pharmacological intervention in the 
treatment of diarrhoea
The word "diarrhoea" is derived from the Greek term "to flow through" [6ia 
(dia, "through") + pew (rhed, "flow")] and is a common manifestation of 
gastrointestinal disease. In developing nations diarrhoea kills approximately 1.5 
million children each year, and globally affects up to 2 billion people(Wardlaw et 
al., 2010). Diarrhoeal diseases can be classified as being infectious or non- 
infectious, with infectious diarrhoea, e.g. rotavirus infection, accounting for up 
to 40 % of hospitalisations due to diarrhoea in children under 5 worldwide, 
including developed countries (Wardlaw et al., 2010; WHO, 2008). Non- 
infectious chronic diarrhoea, with a duration of > 4 weeks, is a primary 
symptom of several gastrointestinal disorders, including IBD, diarrhoea- 
^predominant IBS, iatrogenic diarrhoeas, such as those induced by 
chemotherapy, microscopic colitis and bile acid malabsorption (Carter et al., 
2004; Maroun et al., 2007; Oelkers et al., 1997; Hofmann, 2009). Together, 
these conditions represent a huge financial burden to Western societies in 
terms of healthcare and lost hours of work.
Many diarrhoeal deaths are due to dehydration, and in children with diarrhoea, 
rehydration and prevention of malnutrition are amongst the main therapeutic 
objectives. Anti-diarrhoeal drugs are not routinely used in children since this is 
not the primary objective, and such drugs can have sometimes fatal 
consequences (WHO, 1990). Dehydration caused by diarrhoea can be 
effectively treated by oral rehydration therapy.
For adults the primary therapeutic approaches for treating diarrhoea include 
adsorbents, such as cholestyramine, which bind the toxins causing the 
diarrhoea, or antimotility drugs, such as loperamide or codeine. These latter 
drugs effectively act by paralysing intestinal smooth muscle, thereby slowing 
motility and allowing increased time for absorption to occur (Read, 1983).
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However, none of these treatments are safe for children and cannot be used in 
the long-term for the treatment of chronic diseases (WHO, 2005). To date, 
there are no therapeutic options available to clinicians that allow direct 
targeting of epithelial transport processes for the treatment of diarrhoea.
1-8 Overall aim
The overall aim of this thesis was to investigate the potential role that HIF- 
hydroxylases play in regulating intestinal epithelial Cl' secretion and to 
determine the therapeutic potential of hydroxylase inhibitors in the treatment 
o f diarrhoeal diseases.
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C h a p t e r  2
M a t e r i a l s  a n d  M e t h o d s
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2 - 1  A n i m a l  s t u d i e s
All animal studies were performed In compliance with Irish Department of 
Health and Children regulations and were approved by the Beaumont Hospital 
Ethics Committee.
Animal licence number: B100/4159
Research Ethics Committee number: 628
2 - 1 .1  A n im a l  t r e a t m e n t s  f o r  e le c t r o p h y s io lo g ic a l  s tu d ie s
Male C57BL/6 mice and male Sprague Dawley rats were bred and maintained in 
the environmentally controlled Biomedical Research Facility at Beaumont 
Hospital. Male animals were used to avoid the confounding factor oestrogen, 
which can alter colonic epithelial ion transport (O'Mahony et al., 2007). 
Experiments were performed on 6-9 week old mice ranging from 20-25 g, and 
on 240-260 g rats of Indiscriminate age. Animals were treated with either 
DMOG or PBS as vehicle control. DMOG was prepared In endotoxin-free PBS, 
and was administered by intraperltoneal (IP) Injection to mice (320 mg/kg) as 
previously described, or to rats (40 mg/kg) as previously described (Cummins et 
al., 2008; Zhao et al., 2010). All mice were sacrificed 24 hours later by cervical 
dislocation, whereas rats were first anaesthetised by exposure to aerosolised 
Isofluorane, before being sacrificed by cervical dislocation. The Intestines of the 
animals were removed and placed in an ice-cold Ringer's solution, and were 
then treated as described in the relevant Methods sections. All drugs and 
equipment used to treat animals were sterile and endotoxin-free.
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2 - 1 . 2  M o u s e  m o d e l  o f  o r a l  a l le r g e n - in d u c e d  d ia r r h o e a
These experiments were carried out in collaboration with Professor Padraic 
Fallon and Dr. Sylvie Amu, Trinity College Dublin, and were based on a 
previously published protocol (Brandt et al., 2003; Perdue et al., 1991). The 
premise behind the protocol for oral allergen-induced diarrhoea is that It Is a 
classic clinical feature of numerous gastrointestinal allergic disorders, such as 
food allergies and eosinophil-associated gastrointestinal disorders. Allergic 
diarrhoeas are associated with significant changes in /sc and Cl' secretion, and 
previous research has shown that OVA-lnduced diarrhoea is predominantly due 
to mast-cell stimulated Cl" secretion (Harari et al., 1987; Perdue et al., 1991). 
Other researchers have corroborated this finding and have suggested that the 
enhanced Intestinal secretion associated with allergic diarrhoea is also 
associated with decreased gut permeability (Wasserman et al., 1988; Field, 
2003; Barrett, 1991; Barrett et al., 1990). Male BALB/c strain mice were 
sensitised twice, 2 weeks apart, with 50 jig of OVA in the presence of 1 mg of 
aluminium potassium sulphate adjuvant by IP injection. Two weeks following 
the Initial sensitisation, the animals were each challenged with oral 
administration of 50 mg OVA in sterile saline, 3 times per week, which previous 
studies have shown to be the lowest dose to induce diarrhoea in this model 
(Brandt et al., 2003). Prior to each oral challenge the animals were fasted for 4 
hours to limit antigen degradation in the stomach. Mice were monitored for 1 
hour following oral OVA administration, and those with profuse watery stool 
were diagnosed as diarrhoea-positive. Mice were treated with either DMOG 
(IP; 160 mg/kg), or PBS alone, 24 hours before each oral challenge with OVA.
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The T84 cell line ¡s a human colonic carcinoma cell line that was established in 
BALB/c nude mice. It was isolated from a lung metastasis from a patient with a 
colon carcinoma, and injected subcutaneously into nude mice. The resulting 
tumour was isolated, homogenised, and cultured in growth medium (Murakami 
and Masui, 1980). When grown on permeable supports, Tg4 cells form a well- 
differentiated, electrically tight, columnar epithelium (Madara and 
Dharmsathaphorn, 1985). They have the appearance of native crypt epithelial 
cells and retain many of their characteristics, including vectorial Cf secretion in 
a basolateral to apical direction (Dharmsathaphorn et al., 1984). While Tg4 cells 
may lack the absorptive phenotype seen in surface cells, the simplicity of the 
model makes it ideal for examining molecular mechanisms that regulate 
intestinal epithelial Cl" secretion. T84 cells were cultured, in DMEM Ham's F12 
media supplemented with 5 % bovine calf serum, 1 % penicillin/streptomycin, 
and 1 % glutamate (Toumi et al., 2011). Culture medium was replaced every 
second day, and on the 7th day, or when cells were approximately 90 % 
confluent, they were passaged by trypsinisation. For trypsinisation, cells were 
first washed with trypsin (0.25 %), and then incubated with trypsin for several 
minutes. Trypsin was deactivated by the addition of culture medium containing 
serum. Trypsinised cells were counted using a haemocytometer and were 
seeded at the densities shown in Table 2-1.
2 - 2  T 84  c e l l  c u l t u r e
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Table 2-1 TM cell culture seeding conditions. T^ cells were trypsinised and counted 
using a hemacytometer. Cells were seeded at various densities ranging from 100,000 -  ' 
2,000,000 cells, depending on the area of the receptacle. MCE = mixed cellulose esters; 
PET = Polyethylene Terephthalate
Hanging
insert
Standing
insert
Standing
insert
Glass
bottom
petri-dish
T75
Application Confocal Ussing Protein/RNA Imaging Culture
Porosity 1 (iM 0.45 (iM 0.45 |iM - -
Material PET MCE MCE glass Plastic
Supplier Millipore Millipore Millipore MatTek Starstedt
Cat PIRP12R48 PIHA01250 PIHA03050 P35G-0- 83.1813.500
number 14-C
Area 0.33 cm2 0.6 cm2 4.2 cm2 1.54 cm2 75 cm2
Number of 1 x1 0 s 5 x10s 2 x 106 5 x10s 2 x 10s
cells
For electrophysiological studies, Tg4 cells were cultured on 0.6 cm2 permeable 
supports and were considered to be suitable for experimentation when their 
transepithelial resistance (Rte) had stabilised at > 1000 Q/cm2, typically between 
7-21 days post seeding. Cells were cultured on 4.2 cm2 inserts for protein 
extraction, RNA isolation, cAMP assays, biotinylation studies, and co- 
immunoprecipitation studies, and were considered to be suitable for 
experimentation once their Rte had stabilised at > 1000 Q/cm2, typically 
between 7-21 days post seeding. The filters used for culturing Tg4 cells were 
composed of MCE and had a resistance of 74.9 ± 1.4 Q/cm2. Time courses for 
the development of Rte across Tg4 cells grown on 0.6 and 4.2 cm2 inserts are 
shown in Figure 2-1.
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Figure 2-1 Time course of the development of ffte across monolayers of TM cells on 
permeable supports. A) Ts4 cells were cultured on 0.6 cm2 permeable supports and the 
ffte was recorded each day for several days. Data are expressed as kflcm 2 (n = 5-6) for 
each point shown. B) T^ cells were cultured on 4.2 cm2 permeable supports and the 
/?te was recorded each day for several days. Data are expressed as kQ.cm2 (n = 4 for 
each point shown).
2 - 2 .1  C e ll t r e a tm e n ts
Once the /?te of the cells had stabilised at plateau levels, Tg4 monolayers were 
routinely washed once on the apical and basolateral sides with serum-free 
culture medium. The inserts containing the monolayers were then transferred 
to a new well of the culture dish, and were cultured in serum-free medium for 
24 hours. This served to synchronize the cells in the quiescent GO phase, to 
prevent confounding effects of serum components, and to prevent serum 
components from binding to and/or enzymatically cleaving the drugs that were 
to be used. T ^  cell culture in serum-free medium for 24 hours caused an
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increase in the basal /?te from 1665.4 ± 90.9 to 1970.8 ± 97.5 Q.cm2 (*p < 0.05; n 
= 48). Following the 24 hour period in serum-free medium, cells were treated 
accordingly, with all treatment solutions being diluted in serum-free medium. 
When pharmacological inhibitors were used they were incubated with the cells 
bilaterally for a minimum of 30 minutes prior to treatment with hydroxylase 
inhibitors. Table 2-2 lists the inhibitors employed, their intended targets, and 
the concentrations at which they were used. The exception to  bilateral 
treatment was methyl p cyclodextrin (MpCD), which was used basolaterally 
only. The mechanisms of action of the inhibitors used in the current studies are 
listed below:
• Dimethlyoxallylglycine (DMOG) is a non-selective inhibitor of HIF 
hydroxylases, collagen 4-hydroxylase and other a-ketogluta rate- 
dependent dioxygenases (Elvidge et al., 2006; Fraisl et al., 2009). DMOG 
was initially developed as a fibrosuppressive agent to inhibit prolyl-4
* hydroxylase-regulated collagen synthesis (Baader et al., 1994). 
Interestingly, DMOG itself is a poor inhibitor of proline hydroxylation in 
purified extracts, but is a potent intracellular inhibitor. This is thought to 
be due to enzymatic processing of DMOG in a manner similar to the 
processing of diethyl 2-4 pyridine-2,4-dicarboxylic acid (2,4-PDCA) 
(Tschank et al., 1991). DMOG was the primary HIF-hydroxylase inhibitor 
used throughout the current studies. While cellular responses to 
hydroxylase inhibition by DMOG and hypoxia are known to differ, 
previous studies in a breast cancer cell line, MCF-7, have found there to 
be striking concordance between patterns of gene expression induced 
by hypoxia and by DMOG (Elvidge et al., 2006). While many of these 
genes are HIF-1 or HIF-2-dependent, not all of the hypoxia or DMOG- 
regulated genes were targets of HIF, highlighting the importance of non- 
HIF targets of hydroxylases (Elvidge et al., 2006).
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FG-4497 is a proprietary compound developed by FibroGen Inc. to 
inhibit the activity of HIF-hydroxylases. FG4497 has been reported to 
inhibit HIF hydroxylases by binding to the active site of the enzymes 
(Fraisl et a i, 2009). The optimal working concentration of FG4497 was 
determined in these studies and it was found to be more potent than 
DMOG.
CoCI2 was used to inhibit H IF -la  degradation by preventing its 
interaction with von Hippal Lindau protein (pVHL), thereby inhibiting its 
proteasomal degradation (Kanaya and Kamitani, 2003; Yuan et a i, 
2003). More recently C0 CI2 was shown to deplete ascorbate in the cell, . 
hence inhibiting the HIF hydroxylases and thereby stabilising H IF -la  
(Salnikow et a!., 2004). The optimal working concentration of .this 
inhibitor was determined in this study.
Actinomycin D (AD) was used to inhibit gene transcription. This drug 
inhibits transcription in a non-specific manner by forming a stable 
complex with double-stranded DNA via deoxyguanosine residues at the 
transcription initiation complex, thereby inhibiting DNA-primed RNA 
synthesis (Sobell, 1985). AD also causes single-strand breaks in DNA.
Cycloheximide (CHX) was used to inhibit protein translation (Schneider- 
Poetsch et a i, 2010). Recent reports show that CHX blocks the 
translocation step in elongation by binding to 60S ribosomal subunits in 
the ribosome. The optimal working concentration of this inhibitor was 
determined in this study.
H89 was used to inhibit cAMP dependent protein kinase (PKA) activity. 
H89 is a non-selective inhibitor of PKA that at higher concentrations is 
also known to inhibit other kinases, such as S6K1, MSK1, ROCK-II, PKBa, 
and MAPKAP-Klp (Davies et a i, 2000). H89 is thought to work by
competitively inhibiting thè binding of ATP to the kinase, and was used 
in these studies at a concentration previously reported to inhibit PKA in 
Tg4 cells (Chijiwa et a i, 1990; Rudolph et al., 2004).
•  BMS-345541 is a highly selective inhibitor of IkB Kinase (IKK) and thus is 
an inhibitor of NFkB activity. BMS-345541 binds to either the peptide 
binding site on IKK, or an allosteric site that changes the binding site, 
thus preventing peptide-binding (Burke et al., 2003).
•  GF 109203X (GF) is reported to be a specific inhibitor of PKC (Toullec et 
al., 1991). It inhibits both classical and novel PKC isoforms via 
competitive inhibition with ATP (Roberts et al., 2005).
•  PP2 is a potent Src family-selective tyrosine kinase inhibitor that works 
via competitive inhibition with ATP (Hanke et al., 1996). It was used in 
these studies at concentrations previously shown to inhibit Src in TM 
cells (Keely et a i, 2000) (20 jiM).
•  Acriflavine specifically binds to the PAS-B domain of H IF -la  and 2a. 
Acriflavine thus prevents HIF-a and HIF-ip dimerisation, and inhibits 
HIF-DNA binding and transcriptional activity (Lee et a i, 2009).
•  MpCD disrupts lipid rafts by chelating cholesterol. It was used in these 
studies at a concentration previously reported to deplete cholesterol 
and disrupt lipid rafts in Tg4 cells (Wolf et a i, 2002). Optimal treatment 
times for the drug were investigated in the present studies.
•  5-(N-Ethyl-N-ìsopropyl)amìloride (EIPA) inhibits NHEs with 
concentration-dependent specificities (Chambrey et a i, 1997; Beltran et 
a i, 2008). Amiloride and its derivatives are thought to bind to the
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external Na+ binding site of NHEs, thus inhibiting their activity (Masereel 
eta!., 2003).
Table 2-2 Concentrations of drugs employed and their intended cellular targets. This
table summarises the inhibitors used and their concentrations employed.
Inhibitor Target Working Concentration
DMOG PHDs 1 mM
FG-4497 PHDs 50 jiM
CoCI2 HIF-la-pVHL interaction 500 |iM
H89 PKA 30 (iM
BMS-345541 IMFk B 10 |iM
GF PKC 5 (iM
Acriflavine H IF-la-H IF-ip  dimérisation 5 \xM
Cycloheximide 60S Ribosomal subunit 5 piM
Actinomycin D Double-stranded DNA 250 ng/ml
EIPA NHE 50 nM
PP2 Src 20 piM
Methyl p cyclodextrin Lipid rafts 4 mM
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2 - 3  E l e c t r o p h y s i o l o g i c a l  m e a s u r e m e n t s
Electrophysiological measurements were performed using VCC MC8 Voltage 
clamps. All epithelial preparations, both tissues and cell cultures, were 
mounted in Ussing chambers (Figure 2-2), bathed in a physiological Ringer's 
solution(s) (see individual protocols below), aerated with a 95 % 0 2, 5 % C02 
mix, and maintained at 37°C ± 1°C. All preparations were clamped to zero 
potential difference (PD), and drug treatments were initiated once baseline 
short circuit current (/sc) and Rte had stabilised. /sc and PD were recorded for 
each experiment, and using Ohms Law, Rte and conductance were calculated. 
All current recordings were normalised and expressed as A /sc (jiA/cm2).
Figure 2-2 Photograph of an Ussing chamber. The Ussing chamber is composed o f 2 
hemi-chambers separated by an epithelial preparation. The epithelium is bathed in 
Ringer's solution, aerated w ith  95 % 0 2, 5 % C02, and maintained at 37°C by a heating 
block. A voltage is applied across the epithelium, which is then clamped to zero 
potential difference, and the current that is applied via the current electrodes to  
maintain the zero potential difference is recorded as /sc.
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Tg4 colonic epithelial cells were grown on 0.6 cm2 permeable supports as 
described in Section 2-2"  ^- -All monolayers "were washed in appropriate 
physiological solutionis), mounted in Ussing chambers, and bathed in 
physiological solutions according to each individual protocol.
2-3.1.1 Electrogenic Cl secretion
Tg4 monolayers were mounted in Ussing chambers and bathed in Ringer's 
solution (Table 2 -3 ) unless otherwise stated. Under such conditions, 
secretagogue-induced A /sc responses across Tg4 monolayers have been shown 
to be wholly reflective of changes in electrogenic Cl' secretion 
(Dharmsathaphorn et a/., 1984; Cartwright et al., 1985; Dharmsathaphorn et al.,
1985). The prototypical secretagogues, carbachol (CCh) and forskolin (FSK), 
were used to stimulate Ca2+ and cAMP activated Cl' secretory responses, 
respectively. The effects of these drugs on T ^  cells have been well- 
characterised. CCh was employed at a concentration of 100 jaM, and was added 
basolaterally, where it acts at muscarinic M3 receptors (Cuthbert et al., 1987). 
FSK (10 fiM) was added apically only since previous results from our laboratory 
showed that no additional increase in currents were observed upon bilateral 
addition of the compound.
2 -3 .1  T 84 c o lo n ic  e p it h e lia l  c e l ls
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Table 2-3 Composition of Ringer's solution. Ringer's solution is an isotonic 
physiological solution that contains a balance of salts and sugars to sustain animal 
tissue in a viable state for long periods of time. It was introduced by the physiologist 
Sidney Ringer in 1882 for studies of frog heart. Once prepared, Ringer's solution was 
aerated with a 95 % 0 2, 5 % C02 mix to achieve a pH of 7.4 and an osmolarity of 285 ± 5 
mOsms.
Component Concentration (mM)
Na+ 140
K+ 5.2
Ca2+ 1.2
Mg2+ 0.8
cr 119.8
h c o 3‘ 25
h 2p o 4‘ 2.4
D-glucose 10
Table 2-4 Composition of D-fructose Ringer's solution. D-glucose is replaced with 
equi-molar D-fructose in D-fructose Ringer's solution. Once prepared, D-fructose 
Ringer's solution was aerated with a 95 % 0 2, 5 % C02 mix to achieve a pH of 7.4 and an 
osmolarity of 285 ± 5 mOsms.
Component Concentration (mM)
Na+ 140
K+ 5.2
Ca2+ 1.2
Mg2+ 0.8
cr 119.8
h c o 3* 25
h 2p o 4‘ 2.4
D-fructose 10
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Apical CFTR currents were measured by modifying previously published 
protocols (Rochwerger et al., 1994; Bijvelds et a l,  2009; DuVall et a l, 1998). 
After mounting in Ussing chambers, an apical to basolateral Cl" gradient (119 .8 - 
4.8 mM) was imposed across the epithelium. Normal Ringer's solution was 
applied to the apical reservoir (Table 2 -3 ), whereas low Cl' Ringer's solution was 
added basolaterally (Table 2-5). While this gradient is opposite to the 
physiological direction of intestinal epithelial Cl" secretion, experiments were 
conducted in this way in order to remove any influence of basolateral 
transporters from the current and to prevent cell swelling. Tg4 monolayers were 
allowed to equilibrate for 15 minutes and were then basolaterally 
permeabilised by the ionophore, nystatin (100 |ig/ml), to allow the passage of 
monovalent anions. After a further 35 minutes, when the basal /sc had re­
stabilised, cells were stimulated with apical FSK (10 jiM ). Under these 
conditions changes in /sc wholly reflect changes in apical Cl" currents through 
CFTR. This was confirmed in the current studies by the use of CFTRmhm (10|aM), 
which attenuated FSK-stimulated lsc responses by 78 %.
2-3.1 .2  A pical Cl cu rrents
Table 2 -5  Composition of low Cl' Ringer's Solution. NaCI was replaced with equi- 
molar Na-gluconate in low Cl’ Ringer's solution. Once prepared, low Cl' Ringer's solution 
was aerated with a 95 % 0 2, 5 % C02 mix to achieve a pH of 7.4 and 285 ± 5 mOsms.
Component Concentration (mM)
Na+ 140
K+ 5.2
Ca2+ 1.2
Mg2+ 0.8
cr 4.8
hco3 25
h2pcv 2.4
D-glucose 10
Gluconate 115
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2-3.1.3 Basolateral K+currents
Basolateral Ca2+-induced K+ currents (KCNN4) were measured as previously 
described (Kirk and Dawson, 1983). Monolayers of T84 cells were mounted in 
Ussing chambers and were apically permeabilised using the ionophore, 
amphotericin B (50 ^M). After baseline /sc had stabilised over 30 minutes K+ was 
driven from the apical to the basolateral compartment by the imposition of a K+ 
gradient (123.2-5.2 mM), created by addition of a high K+ Ringer's solution 
(Table 2 -6 ) to the apical reservoir. The Na+/K +-ATPase-specific inhibitor, 
ouabain (100 juM), was added basolaterally to remove any contribution of 
Na+/K+-ATPase activity to /sc responses. Under these conditions changes in /sc 
are wholly reflective of changes in basolateral K+ currents through KCNN4.
Table 2 -6  Composition of high K+ Ringer's solution. NaCI was substituted with K+- 
gluconate in high K+ Ringer's solution. Once prepared, high K+ Ringer's solution was 
aerated with a 95 % 0 2, 5 % C02 mix to achieve a pH of 7.4 and an osmolarity of 285 ± 5 
mOsms.
Component Concentration (mM)
Na+ 25
K+ 123.2
Ca2+ 1 .2
Mg2+ 0 .8
cr 4.8
HC03‘ 25
h 2p o 4' 2.4
D-glucose 1 0
Gluconate 115
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Na+/K +-ATPase activity was measured by a method based on previously 
published protocols (DuVall et al., 1998; Gomes and Soares-Da-Silva, 2002; Lam 
et al., 2003). Monolayers of Ts4 cells were mounted in Ussing chambers and 
bathed bilaterally in low sodium Ringer's solution (Table 2 -7 ). The monolayers 
were apically permeabilised by the ionophore, amphotericin B (50 juM). 
Following permeabilisation, the monolayers were allowed to re-equilibrate prior 
to stimulation with basolateral CCh (100 juM). Under these conditions changes 
in /sc are wholly reflective of electrogenic transport by the Na+/K+-ATPase.
Table 2-7 Composition of low Na+ Ringer's Solution. NaCI was substituted with 
equimolar N-methyl-D-glucamine (NMDG)-CI' In the low Na+ Ringer's solution. Once 
prepared, low Na+ Ringer's solution was aerated with a 95 % 0 2, 5 % C02 mix to achieve 
a pH of 7.4 and an osmolarity of 285 ± 5 mOsms.
2-3 .1 .4  N a+/K +-A T P a se  activ ity
Component Concentration (mM)
Na+ 25
K+ 5.2
Ca2+ 1 .2
Mg2+ 0 .8
cr 119.8
HC03‘ 25
h 2p o 4" 2.4
D-glucose 1 0
NMDG 115
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All intestinal tissues were transported to the laboratory in ice-cold physiological 
Ringer's solution(s), the specific type of which dependent on the transporter to 
be investigated. Animal tissues with the exception of murine jejunum were 
microscopically stripped of underlying muscle layers. Murine tissues were 
mounted on inserts with an aperture o f 0.3 cm2, whereas rat tissues were 
mounted on larger inserts with an aperture of 0.5 cm2
2-3.2.1 Colonic epithelial Cl' secretion
The large intestine was transported on ice to the laboratory in Ringer's solution 
(Table 2-3). All experiments were performed on distal colon which was 
distinguished from proximal colon by the lack of striation distinct to the 
proximal colon. The mesenteric fat and blood vessels were trimmed from the 
colon. The colon was then cut longitudinally along the mesenteric boarder and 
luminal contents were removed and the colon was washed in ice-cold Ringer's 
solution. The colonic tissue was then microscopically dissected, separating the 
epithelium from the underlying muscle layers. The colon was then cut laterally 
into 2 -3  sections. Tissues were then mounted on inserts, and bathed in 
Ringer's solution (Table 2 -3 ) in Ussing chambers at 37°C. Tissues were 
equilibrated for 25 minutes during which time PD, /sc, and conductance (G) were 
recorded. Once the /sc had stabilised, amiloride (100 jaM) was added to the 
apical bath to inhibit Na+ absorption by ENaC, thereby removing any possible 
contribution of apical Na+ absorption to the observed current. Ca+-activated Cl" 
secretion was then stimulated by the basolateral addition of CCh (100 ^iM), and 
once the /sc had returned to pre-stimulated levels, FSK (10 ^iM) was added to  
the apical bath to stimulate cAMP-activated Cl" secretion. Bumetanide (100 
^M) was added at the end of each experiment to the basolateral bath to inhibit 
NKCC1 activity, and thus provide a measure of the contribution of Cl' secretion 
to observed /sc responses.
2 -3 .2  In t e s t in a l t is s u e
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Studies of SGLT-1 mediated absorption ¡n mouse intestine were carried out 
using a protocol modified from previously published studies (Grubb, 1995). The 
small intestine was transported on ice to the laboratory in mannitol Ringer's 
solution (Table 2-8). This solution lacked D-glucose so as to maintain glucose 
transporters in a quiescent state. To identify the jejunum, the Ligament of 
Treitz was first identified, with the jejunum beginning approximately 4 cm distal 
to this and extending distally for approximately 10 cm. The mesenteric fat and 
blood vessels were trimmed away and the jejunum was cut longitudinally and 
then laterally into several sections. Unlike colonic tissue, jejunal tissue was 
mounted unstripped of underlying muscle layers. This was due to the 
abundance of lymphoidic Peyer's patches in jejunum which add to the fragility 
of the tissue and create technical difficulties for stripping away the muscle 
layers. SGLT-1 is known to be expressed apically in murine jejunum, therefore 
mannitol-contaming Ringer's solution (5 mM) was added to the apical bath 
(Table 2-8), and D-glucose-containing Ringer's solution (5 mM) to the 
basolateral bath (Table 2-9). The concentrations of the carbohydrates used 
were adapted from a previously published protocol (Grubb, 1995). Tissues were 
allowed to equilibrate for 25 minutes to allow the /sc to stabilise. Bumetanide 
(100 |iM ) was added to the basolateral bath to inhibit NKCC1 and thus any 
contribution of Cl' secretion to observed currents. Amiloride was not routinely 
added to jejunal preparations since initial investigations revealed there was.no 
observable ENaC-mediated current in these tissues. Na+ absorption by SGLT-1 
was stimulated by the addition of D-glucose (25 mM) to the apical bath. 
Mannitol (25 mM) was simultaneously added to the basolateral bath to 
maintain equi-osmolarity. The D-glucose-stimulated SGLT-1 current recorded 
was attenuated by the SGLT-specific inhibitor, phloridzin (1 m M).
2-3.2.2  SG LT-1  activ ity
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Table 2-8 Composition of manhitol-containing Ringer's solution. Mannitol-containing 
Ringer's solution lacks D-glucose which is substituted with 5 mM mannitol. Once 
prepared, mannitol-containing Ringer's solution was aerated with a 95 % 0 2, 5 % C02 
mix to achieve a pH of 7.4 and an osmolarity of 285 ± 5 mOsms
Component Concentration (mM)
Na+ 140
K+ 5.2
Ca2+ 1.2
Mg2+ 0.8
c r 119.8
h c o 3* 25
H2P04' 2.4
Mannitol 5
Table 2-9 Composition of D-glucose-containing Ringer's solution. D-glucose- 
containing Ringer's solution has less D-glucose (5 mM) than normal Ringer's solution 
(10 mM) (Table 2-3). Once prepared, 5 mM D-glucose Ringer's solution was aerated 
with a 95 % 0 2, 5 % C02 mix to achieve a pH of 7.4 and an osmolarity of 285 ± 5 mOsms.
Component Concentration (mM)
Na+ 140
K+ 5.2
Ca2+ 1.2
Mg2+ 0.8
c r 119.8
h c o 3' 25
H2P04’ 2.4
D-glucose 5
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Na+ absorption by ENaC was recorded from rat rectal tissue using a protocol 
modified from previously published studies (Inagaki et a l, 2004). Anatomically, 
the rectum of the rat is located in the pelvic cavity, behind the pelvis. 
Surrounding fat and muscle tissues were rem oved. before excision of the 
rectum, which extends approximately 3 cm proximal from the anus. The tissue 
was isolated and transported to the laboratory in ice-cold Ringer's solution 
(Table 2 -3 ). The tissue was microscopically stripped of underlying muscle layers 
and the mucosa was then mounted in Ussing chambers. The tissue was 
equilibrated in Ringer's solution for 25 minutes prior to addition of amiloride 
(10 ^iM) to the apical bath to inhibit ENaC activity.
2 - 3 .2 3  EN aC activ ity
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2 - 4  P r e p a r a t i o n  o f  p r o t e i n  l y s a t e s  f r o m  a n i m a l
t i s s u e
Segments of tissue were isolated from animals that has been treated with 
DMOG or vehicle control. The segments were cleaned of luminal debris using 
ice-cold Ringer's solution (fable 2-3) and were then snap-frozen in liquid 
nitrogen. Tissues were then stored at -80°C until required. Segments of tissue 
were ground to a fine powder in liquid nitrogen using a pestle and mortar kept 
on dry ice. The ground tissue was then weighed and NP-40 lysis buffer (Table 
2-10) was added in a ratio of 1 g tissue: 5 ml lysis buffer. Samples were 
immediately vortexed and incubated on ice for 45 minutes, with intermittent 
vortexing every 10 minutes. Samples were then centrifuged at 10,621 x g for 20 
minutes at 40C. The supernatant was retained and analysed for protein content 
(Section 2-6). Protein content of each sample was then normalised using lysis 
buffer as a diluent. Samples were then separated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Section 2-7), and proteins were 
detected by western blotting.
2 - 5  P r e p a r a t i o n  o f  p r o t e i n  l y s a t e s  f r o m  c e l l s
Ts4 cells were cultured for protein extraction as described in Section 2-2. 
Following treatment, monolayers were washed twice in ice-cold 1 x phosphate 
buffered saline (PBS). Cells were then lysed in situ using Nonidet P40 (NP40) 
lysis buffer containing protease and phosphatase inhibitors (Table 2-10) for 45 
minutes at 2-8°C. Lysed cells were scraped from inserts and were sonicated (3 
x 10 second pulses) to solubilise membrane proteins. Sonicated lysates were 
centrifuged at 15,294 x g for 10 minutes at 4°C. The supernatant was retained 
and analysed for protein content (Section 2-6).
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2 - 6  A n a l y s i s  o f  p r o t e i n  c o n t e n t
The amount of protein in cell and tissue lysates was measured using the Lowry 
method (Lowry et al.f 1951). Using bovine serum albumin (BSA), a standard 
curve was prepared for each set of samples, an example of which is illustrated 
in Figure 2-3. A coefficient of determination (R2), which is a statistical measure 
of how well the regression line approximates the real data points, was created 
from the standards. An R2 of 1.0 indicates that the regression line perfectly fits 
the data. An R2 of > 0.95 was determined to be the cut-off point, and any 
standard curves with R2 values below this were repeated. Protein content was 
estimated from the standard curve using the equation: y = mx + c.
[ B S A ]  (m g / m l)
Figure 2-3 An example of a standard curve for protein determinations. Known 
concentrations of BSA (0-4 mg/ml) were prepared in lysis buffer. BSA standards and 
samples were incubated with Folin reagent for 20 minutes, and their absorbance was 
then measured at 750 nm. Protein concentrations in samples were calculated from the 
standard curve using the equation, y = mx + c.
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2 - 7  W e s t e r n  b l o t t i n g
Protein content of each sample was normalised using lysis buffer as a diluent. 
Samples were mixed with a half volume of 2 x loading buffer (Table 2-11) and 
then heated to either 37°C or 95°C to aid in the protein-denaturing process. 
Samples were then separated by SDS-PAGE using the appropriate percentage of 
acrylamide to separate proteins based on their size (Table 2-12). Separated 
proteins were transferred onto polyvinylidene difluoride (PVDF) membranes 
using a semi-dry electrophoretic transfer apparatus. Membranes were 
routinely blocked with appropriate blocking reagents (Table 2-13) for 1 hour 
with horizontal rotation prior to addition of the appropriate primary antibody 
diluted in the blocking reagent (Table 2-14). Following 2 washes in Tris buffered 
saline with 1 % tween. (TBST), the secondary HRP-linked antibodies, diluted in 
the blocking reagents were routinely added for 1 hour with rotation at room 
temperature. Secondary antibody solutions were then removed and the 
membranes were washed a further 4 times. Immuno-reactive proteins were 
detected by enhanced chemiluminescence (ECL). Table 2-14 shows the transfer 
times used for each protein of interest, the blocking reagent used, the primary 
and secondary antibody concentrations used, and the optimum exposure time 
in ECL or ECL plus reagent.
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Table 2-10 Composition of NP40 lysis buffer: NP40 is a non-ionic, non-denaturing 
detergent used to solubilise membrane proteins (Stephens, 1985). 
Phenylmethanesulfonyl fluoride (PMSF) is a serine and cysteine-protease inhibitor that 
also inhibits acetylcholinesterase, whereas sodium orthovanadate (Na3V04) inhibits 
ATPase, alkaline phosphatase and tyrosine phosphatase (Turini et al., 1969; Huyer et 
al., 1997). Complete mini EDTA-free protease inhibitor tablets from Roche Diagnostics 
inhibit serine and cysteine proteases.
Component Concentration
Nonidet P40 1%
NaCI 150 mM
Trisbase 50 mM
PMSF 0.1 mg/ml
Complete mini EDTAfree protease 1 tablet /  10ml
inhibitor tablet -
Na3V 0 4 1 mM
Table 2 - i l  Composition of 2 x gel loading buffer. DL-Dithiothreitol (DTT) is used in 
sample loading buffers to reduce protein disulfide bonds prior to SDS-PAGE. Glycerol 
(5-10 %) increases the density of a sample so that the sample will layer at the bottom 
of the sample well. It also acts as a protein stabiliser and storage buffer component. 
SDS is a non-ionic detergent used to denature proteins and to confer them with a
negative charge.
Component Concentration
Tris HCI 50 mM
DTT 100 mM
Glycerol 40%
SDS 4 %
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Table 2-12 Polyacrylamide gels. Low percentage gels are recommended for the 
analysis of larger proteins and vice versa. The following protein molecular weights are 
approximate and were transcribed from Fermentas.com.
Recommended poly acrylamide gel (%) Protein molecular weight range (kDa)
8 40 -  250
10 3 0 -2 0 0
12 20 -1 5 0
Table 2-13 Composition of blocking reagents for western blotting. Dried milk (Marvel) 
was used as a blocking reagent for most antibodies employed in these studies. 
However, for some antibodies more complex blocking reagents were used, such as goat 
serum for p-kBa, as previously described (Taylor et al., 1999).
Component
Milk Blocker
Concentration 
Goat Blocker BSA Blocker
Milk 5% - -
Normal Goat serum - 5% -
BSA ■. 3% 5%
1 x TBST + - +
NaCf - 250 mM -
Tween 20 - 0.02 % -
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Table 2-14 Parameters for western blot analysis of proteins. Conditions detailed below were optimised for use of antibodies with T84 cell lysates,
with the exception of mHIF-1 a, which was optimised for lysates from murine intestine.
Protein Protein
size
(kDa)
Lysate
quantity
(Mg)
Incubation
temperature
(°C)
Transfer
time
(mins)
Blocking
reagent
Primary 
antibody 
. dilution
Primary.
antibody
source
Cat.
number
Developing
reagent
Exposure
time
(mins)
ATP Synthase a 55 30 95 60 Milk 1/10,000 BD 612516
+uLU 0.5
ß-actin 42 30 3 7 /9 5 any any 1/20,000 Sigma A5316 ECL+ 1
CFTR 168 40 37 90 Milk 1/800 Upstate 05-583 ECL+ >120
FIH-1 40 30 95 40 Milk 1/1000 Santa Cruz sc-26219 ECL+ 0.5
HIF-la 120 30 37 80 Milk 1/500 BD 610959
+—iuLU 30
KCNN4 40 40 95 60 BSA 1/2000 Sigma P4997 . ECL + 0.5
KCNQ1 75 30 37 80 Milk 1/400 Sigma P5372
+—iuLU 0.5
mHIF-la 120 40 37 80 Goat 1/3000 Calbiochem 400080 ECL+ 0.5
MONaKA 65 30 95 65 Milk 1/3000 Santa Cruz sc-100107
+uLU 1
Na+/K+-ATPase ct] 112 30 37 80 Milk 1/10000 Abeam . ab7671 ECL 2
N a+/K+-ATPase ßi 35-55 30 37 45 Milk 1/3000 Abeam ab8344 ECL+ 2
NKCCl Í30 30 95 80 Milk 1/1000 Santa Cruz * sc-21545 ECL 4
phospho-kBa 40 40 95 40 Goat 1/1000 Upstate 9246 ECL+ 12
PKCÇ 80 30 95 60 Milk 1/2000 Upstate 22080 ECL 0.5
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2 - 8  C e l l  s u r f a c e  b i o t i n y l a t i o n .
The surface expression of Na+/K+-ATPase a i  was analysed by employing a 
biotinylation technique adapted from previously published studies (Del Castillo 
et al., 2005; Liu et al., 2002). Tg4 cells were cultured for protein extraction, as 
described in Section 2-2. Following DMOG (1 mM; 24 hours) treatment, 
monolayers were washed thrice in ice-cold PBS. Biotinylation buffer was 
prepared fresh for each experiment as 1 mg/ml sulfo- N-hydroxysuccinimide 
(NHS)-biotin in PBS. The biotinylation buffer was added to the basolateral side 
of Tg4 monolayers on ice for 15 minutes with horizontal rotation, during which 
time biotin binds to amine groups of extracellular proteins. Due to the short 
half-life of sulfo-NHS-biotin at alkaline pH, the biotinylation buffer was replaced 
with a second fresh aliquot for a further 15 minutes with rotation. The reaction 
was stopped by addition of glycine (100 mM), the amine groups of which bind 
to and quench unbound biotin. Cells were then lysed in NP40 lysis buffer (Table 
2-10) for 30 minutes at 2 -8 °G  Cell lysates were prepared and centrifuged 
(14,000 x g; 6 minutes; 4°C). Protein content of the supernatant was 
determined and 500 |ig of protein was incubated with vertical rotation 
overnight at 2-8°C in the presence of 40 |iL streptavidin-agarose beads, which 
bind strongly to biotin-protein complexes.. The following day the beads were 
centrifuged, washed thrice in lysis buffer to remove any unbound proteins, and 
mixed with 2 x loading buffer (Table 2-11). Samples were heated (55°C; 30 
minutes) and protein complexes were isolated from the beads by centrifuging 
through spin columns. Samples were prepared for SDS-PAGE, but were not 
boiled so as to prevent aggregation of Na7K+-ATPase subunits that can occur 
through binding of the hydrophobic residues within their transmembrane 
domains (Yan et al., 2004; Ura et al., 1996; Donnet et al., 2001): Proteins were 
then separated by SDS-PAGE and Na+/K+-ATPase a i  was detected by western 
blotting (Section 2-7). Densitometric analysis of blots was performed and 
surface expressed Na+/K+-ATPase a i  was calculated by the following equation:
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Where:
x = Na+/K+-ATPase surface expression 
b = biotinylated Na+/K+-ATPase 
a -  p-actin
t -  total Na+/K+-ATPase a a
2 - 9  C o - i m m u n o p r e c i p i t a t i o n
Tg4 monolayers were grown on 4.2 cm2 permeable supports as described in
Section 2-2. Cells were lysed in situ by apical addition of NP40 lysis buffer
(Table 2-10) for 30 minutes at 2-8°C. The cells were scraped from the inserts
and the lysates centrifuged at 15,294 x g for 10 minutes at 4°C. The lysates
were 'pre-cleared' to remove any non-specific antigen-antibody interactions by
incubating the samples with donkey serum for 1 hour at 2-8°C  with vertical
rotation. The lysates were next incubated with protein-G sepharose beads for 1
hour with vertical rotation at 2-8°C to remove serum-bound antigens and any
non-specific antibodies. These bead-lysate suspensions were then centrifuged
at 14,000 x g for 10 minutes at 4°C. The supernatant was retained and further
incubated with the relevant primary antibody for 1 hour at 2-8°C with vertical
rotation. Protein-G bead suspension was then added to the antibody-antigen
solution, and incubated at 2-8°C overnight with vertical rotation. On the
second day the protein-G beads-antibody-protein complexes were added to
spin columns and the supernatant was discarded. The beads were washed
thrice with ice-cold NP40 lysis buffer. Aliquots of these washes were used to
detect protein content to ensure optimal washing conditions, and no protein
was detected even after 1 wash. The bound proteins were finally eluted.
Proteins were then separated by SDS-PAGE and detected by western blotting
(Section 2-7). The concentrations of the antibodies used to immunoprecipitate
(IP) and immunoblot (IB) the protein of interest were determined from
preliminary experiments (Figure 2-4), as were the pre-clearing steps and
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n um ber o f washes em ployed  to  rem ove unbound p ro te ins. Expression o f P- 
actin  was investiga ted  since it  should n o t co-IP w ith  e ith e r Na+/K +-ATPase c ii, 
Na+/K +-ATPase P i, o r MONaKA, and th e re fo re  served as a negative co n tro l fo r  
these studies.
IP: Na+/K*-ATPase a, in p u t
u
L
! Ft1 N a +/ K +- A T P a s e  P j
p A c t in
Figure 2-4 p-actin was absent from anti-Na+/K+-ATPase oti subunit 
immunoprecipitates. T84 cells were grown as monolayers on permeable supports until 
/?te stabilised at plateau levels. cells were lysed and were immunoprecipitated using 
the following dilutions of Na+/K+-ATPase oti antibody: lanes 1 and 2, 1/250; lanes 3 and 
4, 1/500; lanes 5 and 6, 1/1000. The red boxes highlight the optimum antibody 
dilutions for IP identified from these studies. Lane 7 was empty, whereas lanes 8 and 9 
contained the total lysate, or input, p-actin was absent from the anti-Na+/K+-ATPase oti 
antibody immunoprecipitates in Lanes 1-6.
N a +/ K +- 
A T P a s e  ctj
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The protocols for measurement of NKCC1 and NHE activities were adapted from  
those previously published (Heitzmann et at., 2000; Reynolds et at., 2007; 
Beltran et at., 2008; Ramirez et at., 2000). T84 cells were cultured on glass, 
bottom petri dishes (1.54 cm2) until they reached an optimal density of 70 -90  
%. The cells were treated as required and were washed twice with modified 
Krebs solution (37°C) (Table 2-15) prior to incubation with the pH-sensitive dye, 
2'-7’-bis(carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl (BCECF-AM). 
BCECF-AM was re-constituted to a concentration of 5 fiM in pluronic acid, which 
aids in the intracellular transport of the dye. BCECF is a pH-sensitive dye, and 
the acetoxymethyl (AM) ester derivative is membrane permeant, allowing bulk 
loading of cells. Once inside the cell, the lipophilic groups are cleaved by non­
specific esterases, resulting in a charged form with 4 -5  negative charges at 
physiological pH values of approximately 7.4 (Han and Burgess, 2010). Cells 
were loaded with the dye diluted in modified Krebs solution (Table 2-15) for 60 
minutes at 37°C. The dye was removed and the cells were washed twice in 
modified Krebs solution, before being incubated in modified Krebs solution 
alone for a further 15 minutes in the dark at room temperature. The second 
incubation was necessary to facilitate leakage of dye from cells that could 
otherwise disrupt baseline readings during the experiments (Han and Burgess, 
2010). Cells were mounted in a perfusion chamber on an epifluorescence Nikon 
microscope stage. Cells were incubated at room temperature in modified Krebs 
solution (Table 2-15) for several minutes before perfusion with NH4 Krebs 
solution (Table 2-15). The initial rise in pH was due to NH3 uptake via NKCC1 
and the plateau phase acidification that follows is due to uptake of NH4+ by 
NKCC1 (Heitzmann et at., 2000). The acid-load was then performed upon the 
removal of the NH4-Krebs solution and perfusion with NMDG-Krebs solution 
(Table 2-15) for approximately 2 minutes to block the activity of NHEs and thus 
amplify the acidification. Under these conditions, acidification is due to the 
dissociation of H+ from NH4+ to form NH3 + H+. Cells were perfused with
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2 - 1 0  I n t r a c e l l u l a r  p H  m e a s u r e m e n t s
recovery after the acid load is due to the extrusion of H+ by NHEs, and thus
i
represents the activity of NHEs. The ratio of BCECF-AM fluorescence with 
excitation at 505 or 450 nm (F 505/450) was measured every 3 seconds and 
images were captured with an intensified charge-coupled device (CCD) camera 
(ICCD200) and a MetaFluor imaging system. The pH recovery rate is expressed 
in arbitrary units (AU) and calculated as the change from t = 0 to t = 1, 
normalised to the value at t = 0 and represented by the following equation:
modified Krebs solution (Table 2-15) for thè remainder of the experiment. pH
p H  re covery rate (A U )  = ^ s » '440 t 1
AF490/440 t -  0
Where: a value of 1 = no recovery in pH,
a value of > 1 = a recovery in pH,
and a value < 1 = negative recovery in pH.
The solutions used for pH imaging are detailed in Table 2-15 and were adapted 
from previously published studies (Beltran et ol.f 2008).
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Table 2-15 Composition of Krèbs solutions used for intracellular pH measurements.
Once prepared, modified Krebs solutions and NMDG-Krebs solutions were brought to a 
pH of 7.4 and an osmolarity of 285 ± 5 mOsms. NH4-Krebs solution was brought to a pH 
of 8.0 and an osmolarity of 285 ± 5 mOsms.
Compound Concentration (mM)
Modified n h 4 NMDG
KCI 5 5 5
NaCI 141 121 -
CaCI2 1 1 1
MgCI2 0.5 0.5 0.5
k h2p o 4 0.4 0.4 0.4
MgS04 0.4 0.4 0.4
Na2HP04 0.3 0.3 0.3
HEPES Na+ salt 10 10 10
D-glucose 0.6 0.6 0.6
NH4CI - 20 -
NMDG Cl - - 141
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2 - 1 1  R N A  i s o l a t i o n
T84 cells were cultured for RNA extraction as described in Section 2-2 . 
Following treatment, monolayers were washed twice in ice-cold PBS. The cells 
were scraped from the inserts re-suspended in 1 ml ice-cold PBS and then 
centrifuged (600 x g; 3 minutes; 4°C). The supernatant was discarded and the 
cell pellet was snap frozen in liquid nitrogen and stored at -80°C. Total RNA was 
isolated using a Qiagen RNeasy Mini Kit. The RNA was then treated with DNase-
I to digest and remove any genomic DNA contamination. RNA was quantified 
and reverse transcription reactions were performed using the purified and 
quantified RNA to create cDNA. A standard quantity of RNA was used for each 
reaction since it is technically difficult to quantify the resultant single-stranded 
cDNA. This is due to the presence of the single-stranded primers that interfere 
with the quantification of cDNA. RNA quality was determined using 
spectrophotometric methods. RNA has its absorption maximum at 260 nm and 
the ratio of absorbances at 260 and 280 nm was used to assess the purity of an 
RNA preparation, with proteins absorbing strongly at 280 nm. Pure. RNA 
measured in water has an A260/A280 of 1.8-2.0. A secondary measure of RNA 
purity is the A260/230 ratio. Carbohydrates and phenols absorb at 230 nm, and 
thus an A260/230 ratio of 1,8 generally means that there are more of these 
contaminants in the sample. An example of the absorbances of purified RNA is 
shown in Table 2-16.
Table 2-16 Purified total RNA measured by spectrophotometric analysis. RNA quality 
was measured on a Nanodrop 8000. Of interest are the A260/280 and A260/230 ratios 
which are an indication of the purity of the RNA.
Sample ID Cone. Units A260 A280 260/280 260/230
1 394.3 ng/ul 9.858 5.251 1.88 1.55
2 338.3 ng/ul 8.457 4.322 1.96 2.05
3 268.3 ng/ul 6.708 3.404 1,97 0.9
4 289.6 ng/ul 7.239 3.7 1.96 1.42
5 304.3 ng/ul 7.608 3.894 1.95 1.92
6 384.5 ng/ul 9.613 4.977 1.93 2.12
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Several of the primer sets employed in the current studies were obtained from  
previously published research (Table 2-1). Primer 3 primer design software was 
employed for genes for which no primer sequences had been previously 
published. The sequences obtained were cross referenced with the NCBI primer 
design Blast utility to ensure that there were no off-target amplicons. Primers 
were ordered from Invitrogen through Biosciences.
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The Improm II reverse transcriptase kit from Promega was used to perform the
reverse transcription reaction. Once a cDNA library was created, amplification
of the genes of interest was performed by semi-quantitative PCR and was
performed using the primer sets shown in Table 2 -17. It was assumed that
reverse transcription occurred with equal efficiency in each reaction, and thus a
standard volume of the newly synthesised cDNA was used for each PCR
reaction. Amplicons were then separated and analysed by agarose gel
electrophoresis. Negative controls were run in each set of primers for each
experiment. The first negative control was for nucleic acid contamination
(Negative Control). In the Negative Control an equal aliquot of water replaced
RNA, and the RT reaction was run in parallel to the reactions containing RNA.
PCR conditions were then optimised for each set of primers. Variables that
were changed in order to optimise conditions were cycle number, annealing
temperature, and elongation time. PCR was then performed using the
optimised conditions, and samples were separated by agarose gel
electrophoresis. Presence of a signal in the Negative Control indicated nucleic
acid contamination of the reaction. The second control was that for genomic
contamination (GC). In the GC control the reverse transcription reaction was
performed without reverse transcriptase. PCR was then performed and
samples were separated by agarose gel electrophoresis. Presence of a signal in
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the GC control indicated genomic contamination of the reaction. Examples of 
these controls are shown in Figure 2-5.
Figure 2-5 Genomic contamination and RNA contamination controls for PCR. In the
Negative Control an equal aliquot of water replaced the RNA, and the reverse 
transcription reaction was run in parallel to the reactions containing RNA. PCR was 
then performed and samples were separated by agarose gel electrophoresis. Presence 
of signal in the Negative Control indicated nucleic acid contamination of the reaction. 
In the GC control the reverse transcription reaction was performed without reverse 
transcriptase. PCR was then performed and samples were separated by agarose gel 
electrophoresis. Lane 1 contains a cDNA sample of 18SrRNA amplified with 18SrRNA 
primers. Lane 2 is empty. Lanes 3 and 4 were loaded with the Negative Control 
sample, whereas lanes 5 and 6 were loaded with the GC control samples. In the 
experiment shown there were no bands in either the Negative Control or GC lanes, 
indicating no RNA or genomic contamination of the sample.
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Table 2-17 Sequences of primers used to amplify cDNA and quantitatively compare mRNA expression. Primers were designed to contain 
approximately 50 % GC content.
Gene Target Sense primer sequence 5'-3' Antisense primer sequence 5'-3' Amplicon 
size (bp)
Source
18SrRNA GTCCCCCAACTT CTT AG AG CACCTACGGAAACCTTGTTAC 421 -
CFTR CCAT C AG CCCCT CCG AC AG TACTAGCACATGGCAAGGG1 1 1 1C 424 -
FIH-1 ACAGTG CCAG CACCCACA A GCCCACAGTGTCATTGAGCG 188 (Metzen e ta i,  2003)
FXYD3 CCTGGACCATTCCAGGAAAA GGGACI 1 1GAGGCTTGTTGG 238 Primer 3
H IF -la CTCAAAGTCGGACAGCCTCA CCCTGCAGTAGGTTTCTGCT 314 (Zhou etal., 2006)
KCIMN4 GCCGTGCGTGCAGGATTTAGG GCCCGGCACCACGTCACCATAG 403 -
KCNQ1 CCAG GG CCG CGTCTACAA AGAACACCAG CACGATC 272 -
MONaKA CCAGCATCGAAGACTGACAA CCCCAG AT CCT G CTG AATT A 164 Primer 3
Na+/K +-ATPase oci TGTCCAGAATTGCAGGTCTTTG TGCCCGCTTAAGAATAGGTAGGT 77 (Murphy et al., 2004)
Na+/K +-ATPase Pi ACCAATCTTACCATGGACACTGAA ACCAATCTTACCATGGACACTGAA 80 . (Murphy et al., 2004)
NKCC1 ACAATGGCGAATGGTGACT CATGGGGTTACI 1 1 1 IGGTTAC 518 -
PHD1 ACGGGCTCGGGTACGTAAG CCCAGTTCTGATTCAGGTAATAGATACA 87 (Cioffi et al., 2003)
PHD2 G ACCT GAT ACG CCACT GT AACG CCCGGATAACAAGCAACCAT 83 (Cioffi et al., 2003)
PHD3 AACT G AAT CTGCCCT CACT G AAG AG AATT CAG G A ACCG TTACT AAA AT G A 82 (Cioffi et al., 2003)
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Tg4 cells were cultured on glass coverslips until they reached an optimal density 
of 80 %. Cells were treated with DMOG (1 mM; 24 hours) and were then 
washed twice with physiological salt solution (PSS) (Table 2 -18) at 37°C. 
Monolayers were then loaded with the Ca2+ biriding dye Fura-2/AM (5 jiM ) in 
PSS at pH 7.4 for 30 minutes. Fura-2/AM was reconstituted in 0.01 % pluronic 
F-127 plus 0.1 % DMSO. Cells were then washed in PSS and mounted in a 
perfusion chamber on an epifluorescence Nikon microscope stage. Cells were 
incubated in room temperature PSS for 5 minutes before addition of CCh (100 
jiM ). The ratio of Fura-2 fluorescence with excitation at 340 or 380 nm 
(F340/380) was measured every 3 seconds and images were captured with an 
intensified CCD camera (ICCD200) and the MetaFluor imaging system.
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Table 2-18 Composition of physiological salt solution (PSS) for Ca2+ imaging! Once 
prepared the solution was adjusted to pH 7.4.
Compound Concentration (mM)
NaCI 140
KCI 5
CaCI2 1
D-glucose 10
HEPES-trimethylamine 10
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cAMP levels in monolayers were measured using a commercially available 
kit, as per the manufacturers7 Instructions. The kit contains an enzyme-linked 
immunosorbent assay (ELISA) that uses a cAMP antibody to bind either cAMP in 
experimental samples or an alkaline phosphatase molecule bound to cAMP. 
Samples or standards, alkaline phosphatase conjugate, and antibody are 
simultaneously incubated at room temperature in a well coated with secondary 
antibody. Excess reagents are then washed away, substrate is added, and the 
resulting colour generated is spectrophotometrically analysed at 405 nm (Figure
2-6). The colour intensity 1s representative of the amount of alkaline 
phosphatase bound, which is inversely proportional to the amount of cAMP in 
the experimental sample.
Ts4 cells were cultured as described in Section 2 -2 . Following DMOG (1 mM; 24 
hours) treatment, monolayers were stimulated with apical FSK (10 |iM ) for 5 
minutes at 37°C, before being lysed on ice with HCI (100 mM) for 10-30  
minutes. HCI also serves to inhibit endogenous phosphodiesterases, which 
hydrolyse cAMP to AMP, thus interfering with the assay. Monolayers were 
scraped and the lysates centrifuged (15,300 x g; 10 minutes; 4°C). Cell pellets 
were discarded and cAMP levels were detected in supernatants that were 
diluted 1:10 with assay buffer. Since basal levels of cAMP in T ^  cells are low, 
samples were acetylated to increase the sensitivity of the assay. cAMP 
acetylation results in a molecule that more closely mimics that of the 
immunogenic conjugate, i.e. the compound against which the antibody was 
originally raised. Therefore, acetylated cAMP has a higher affinity for the cAMP 
antiserum and raises the sensitivity of the assay. cAMP levels were quantified 
from 2 separate standard curves for acetylated and non-acetylated cAMP. 
Results were expressed as pmol cAMP/mg protein.
2 - 1 5  c A M P  a s s a y
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Y  secondary antibody 
adsorbed to well
Figure 2-1 Schematic representation of the cAMP EIA. Antiserum, sample or standard, 
and cAMP-bound tracer were added simultaneously to the wells of a 96-well plate. 
Wells were washed, substrate was added, and the absorbance of the resulting colour 
was read at 405 nm.
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The lactate dehydrogenase (LDH) assay was performed using a commercially 
available kit. LDH is an enzyme that interconverts pyruvate and lactate with the 
coincidental interconversion of NAD and NADH. LDH is a relatively stable 
enzyme in the cytosol, which is rapidly released from the cell upon damage to 
.the plasma membrane. In the assay NAD gets reduced to NADH by LDH. NADH 
is then used to reduce a tetrazolium dye which forms a coloured compound 
upon reduction. Tetrazolium redox dyes scavenge electrons from  
oxidation/reduction reactions and are intracellularly reduced to brightly 
coloured formazan precipitates.
Tg4 cells were cultured as described in Section 2-2. Following DMOG (1 mM; 24 
hours) treatment, culture medium from control and DMOG-treated cells was 
analysed for LDH release. A separate set of cells was incubated with lysis buffer 
at 37°C for 45 minutes, and the culture medium from these cells served as a 
positive control. Sterile serum-free culture medium was used as a negative 
control, the value of which was subtracted from sample readings. An equal 
volume (40 jal) of apical and basolateral media were combined and placed in the 
wells of a 96-well plate. Assay reagent was added to each well at a volume 
equal to twice that of medium sample used, and the reaction was incubated in 
the dark at room temperature for 25 minutes. The reaction was terminated 
upon the addition of 1 /10 volume of HCI (1 M) (24 |il). The absorbance was 
then measured spectrophotometrically at 490 nm.
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Aminotransferases are enzymes which catalyse the reversible transformation of 
a-keto acids into amino acids by the transfer of amino groups. Alanine 
aminotransferase (ALT) is present in the cytosol of hepatocytes, and increased 
levels of ALT in the serum indicates a reduction in the integrity of hepatocyte 
plasma membrane. Thus, serum ALT was used in these experiments as a 
measure of liver toxicity in mice treated with DMOG. The reaction is based on 
the following principle: ALT in the presence of pyridoxal phosphate transfers 
the amino group of alanine to a-ketoglutarate to form pyruvate and glutamate. 
Pyruvate then enters an LDH-catalysed reaction with NADH to form lactate and 
NAD+. Decreases in absorbance due to the consumption of NADH are measured 
at 340 nm and are proportional to ALT activity in the sample.
A L T
a-ketoglutarate + L-alanine ---------------> L-glutamate + pyruvate
L D H
pyruvate + NADH + H+ ---------------> L-lactate + NAD+
Blood was collected from mice and coagulated at room temperature for 20 
minutes. Samples were then centrifuged (1200 x g; 15 minutes; 4°C), and the 
serum was retained for analysis. The ALT assay was performed using an 
Olympus Analyser and results were expressed as international units per litre 
(IU/L).
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Creatinine is a break-down product of creatine phosphate in muscle, and is 
usually produced at a fairly constant rate by the body. Creatinine is a 
spontaneously formed cyclic derivative of creatine and is filtered out of the 
blood by the kidneys. Deficient kidney filtration causes creatinine blood levels 
to rise. Thus, serum creatinine levels can be used to calculate creatinine 
clearance, which reflects the glomerular filtration rate and which, in turn, is a 
measure of renal function. The reaction is based on the following principle: 
Creatinine forms a yellow-orange coloured compound with picric acid in an 
alkaline medium. The rate of change in absorbance at 520/580 nm is 
proportional to the creatinine concentration in the sample.
creatinine + picric acid --------> creatinine picrate complex
Blood was collected from mice and coagulated at room temperature for 20 
minutes. Samples were then centrifuged (1200 x g; 15 minutes; 4 °C), and the 
serum was retained for analysis. The creatinine assay was performed using an 
Olympus Analyser and results are expressed mM per sample.
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The ATP levels in Tg4 monolayers were measured using a commercially available 
kit as per the manufacturers' instructions. Tg4 cells were cultured as described 
in Section 2 -2 . Following treatment (DMOG 1 mM; 0 -2 4  hours) cells were 
washed twice in ice-cold PBS. Cells cultured on 0.6 cm2 inserts were then lysed 
on ice in 200 jil of hypotonic lysis buffer (Table 2-19), before being frozen in situ 
at -80°C until use. The assay uses recombinant luciferase to catalyze the 
following reaction:
ATP + D-luciferin + 0 2 -> oxyluciferin + AMP + PPi + C02 + light (560 nm)
A 1/200 dilution of samples was made prior to analysis. An equal volume of 
diluted sample and substrate were mixed in a black 96-well plate and 
luminescence was detected. Protein content was also measured (Section 2 -6 ) 
and results were expressed as nmol ATP per jig protein.
Table 2-19 Hypotonic Lysis Buffer
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Component Concentration
Tris base 100 mM
EDTA 2 mM
Acetic acid As required to bring to pH 7.75
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The MSD electro-chemiluminescence technology uses SULFO-TAG™ labels 
which emit light upon electrochemical stimulation at an electrode surface. The 
electrode is located at the base of the well of a 96-well plate. The antibody of 
interest (H IF -la  and HIF-2a) was purchased from MSD pre-adsorbed to the 
base of the well. The wells were blocked with 3 % Blocker A (MSD catalogue 
number R93AA-1) for 1 hour at room temperature. Wells were then washed x 3 
with PBS + 0.05 % tween 20 (PBS-T). Lysate (25 |il) was then added to each well 
for 1 hour at room temperature with horizontal rotation. The wells were once 
again washed x 3 with PBS-T. Detection antibody (1 |ig/ml labelled HIF-2a 
antibody + 10 nM labelled H IF -la  antibody in 1% Blocker A in PBS-T + 0.2 % IgG) 
was then added for 1 hour, and the plate was again washed x 3 in PBS-T. A 
detection buffer (Read buffer) which contains reactants that allow for 
amplification of the signal emitted by the labelled antibody was then added to 
the wells. A voltage was applied and the tags emit light to indicate the presence 
of substrate. The MSD assay platform utilises ruthenium (II) tris-bipyridine-(4- 
methylsulfone) [Ru(bpy)3] that, once conjugated to the analyte, serves as the 
tracer in competitive assays. The Ru(bpy)3-based tag undergoes a rapid redox 
reaction that emits light in the presence of an applied voltage. Only label bound 
in proximity of the electrode is detected and the plates are read at 620 nm in a 
Mesoscale Sector® Imager 2400 (Figure 2-7).
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Figure 2-7 Schematic representation of meso scale discovery (MSD) assay.
A) Antibodies are adsorbed to the electrode, after which substrate binds. Labelled 
antibody is then loaded and light is emitted once an electrical current received from 
the electrode stimulates the tag. B) The format used in these experiments was the 96 
well 4-spot format, from which multiple analytes can be measured from the same well. 
BSA was used as a loading control and standard curves were created with known 
concentrations of recombinant HIF-la and HIF-2a.
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siRNAs are double stranded RNAs with 2 nucleotide-long 3' overhangs. Once 
they enter the cell they form a ribo-nuceloprotein complex called RNA induced 
silencing complex (RISC). RISC separates the double stranded siRNA, by 
argonaute 2 cleaving the sense strand. RISC and the antisense-strand then bind 
to the target sense strand mRNA. Slicer protein, part of RISC, then cleaves the 
target mRNA which is then degraded by the cell (Figure 2-8). siRNAs were 
purchased from Ambion. NeoFX transfection reagent was used to transfect 
cells as per the manufacturer's protocol. The optimum conditions for negative 
control transfection were 30 nM siRNA, using 4 % transfection reagent for 24
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hours. This was assessed by analysis th e  FAM -labelled negative  co n tro l siRNA 
by im m unofluo re scence  as o u tlin e d  in Section 2 -2 3 . The perinuc lea r sta in ing  
ind ica tive  o f successful tra n s fe c tio n  was p resent fo r  24 hours b u t had dissipated  
by 3 days.
SiRNA
Y A Y A Y >
Long dsRNA
V A Y A Y A Y A Y A Y A
VAVAV/
/ / /
Target mRNA recognition 
/
I '  RecydedRISC siRNA
Target mRNA cleavage activated complex
\ / \ / v  i y \ / \ / v
Cleaved sense straod
\ / \ / Y  Sense strand 
‘V / \ / V  Antisense strand 
’ \  /  \  /  \ . Target mRNA
Nature Reviews | Drug Discovery
Figure 2-2 Mechanism of RNA interference and gene expression knockdown. siRNAs 
enter the cell and associate w ith  RISC. The sense-strand o f the siRNA is cleaved, and 
the RISC-siRNA anti-sense strand then binds to and cleaves target mRNA, thus silencing 
the target gene. This figure was adapted from  (Whitehead et ai, 2009).
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There are several methods by which colonic crypts may be isolated (Wildrick et 
a i, 1997). The approach employed in these studies used a combination of Ca2+ 
chelation and mechanical perturbation techniques. Colons from mice and rats 
were transported to the laboratory in ice-cold physiological solution (Table 2-3, 
Table 2-20). Human resected colonic tissue was transported to the lab from the 
Pathology Department at Beaumont hospital. This tissue was removed proximal 
to the resection margin and was determined by the pathologist to be normal. 
Tissues were cleaned of any debris using ice-cold Krebs Heinsleit solution (Table
2-20), and were then cut longitudinally and laterally into several pieces, and 
placed in crypt isolation buffer (Table 2-21) for 20 minutes at room 
temperature. The tissue was then vortexed vigorously for 1 minute to release 
the crypts, after which the tissue pieces were discarded. Crypts were then 
centrifuged at 600 x g at room temperature for 3 minutes. The supernatant was 
removed and the crypts were re-suspended in room temperature Krebs 
Heinsleit solution (Table 2-20), before centrifuging at 600 x g at room 
temperature for a further 3  minutes. The supernatant was again decanted, and 
the isolated crypts were re-suspended in 1 ml of PBS. Crypts were visualised at 
40 x magnification under a light microscope to confirm isolation and integrity 
(Figure 2-9). Isolated crypts were then attached to chamber slides using Cell- 
Tak™ (Section 2-22), washed with PBS, and once again visualised to ensure 
attachment. The crypts were then fixed in 100 % ice-cold methanol for 20 
minutes. Crypts were then stained as per the confocal microscopy protocol 
detailed in Section 2-23.
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Figure 2-9 An isolated rat colonic crypt. Following isolation, colonic crypts were 
visualised using 40 x magnification under a light microscope. The different cell types 
indicated are approximate in location and were adapted from previously published 
studies (Barker et al., 2009).
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Table 2-20 Crypt isolation buffer. This buffer is Ca2+ and Mg2+-free and contains Ca2+ 
chelators that serve to dislodge crypts from their basement membranes. Sorbitol and 
sucrose aid in the sedimentation of the crypts. DTT was used to dissolve mucus and 
was added freshly to the crypt isolation buffer each day as it is unstable in solution. 
The pH was adjusted to 7.4 by the addition of NaOH, and the osmolarity was 380 ± 5 
mOsms.
Component Concentration (mM)
NaCI 96
KCI 1.5
EDTA 27
Sorbitol 55
HEPES free acid 10
Tris base 10
Sucrose 44
DTT 1
Table 2-21 Krebs-Heinsleit solution. The Krebs-Heinsleit solution was adjusted to pH 
7.4 by the addition of HCI and the osmolarity was recorded as 290 ± 5 mOsm.
Component Concentration (mM)
NaCI 140
KCI 5
MgCI2,6H20 1
CaCI2.2H20 2
HEPES free acid 10
Tris base 10
D-glucose 10
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Chamber slides were used to visualise isolated colonic crypts. However, the 
slides had to be first prepared with Cell-Tak™, a protein solution that 
immobilises cells and tissue. Each well of the chamber slide was coated with 
200 [i\ of Cell-Tak™ solution (Table 2-22). Cell-Tak™ was allowed to adhere to 
the slides for at least 40 minutes before being aspirated. Wells were then 
washed thrice with de-ionised water, air dried, and stored at 2-8°C  for 10-14  
days until use.
Table 2-22 Cell-Tak™ preparation. Cell-Tak™ was prepared in order to add 
approximately 50 jig per chamber. The solution was prepared fresh and NaOH was 
only added immediately before use since Cell-Tak™ is unstable at basic pH ranges for
2 - 2 3  S l i d e  p r e p a r a t i o n  w i t h  C e l l - T a k ™
long periods.
Component Quantity (|il)
Cell-Tak™ 6
NaOH (1 M) 3
NaHC03 (0.1 M; pH8) 191
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Laser scanning confocal microscopy is a widely used technique, employed to 
visualise deep within specimens. It allows for the control of depth of field, the 
elimination of out-of-focus information, and the ability to collect serial optical 
sections from specimens whose thickness exceeds the immediate plane of 
focus. Light emitted from the laser passes through a pinhole aperture, and via a 
dichroic mirror, focuses a scanning point on the specimen. The fluorescence of 
the excited probe in the specimen is passed back through the dichroic mirror 
and focussed as a confocal point at the detector pinhole aperture. Any out of 
focus light is omitted from the image. Samples are scanned and pixel 
information is composed to form an image.
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Figure 2-10 Schematic representation of a confocal laser scanning microscope. A
confocal microscope is composed o f multiple laser sources, a scan head w ith  optical 
and electronic components, detectors, and a computer. This image was downloaded 
from  the Carl-Zeiss Inc. website.
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Tg4 cells for confocal imaging were grown on transparent permeable supports as 
described in Section 2 -2 . After treatment cells were washed thrice in ice-cold 
PBS. Both Tg4 cells and isolated colonic crypts (Section 2—21) were fixed on ice 
for 20 minutes with ice-cold methanol (100 %), washed thrice x 5 minutes, and 
permeabilised in Triton X-100 (0.4 %) for 3 minutes at room temperature. After 
a further 3 x 5  minute washes in PBS, non-specific binding was blocked with 10 
% BSA in PBS for 15 minutes at room temperature. Cells or crypts were then 
incubated with the appropriate primary antibodies diluted in 5 % BSA in PBS for 
2 hours at room temperature. Table 2 -23  describes the optimal dilutions of 
antibodies used in these studies. Following 3 x 5  minute washes in PBS, cells or 
crypts were incubated with appropriate Alexa Fluor ®  secondary antibodies, as 
detailed in Table 2 -23, for 30 minutes in the dark at room temperature. Cells 
and crypts were washed a further 3 x 10 minutes in PBS. In the case of T ^  cells, 
membranes were cut out of the hanging inserts and air dried, and mounted 
apical-side-up on glass slides. All preparations were then stained with hard-set 
Vectashield ®  containing DAPI for nuclear detection. A cover-slip was gently 
placed over the sample and the slides were then dried in the dark at room 
temperature for at least 30 minutes, followed by overnight storage at 2-8°C. 
Confocal analyses were carried out using laser scanning microscopes (LSM) 710 
and LSM 510 Zeiss microscopes. Negative controls for each of the Alexa Fluor 
©-conjugated secondary antibodies used were incorporated into the 
experimental design, whereby confocal staining was performed in the absence 
of primary antibody (Figure 2-11). The capture settings of the microscope were 
then calibrated to this negative control, so that any signal could be confirmed to 
be due to binding of the primary antibody, and not due to non-specific binding 
of the secondary antibody, or auto-fluorescence.
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Figure 2-11 Antibody control for immunohistochemical studies. T84 cells were 
cultured as monolayers on permeable supports until Rte stabilised at plateau levels. 
Cells were washed in PBS, fixed in 100 % methanol, permeabilised with Triton X-100, 
and then treated with DAPI and anti-Na+/K+-ATPase ax antibodies, or BSA alone, 
followed by secondary rabbit anti-mouse Alexa Fluor 488. Pseudo-colours were 
assigned to the various fluorophores, with Na+/K+-ATPase a i being represented in 
green and nuclei in blue.
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Table 2-3 Antibodies used for immunohistochemical studies. Conditions detailed below were optimised for use with T84 cells in the current 
studies.
Protein Primary
antibody
source
Incubation
time
(mins)
Dilution
factor
Secondary
antibody
source
Cat
number
Species
reactivity
Excitation 
X (nm)
Emission 
X (nm)
Incubation
time
(mins)
Dilution
factor
F-actin Sigma 120 1/2000 - P1951 - 551 573 - -
FIH-1 Santa Cruz 120 1/1000 Molecular
Probes
A11079 rabbit anti goat 
Alexa 568
576 603 30 1/500
KCNQ1 Sigma 120 1/2000 Molecular
Probes
A1108 goat anti rabbit 
Alexa 488
493 520 30 1/500
MONaKA Santa Cruz 120 1/100 Molecular
Probes
A11079 rabbit anti goat 
Alexa 568
576 603 30 1/500
NaVK+- 
ATPase a i
Abeam 120 1/400 Molecular
Probes
A21204 rabbit anti 
mouse Alexa 
488
493 520 30 1/500
IMa+/K+-
ATPaseßi
Abeam 120 1/400 Molecular
Probes
A21204 rabbit anti 
mouse Alexa 
488
493 520 30 1/500
NKCC1 Santa Cruz 120 1/500 Molecular
Probes
A11078 rabbit anti goat 
Alexa 488
493 520 30 1/500
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All results are expressed as mean ± standard error of the mean (SEM) for a 
series of n experiments. Statistical analyses were performed using GraphPad 
Instat software, by paired t-test for comparisons of paired treatments between
2 groups, unpaired t-tests for comparisons of unpaired treatments between 2 
groups, and one way ANOVA using Tukey multiple comparisons test for 
treatments of 3 groups or more, p values < 0.05 were considered to be 
significant.
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Ambion, TX, USA: DNase I; Neo FX siRNA.
Antibodies: All antibody sources are indicated in Table 2 -14  and Table 2-23.
BD Biosciences, NJ, USA: BD CELL-TAK™.
Calbiochem, Darmstadt, Germany: Bisindolylmaleimide I, BMS-345541.
Cayman, Frankfurt, Germany: DMOG.
FibroGen Inc., CA, USA: FG4497.
GE Healthcare, UK: PVDF membrane.
New England Biolabs, Inc., UK: lOObp DNA ladder, lkb  DNA ladder.
Pierce, IL, USA: Sulfo-NHS-biotin, spin columns.
Promega, Wl, USA: Improm II reverse transcriptase kit; ENLITEN® ATP Assay. 
Qiagen, Hilden, Germany: Qiagen RNeasy Mini Kit, RNA later.
Roche, Basel, Switzerland: Nonidet P40.
Sigma Aldrich, Wicklow, Ireland: All chemicals, kits and reagents, unless 
otherwise stated.
Thermo Scientific, IL, USA: Lab-Tek™ Chamber Slide™ System, HyClone bovine 
calf serum, Restore™ western blot stripping buffer.
Tocris, Bristol, UK: H89,4-phenylbutyrate.
Vector Laboratories, CA, USA: VECTASHIELD HardSet Mounting Medium with 
DAPI.
100
H y d r o x y l a s e s  r e g u l a t e  i n t e s t i n a l  e p i t h e l i a l  i o n
t r a n s p o r t
C h a p t e r  3
101
3 - 1  I n t r o d u c t i o n
One of the primary functions of the intestinal epithelium is to transport 
electrolytes and fluids across the epithelium. Intestinal fluid movement is 
driven by osmotic gradients that are, in turn, established by active ion transport 
across the epithelium. Fluid absorption normally predominates and is promoted 
by Na+ absorption, while fluid secretion is driven by Cl‘ secretion.
All epithelial transport, whether it is absorption or secretion, is highly 
dependent on the availability of 0 2 for generation of cellular energy (Mandel 
and Balaban, 1981; Durand et al., 1988; Carra et al., 2011). HIF hydroxylases are 
the primary intracellular sensors of 0 2 availability (Epstein et al., 2001; Bruick 
and McKnight, 2001; Metzen and Ratcliffe, 2004). They are enzymatically active 
in the presence of sufficient a-ketoglutarate, Fe II, ascorbate, and 0 2 which they 
use to hydroxylate target proteins. The 3 HIF prolyl hydroxylase enzymes 
(PHD1-3) and 1 HIF asparaginyl hydroxylase, known as Factor Inhibiting HIF 
(FIH-1), hydroxylate H IF -la  at prolines 402 and 564 and asparagine 803, 
respectively (Mahon et al., 2001; Lando et al., 2002a). Proline hydroxylation 
targets H IF -la  and HIF-2a for degradation via interaction with pVHL, whereas 
asparagine hydroxylation inhibits the binding of the p300/CBP transcriptional 
co-activator proteins to H IF -la , thus inhibiting HIF-1 transcriptional activity.
Acute hypoxia has been shown to affect intestinal electrogenic transport, and 
although chronic hypobaric hypoxia is known to have whole-body physiological 
implications in those living at higher altitudes, there are few studies relating to 
the effects of chronic hypoxia in the intestine (Saravi et al., 1996; Chinn and 
Hannon, 1969). Recent studies have implicated HIF-1 and HIF hydroxylases as 
being important regulators of intestinal epithelial barrier function. These 
studies have shown that increased HIF activation in the colon was protective 
against the onset of chemically-induced colitis in mouse models (Karhausen et 
a l, 2004; Cummins et al., 2008; Robinson et al., 2008). Our collaborators, and
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others have shown that hydroxylase inhibition was protective against colitis, by 
inhibiting apoptosis associated with the onset of disease, and by activating HIF- 
1 and NFkB pathways (Robinson et al., 2008; Cummins et al., 2008). More 
recently our collaborators have identified that the anti-apoptotic effect of 
hydroxylase inhibition is PHDl-dependent (Tambuwala et al., 2010). Both the 
HIF and NFkB pathways are associated with protective roles in intestinal 
epithelial cells, as shown using conditional intestinal epithelial cell knockout 
mice for H IF-la  and IKKp, respectively (Karhausen et al., 2004; Greten et al., 
2004; Chen et a i, 2003). PHD inhibition has been investigated in other systems 
for exploitation of its therapeutic potential and has been shown: A) to be 
protective against post-ischemic cardiac injury via induction of the unfolded 
protein response (UPR) (Natarajan et al., 2009), B) to delay neuronal cell death 
caused by trophic factor deprivation (Lomb et a i, 2007), and C) to be beneficial 
in the treatment of anaemia (Muchnik and Kaplan, 2011). PHD inhibition has 
also been hypothesised to have beneficial effects in disease conditions, such as 
stroke (Ratan et al,, 2004).
With these previous studies in mind, we hypothesised that HIF-hydroxylases 
might also be useful targets for development of new therapies for intestinal 
disorders associated with dysregulated fluid and electrolyte transport. 
However, little was known of the role that hydroxylases play in the regulation of 
intestinal epithelial transport function.
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3 - 2  A i m
Based on the hypothesis that HIF-hydroxylases may be important regulators of 
intestinal fluid and electrolyte transport, the main aim of this chapter was to  
investigate their potential role in regulating epithelial secretory function in vitro 
and in vivo (Cummins et ai., 2008; Robinson et al., 2008).
More specifically, the primary aims of the chapter were:
1. To determine the effects of hydroxylase inhibition on intestinal epithelial 
Cl' secretion in in vitro and in vivo models.
2. To test the efficacy of hydroxylase inhibitors in preventing diarrhoea in 
vivo.
3. To investigate the effects of hydroxylase inhibition on intestinal 
absorptive processes.
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3 - 3  R e s u l t s
3-3.1 HIF hydroxylase inhibition increases H IF-la  
expression in T8 4 cells
Previous studies have shown that although individual PHD isoforms differ in the 
relative abundance of their mRNA, all 3 show a ubiquitous pattern of expression 
across various tissues. PHD2 has been found to be expressed in all tissues 
examined, PHD1 ¡s expressed most highly in the testes, and PHD3 in the heart 
(Fong and Takeda, 2008; Lieb et al., 2002; Wiliam et al., 2006). As a starting 
point for these studies, expression of the HIF prolyl hydroxylase isoforms in Tg4 
cells was examined. Using primer sequences modified from those previously 
published, mRNA expression of the 3 HIF prolyl hydroxylases (PHD1-3) was 
analysed by semi-quantitative RT-PCR (Demidenko et al., 2005). In agreement
with previous studies in mouse colonic epithelium, all three HIF PHDs were
i
found to be expressed at the mRNA level in T84 cells (Figure 3 -1 ) (Robinson et 
al., 2008).
bp PHD1 PHD2 PHD3
200 
100
Figure 3 -1  PHDs 1-3 are expressed in colonic epithelial cells. T84 cells were grown 
on permeable supports until transepithelial electrical resistance (flte) stabilised at 
plateau levels and total RNA was isolated. Analysis of the expression of the transcripts 
of PHDs 1-3 was performed by semi-quantitative reverse transcription polymerase 
chain reaction (RT-PCR).
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In further studies the expression of PHD isoforms was also analysed following 
treatment of T84 cells with the hydroxylase inhibitor, DMOG. It was found that 
in line with previous findings, although PHD1 mRNA expression was unaltered 
by DMOG treatment (Figure 3 -2  A), both PHD2 (Figure 3 -2  B) and PHD3 (Figure
3 -2  C) mRNA were increased (Epstein et a!., 2001; Berra et a/., 2003; Marxsen et 
o i, 2004). Interestingly, PHD3 appeared to be significantly downregulated at 3 
hours, compared to 1 hour, but remained elevated thereafter.
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Figure 3—2 Hydroxylase inhibition increases PHD2 and PHD3 mRNA expression.
cells were grown on permeable supports until Rte stabilised at plateau levels. Cells 
were treated bilaterally with DMOG (1 mM) for various periods of time indicated 
above. Following this, total RNA was isolated and PHD mRNA expression was analysed 
by semi-quantitative RT-PCR. 18SrRNA was used as a loading control (n = 4-5; ANOVA; 
*p < 0.05, **p < 0.01, ***p  < 0.001 compared to controls; + p < 0.05 compared to 1 
hour time point).
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The expression of the asparaginyl hydroxylase, FIH-1, was also investigated both 
at the mRNA and protein levels. Analysis of FIH-1 mRNA revealed that it is 
expressed in T& cells but, in contrast to PHD2 and PHD3, its expression is not 
altered by hydroxylase inhibition (Figure 3 -3  A). This was confirmed by analysis 
of FIH-1 protein levels in control and DMOG (1 mM; 24 hours)-treated cells 
(Figure 3 -3  B).
A B
DMOGImM (hours)
Figure 3-3 FIH-1 expression in TM cells is not altered by hydroxylase inhibition. A) Tg4
cells were grown on permeable supports until Rte stabilised at plateau levels. Cells 
were treated bilaterally with DMOG (1 mM) for various periods of time indicated in 
panel A, and for 24 hours in panel B. Total RNA was isolated and FIH-1 mRNA 
expression was analysed by semi-quantitative RT-PCR. 18SrRNA was used as a loading 
control (n = 4). B) FIH-1 protein expression was analysed by western blot, p-actin was 
used as a loading control (n = 4).
Given their primary role in regulating cellular H lF -la  levels, it was expected that 
hydroxylase Inhibition would Increase H IF -la  expression in T^ cells. This was 
found to be the case with DMOG treatment increasing H IF -la  levels in a dose-
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dependent manner as measured by western blotting (Figure 3-4). Conversely, 
mRNA expression of HlF-la was significantly reduced after 24 hours treatment 
with DMOG (1 mM).
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Figure 3 -4  Hydroxylase inhibition increases HIF-la protein expression, but decreases 
HIF-la mRNA abundance. cells were grown on permeable supports until Rte 
stabilised at plateau levels. Cells were treated bilaterally with DMOG (1  mM) for 
various periods of time indicated above, after which A) HIF-la mRNA expression was 
measured by semi-quantitative RT-PCR. 18SrRNA was used as a loading control (n = 4; 
ANOVA, *p < 0.05 compared to control). B) HIF-1 a  protein expression was measured 
by western blot, p-actin was used as a loading control (n = 4; ANOVA; *p ^ 0.05, **p < 
0 .0 1  compared to control).
HIF-a levels were also quantified in T84 cells using an MSD assay. Ts4 cells were 
cultured as monolayers on permeable supports, and were treated with DMOG 
(1 mM), at various concentrations, for 24 hours. Proteins were isolated, and HIF 
levels were quantified. Using this approach both HIF-la and HIF-2a proteins 
were found to accumulate in Tg4 cells in response to DMOG-treatment, in a
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concentration-dependent manner. HIF-la protein levels were 560 ± 170 rig/ml 
in control cells, rising to 1194.4 ± 369.5 ng/ml following DMOG treatment, while 
HIF-2a protein levels were 43.4 ± 22.8 ng/ml in control cells, rising to 171.2 ± 
21.5 ng/ml following DMOG treatment (Figure 3-5).
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Figure 3-5 Hydroxylase inhibition by DMOG resulted in accumulation of HIF-la and
HIF-2a in TM cells. T84 cells were grown as monolayers on permeable supports until Rte 
stabilised at plateau levels. Cells were treated bilaterally with various concentrations 
of DMOG in serum free medium for 24 hours, after which proteins were extracted. 
Concentrations of A) HIF-la and B) HIF-2a were extrapolated from the standard curves 
generated for each (n = 4; ANOVA; * p < 0.05 compared to control).
Next, the possibility that DMOG may have toxic effects on T84 cells at the 
concentrations employed was examined. One of the characteristics of colonic 
epithelial cells is that they form electrically 'tight' monolayers. This tightness is 
referred to as the Rte and ¡s generally high in healthy cells but is reduced in 
damaged cells. Thus, Rte can be used as a marker of epithelial cell viability. It 
was found that treatment of T84 cells with DMOG (1 mM) significantly increased 
Rte by 18.4 ± 7.1 % (n = 21 individual filters from 7 independent experiments;
paired t-test; * p < 0.05) indicating that ¡t does not exert toxic effects on the 
cells (Figure 3-6 A). Another, more direct, measure of toxicity is the release of 
lactate dehydrogenase (LDH). In further experiments, cells were treated with 
DMOG (1 mM) for 3 and 24 hours, time points corresponding to when the 
antisecretory actions of the drug are initiated and are maximal, respectively 
(Figure 3-9 A). As seen in Figure 3-6 B, analysis of the culture medium in which 
the cells were grown, revealed that treatment with DMOG (1 mM) for either 3 
or 24 hours did not cause an increase in LDH release compared to untreated 
control cells.
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Figure 3 -6  DMOG does not exert toxic actions on TM cells. T84 cells were grown as 
monolayers on permeable supports until Rte stabilised at plateau levels. A) Cells were 
treated bilaterally with DMOG (1 mM) for 24 hours and subsequent Rte measurements 
were recorded using an epithelial voltohmeter, EVOM2 (n = 21; * p < 0.05). B) Cells 
were treated bilaterally with DMOG (1 mM) for 3 or 24 hours. Lysate cells were 
treated with lysis buffer for a minimum of 30 minutes prior to analysis. An equal 
aliquot of apical and basolateral culture medium was taken, and LDH released into the 
culture medium was detected using a commercially-available assay (Section 2-16) (n =
3-6; ANOVA; * * *  p < 0.001 compared to control).
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3-3.2 Hydroxylase inhibition attenuates Cl' secretion 
across T84  cells
The effects of hydroxylase inhibition on epithelial secretory function were next 
examined. /sc responses to CCh (100 jaM) and FSK (10 jiM) have previously been 
shown to be due to Cl" secretion in T84 cells (Dharmsathaphorn and Pandol,
1986). It was found that treatment of T84 monolayers with DMOG (1 mM) for 
24 hours exerted a profound antisecretory effect on the cells. When 
monolayers were mounted in Ussing chambers responses to the Ca2+- 
dependent agonist, CCh (100 |xM), and the cAMP-dependent agonist, FSK (10 
jliM) were reduced to 20.2 ± 2.6 % (n = 16; p < 0.001) and 38.8 ± 6.7 % (n = 16; p 
< 0.001) of those in control cells, respectively (Figure 3-7).
Time (min)
Figure 3-7 Hydroxylase inhibition attenuates Cl" secretory responses in T^ cells. T84
cells were grown as monolayers on permeable supports until tfte stabilised at plateau 
levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free medium for 24 
hours. Cells were washed, mounted in Ussing chambers and bathed in Ringer's 
solution (Table 2-3). After an initial stabilisation period Cl' secretory responses to CCh 
(100 jliM) and FSK (10 jllM) were measured as changes in /sc.
I l l
Since DMSO was used as a vehicle for DMOG, in initial studies a 0.1 % solution 
of DMSO was routinely added to control cells. However, analysis of cells 
treated with vehicle (0.1 % DMSO) for 24 hours revealed no significant 
difference from those untreated, in secretory responses to CCh (100 jiM) 
(128.99 ± 17.63 %) or FSK (10 ¿iM) (86.79 ± 9.70 %) (n = 3 -4 ).
Ca2+-mediated Cl" secretory responses in T84 cells stimulated by CCh occur 
following G protein-coupled receptor activation. Thus, in order to determine 
whether the antisecretory effect of DMOG on Ca2+-mediated secretory 
responses occur at the level of receptor activation, thapsigargin (2 jaM) was 
employed. Thapsigargin acts by inhibiting Ca2+ ATPase pumps on the 
sarcoplasmic and endoplasmic reticulum, thereby elevating intracellular Ca2+ in 
a receptor-independent fashion (Treiman et a/., 1998). As shown in Figure 3-8, 
thapsigargin-stimulated secretory responses were also significantly attenuated 
in DMOG-treated (1 mM; 24 hours) cells.
Figure 3-8 Hydroxylase inhibition attenuates thapsigargin-stimulated Cl' secretory
responses. T^ cells were grown as monolayers on permeable supports until ffte
stabilised at plateau levels. T84 cells were treated bilaterally with DMOG (1 mM) in
serum-free medium for 24 hours. Cells were then washed, mounted in Ussing
chambers and bathed in Ringer's solution (Table 2-3). After an initial stabilisation.
period, Cl' secretory responses to bilateral addition of thapsigargin (2 fiM) were
measured (n = 3; paired t-test; **  p < 0.01).
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The effects of DMOG (1 m M) on agonist-induced secretory responses were 
time-dependent. When cells were treated with DMOG (1 m M) for several 
different time points, the antisecretory effects of DMOG on CCh (100 ^M ) and 
FSK (10 jxM)-stimulated responses were found to be half maximal at 
approximately 8  hours (Figure 3 -9  A). Effects of DMOG on Cl" secretion were 
also found to be concentration-dependent. When cells were treated with 
DMOG for 24 hours, antisecretory effects were maximal at a concentration of 1 
mM, the highest concentration employed (Figure 3 -9  B).
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Figure 3 -9  The antisecretory effects of hydroxylase inhibition in TM cells are time- 
and concentration-dependent. TM cells were grown as monolayers on permeable 
supports until flte stabilised at plateau levels. A) Cells were treated bilaterally with 
DMOG (1 mM) in serum-free medium for various time points. Cells were then washed, 
mounted in Ussing chambers and bathed in Ringer's solution (Table 2-3). After an 
initial stabilisation period, CP secretory responses to CCh (100 jljlM )  and FSK (10 jj.M) 
were recorded (n = 3-8; ANOVA; * p < 0.05, **  p < 0.01, * * *  p < 0.001 compared to 
control). B) Cells were treated bilaterally with various concentrations of DMOG in 
serum-free medium for 24 hours, and subsequent Cl' secretory responses to CCh (100 
#iM) and FSK (10 jaM) were measured (n = 8 ; ANOVA; * p < 0.05, * * *  p < 0.001 
compared to control).
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3-3.3 DMOG does not alter secretagogue-induced 
generation of second messengers in Tg4 cells
There are many potential mechanisms by which DMOG could exert its 
antisecretory effects on the colonic epithelium. One possibility is that it alters 
the production of pro-secretory second messengers in the cell. Secretory 
responses in epithelial cells are stimulated by endogenous agonists, such as ACh 
and VIP, which act by increasing the abundance of intracellular second 
messengers, such as Ca2+ and cAMP. These effects can be mimicked by CCh and 
FSK, respectively. However, analysis of both basal and stimulated second 
messenger levels revealed that there were no alterations in the levels of either 
Ca2+ (Figure 3 -10) or cAMP (Figure 3 -11) in cells that were treated with DMOG 
(1 mM; 24 hours) compared to control cells.
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Figure 3-1 Hydroxylase inhibition does not alter CCh-stimulated Ca2+ mobilisation in 
Tm monolayers. T84 cells were cultured on glass cover slips and were treated with 
DMOG (1 mM) for 24 hours. Cells were then washed and loaded with the Ca2+-sensitive 
dye Fura-2 AM. A) Ca2+ mobilisation was analysed by recording Fura-2 fluorescence at 
intervals of 3 seconds. Data are expressed as mean fluorescence ratio at 340 and 380 
nm. B) Maximal changes in intracellular Ca2+ following stimulation with CCh (100 jiM) 
were calculated as the maximal change in fluorescence ratio before and after agonist 
addition (n = 3).
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Figure 3-11 Intracellular cAMP levels are unaltered by hydroxylase inhibition.
cells were grown as monolayers on permeable supports until Rte stabilised at plateau 
levels. Cells were then treated bilaterally with DMOG (1 mM) for 24 hours. Cells were 
stimulated with apical FSK (10 jiM) for 5 minutes, after which they were lysed in HCI 
(100 mM). cAMP levels were measured using a commercially available kit (Section 2- 
15). A) A standard curve was prepared for low concentrations of cAMP: B) A standard 
curve was prepared for higher concentrations of cAMP. C) Values are expressed as 
pmol cAMP per mg protein (n = 5).
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3-3.4 Hydroxylase inhibition attenuates Cl' secretion in ex 
vivo mouse colon and ameliorates allergic diarrhoea in 
vivo
Having shown that hydroxylase inhibition with DMOG exerts antisecretory 
actions in an in v itro  culture model, these studies were next extended to a more 
physiological setting. A mouse model (C57BL/6) was chosen since this model 
has been successfully used by other researchers investigating the effects of HIF 
activation on the development of colitis. Mice were treated with DMOG (320 
mg/kg) by IP injection. 24 hours later, the animals were sacrificed and their 
colons removed, stripped of underlying muscle layers, and mounted in Ussing 
chambers. Tissues were bathed in Ringer's solution (Table 2-3) and monitored 
for changes in /sc. Each preparation was treated with apical amiloride (100 |iM) 
prior to addition of secretagogues to prevent any contribution of ENaC to the 
observed (sc responses. Responses to both CCh (100 jiM) and FSK (10 jxM) were 
significantly attenuated in DMOG-treated tissues (Figure 3-12). It is known that 
CFTR can conduct both Cl“ and HC03", therefore at the end of each experiment 
basolateral bumetanide (100 juM) was added to determine the Cl'-dependent 
portion of the lsc response. Following inhibition of NKCC1, the remaining 
current was assumed to be predominantly apical HC03" secretion, as previously 
reported in murine duodenum and rat colon (Clarke et a/., 2001; Schultheiss e t  
a l., 1998).
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Figure 3-12 Hydroxylase inhibition exerts antisecretory effects in ex  vivo mouse 
colon. Mice were treated with DMOG (320 mg/kg) or PBS by IP injection. After 24 
hours, mice were sacrificed by cervical dislocation, and their colons removed. A) 
Colons were stripped of their muscularis layers by microdissection, mounted in Ussing 
chambers, and bathed in Ringer's solution (Table 2-3). Following a period of 
stabilisation, the epithelial sodium channel blocker, amiloride (100 jiM), was added to 
the apical bath. Cl‘ secretory responses were then stimulated with CCh (100 jiM) and 
FSK (10 jlaM ). Bumetanide (100 ¿iM) was added basolaterally at the end of each 
(experiment to confirm responses were largely due to Cl" secretion. B) Maximal 
responses to CCh and FSK were plotted as fold change over control A /sc responses (n = 
11; paired t-tests; * p < 0.05, *** p < 0.001).
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Having shown that hydroxylase inhibition exerts antisecretory effects in mouse 
colon, it was next investigated whether its effects could be translated into a 
pathophysiological model of diarrhoea. For these experiments an orally- 
induced allergic diarrhoea model was chosen, as was previously described 
(Brandt e t  a l ,  2003). Mice were sensitised with ovalbumin (OVA) by IP injection 
twice, 2 weeks apart Two weeks later, the animals were challenged orally with 
OVA 3 times per week and were monitored for stool output for 1 hour following 
oral administrations (Figure 3-13 A). Mice with profuse watery stool were 
recorded as being diarrhoea-positive. Mice were treated with IP DMOG (160 
mg/kg) or PBS alone, 24 hours before each challenge with OVA. As seen in 
Figure 3-13 B, mice treated with DMOG had normal faecal pellet formation in 
the colon. The occurrence of diarrhoea is shown graphically in Figure 3-13 C. It 
was noted that after just 4 allergen challenges 100 % of mice sensitised to 
ovalbumin were diarrhoea-positive, whereas in those pretreated with DMOG, 
only 20 % displayed symptoms of diarrhoea.
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Figure 3 -1 3  H ydroxylase in h ib it io n  am e lio ra tes a lle rgen-induced d ia rrhoea  in a 
m ouse m odel. Ovalbum in-sensitised m ice w ere p re -trea ted  w ith  in trape ritonea l 
DMOG (160 m g/kg) and a fte r 24 hours w ere challenged by ora l gavage w ith  OVA (50 
m g/m ouse). M ice w ere  trea ted  w ith  DMOG and OVA in th is  w ay every 2 days. A) M ice  
dem onstra ting  profuse diarrhoea w ith in  1 hour a fte r OVA challenge w ere  recorded as 
being d iarrhoea-positive  (n = 10). B) Colons o f the  m ice w ere  isolated and analysed fo r  
the  presence o f faecal pe lle t fo rm a tion , indicated by the  arrow s. C) Graphical 
rep resen ta tion  o f  the  incidence o f  d iarrhoea in the  m ice (n = 10).
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The possibility that DMOG might exert toxic effects in the mice was also 
addressed by measuring serum markers of liver and kidney toxicity/ALT and 
creatinine, respectively. From the results of this analysis shown in Figure 3-14, 
it was clear that DMOG (160 mg/kg) did not exert toxic effects in either the liver 
or kidneys. This data was in concordance with our in v itro  LDH data (c.f. Figure
3-6 B) showing that DMOG did not cause an increase in release of LDH from 
cultured colonic epithelial cells.
A B
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Figure 3— 14 DMOG d id  n o t e xe rt liv e r o r k idney to x ic ity  in m ice. M ice w ere  trea ted  by 
IP in jection  w ith  DMOG (160 m g/kg) fo r  24 hours. Blood was collected from  the  mice 
and was analysed fo r  serum  m arkers o f kidney and liver to x ic ity  (Sections 2 -1 7  and 2 -  
18). A) Renal tox ic ity  was assessed by m easurem ent o f serum  creatin ine  levels (n = 5). 
B) Hepatic to x ic ity  was assessed by m easurem ent o f serum  ALT levels and is expressed 
as in te rna tiona l units per litre  (IU/L) (n = 5).
121
In the ex  vivo  studies, mice were administered DMC)G.(320 mg/kg) by I.P 
injection using a dose that had previously been reported to increase the levels 
of mouse H IF-la  (m HIF-la) in the intestine (Cummins e t  a i ,  2008). However, 
we also carried out experiments to ensure that, at this concentration, DMOG 
was inhibiting hydroxylases, and in turn stabilising m HIF-la. Indeed, it was 
found that there was robust accumulation of m HIF-la following treatment with 
DMOG. The m HIF-la antibody was raised in mice to detect human HIF-la, and 
is cross reactive with mouse HIF-la. It has been used previously to detect 
m HIF-la (Cummins e t  a i ,  2008). As a control for non-specific binding of the 
mouse HRP-linked secondary antibody, 2 lanes of whole tissue lysate were also 
run but were not exposed to primary H IF-la antibody. It is clear from the blot 
that under the same exposure, there is little if any m HIF-la present in these 
lanes (Figure 3-15).
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Figure 3-15 Hydroxylase inhibition stimulates accumulation of HIF-la protein in 
mouse colonic tissue. Mice were treated with DMOG (320 mg/kg) by IP injection for 
24 hours. Intestinal tissue was harvested and lysed. Proteins were then resolved by 
SDS-PAGE and probed with antibodies to mHIF-la. The right-most 2 lanes were not 
treated with primary antibody. (3-actin was used as a loading control (n = 4; paired t- 
test; * p <0.05).
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3-3.5 Hydroxylase inhibition attenuates ENaC activity in T84 
cells
Having shown that hydroxylase inhibition exerts antisecretory actions on colonic 
epithelial cells, its effects on absorptive processes were next examined. cells 
are a model of Cl' secretion and do not express functional ENaC. However, a 
recent study (lordache and Duszyk, 2007) has shown that short chain fatty acids 
can cause T84 cells to change their phenotype to that of an absorptive 
enterocyte. By treating the cells with 4-phenyl butyrate (4-PBA) (5 mM), T84 
cells develop an amiloride-sensitive current. As shown in Figure 3-16, 
treatment of T^  cells with 4-PBA (5 mM) for 24 hours reliably induced an 
amiloride-sensitive current of 20.8 ± 0.5 nA/cm2. Treatment of the cells with 
DMOG (1 mM; 24 hours) to inhibit hydroxylase activity significantly reduced this
4-PBA-lnduced basal current (n = 5; * p < 0.05).
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Figure 3-16 Hydroxylase inhibition attenuates ENaC-mediated Na+ absorption in cells. T&
cells were treated with 4-PBA (5 mM; 24 hours) to  induce an amiloride-sensitive current. Cells 
were treated bilaterally with DMOG (1 mM; 24 hours) to  inhibit hydroxylase activity. A) Cells 
were washed, mounted in Ussing chambers and amiloride (10 jaM) was added to the apical 
compartment to inhibit Na+ absorption through ENaC (n = 5; paired t  tests; * p < 0.0S compared 
to control values of the same time point). B) Maximal amiloride-inhibited current was plotted as 
A /sc. (n = 5; paired t  test;** p < 0.01).
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3-3.6 Hydroxylase inhibition attenuates ENaC activity in 
rat rectal tissue
Electrogenic Na* absorption through luminal ENaC is confined to the surface
epithelium of the distal colon and it has been shown to contribute more to 
absorptive processes in humans and rats than it does in mice (Kunzelmann and 
Mall, 2002). Indeed, in C57BL/6 mice there was no detectable amiloride- 
sensitive current across stripped colonic tissue. Furthermore, pretreatment 
with DMOG (320 mg/kg) by IP injection for 24 hours did not alter the lack of 
sensitivity o f  these tissues to amiloride (Figure 3-17). The basal current shown 
in Figure 3-17 is composed of Cl" and HC03 secretion, and was significantly 
reduced in DMOG-treated tissues.
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Figure 3-17 Hydroxylase inhibition did not induce or reduce an amiloride-sensitive 
current in the mouse colon. Mice were treated with DMOG (320 mg/kg) by IP injection 
for 24 hours. The colons were removed, washed in Ringer's solution, and mounted in 
Ussing chambers. Amiloride (10 |iM) was added to the apical bath to inhibit Na+ 
absorption through ENaC (n = 3-5).
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In order to investigate the effects of hydroxylase inhibition on electrogenic Na+ 
absorption in intact intestinal tissue, the rectum of male Sprague Dawley rats 
was employed. It was found that under control conditions, muscle-stripped 
sections of rat rectum exhibited a basal current of 40.79 ± 6.61 jjA/cm2. As 
previously reported this current was approximately 58 % sensitive to amiloride, 
indicating a large component-is due to Na+ absorption through ENaC (Inagaki e t  
a l ,  2004). In rats treated with DMOG (40 mg/kg by I.P injection, a 
concentration previously employed (Zhao e t  a/., 2010)) for 24 hours the 
amiloride-sensitive current was significantly lower, being 67 ± 13.3 % of that of 
controls (n = 6; ** p < 0.01) (Figure 3-18).
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Figure 3-18. Hydroxylase inhibition attenuates Na* absorption through ENaC in rat 
rectum. Rats were treated by IP injection with DMOG (40 mg/kg) for 24 hours. A) Rats 
were sacrificed, their rectum removed, stripped of underlying muscle layers, and 
mounted in Ussing chambers for measurements of /sc. After an initial stabilisation 
period, amiloride (10 jiM) was added to the apical bath to inhibit Na+ absorption 
through ENaC (n = 6). B) Maximal amiloride-sensitive current was plotted as A /sc (n = 
6; paired t test;** p < 0.01).
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3-3.7 Jejunal SGLT-1 activity is unaltered by DMOG
SGLT-1 is an important transporter in the context of the jejunum (Wright e t  at., 
2011). It co-transports glucose and Na+ from the lumen of the Gl tract, with 
water following due to the osmotic gradients created. Mice were treated with 
DMOG (320 mg/kg by IP injection) for 24 hours, after which they were sacrificed 
arid unstripped segments of jejunum were mounted in Ussing chambers. 
Jejunal tissues were then bathed mucosally in a mannitol-Ringer's solution 
(Table 2-8) and serosally in D-glucose-Ringer's solution (Table 2-9) in order to 
maintain apical SGLT-1 in a quiescent state. As shown in Figure 3-19 A, 
bumetanide (100 jxM) was added to the serosal bath to inhibit Cl" secretion into 
the apical compartment and thus prevent its contribution to the observed 
currents. SGLT-1 activity was stimulated by the mucosal addition of D-glucose 
(25 mM) and the SGLT-1 specific inhibitor, phloridzin (1 mM), was added after 
the D-glucose-stimulated current had peaked. Treatment of mice with DMOG 
did not alter the phloridzin-sensitive D-glucose-stimulated influx of Na+ from the 
luminal compartment when compared to control tissues (Figure 3-19 B).
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Figure 3-19 Jejunal SGLT-1 activity is unaltered by hydroxylase inhibition. A) Mice 
were treated with DMOG (320 mg/kg) by IP injection. 24 hours later, mice were 
sacrificed and their small intestine was removed. A) The jejunum was isolated, opened 
along the mesenteric boarder, rinsed in ice-cold mannitol-Ringer's solution (Table 2-8), 
and segments were mounted in Ussing chambers. The apical bath contained 5 mM 
mannitol-Ringer's solution, whereas the basolateral compartment contained 5 mM D- 
glucose-Ringer's (Table 2-9). The NKCC1 inhibitor, bumetanide (100 jiM), was added 
to the basolateral bath, and SGLT-1 was stimulated by the addition of D-glucose 
apically (25 mM). SGLT-1 transport activity was inhibited by apical addition of 
phloridzin (1 mM). B) Maximal phloridzin-sensitive currents in control and DMOG- 
treated mice were plotted as A /sc (n = 6).
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3-3.8 Hydroxylase inhibition attenuates NHE activity in T84 
cells
Having already investigated the activity of 2 of the primary Na+ transporters, our 
attention next turned to the NHEs. IMHE3 is responsible for the majority of Na+ 
absorption in the intestine (Zachos e t  o i ,  2005), therefore we wished to 
investigate the effect of hydroxylase inhibition on NHE activity in T84 cells. 
However, recent studies have shown that cells do not express NHE3, but 
rather, they express NHE1 and NHE4 which are responsible for the maintenance 
of intracellular pH (Beltran e t  a l ,  2008). We found that hydroxylase inhibition 
attenuated NHE activity in T84 cells, as demonstrated by their inability to return 
to steady-state pH following an acid-load (Figure 3-20).
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Figure 3-20 Hydroxylase inhibition attenuates NHE activity in T84 cells. T84 cells 
cultured on glass cover slips were treated with DMOG (1 mM; 24 hours). Cells were 
then washed and loaded with the pH-sensitive dye, BCECF/AM (5 juM; 60 minutes). A) 
Intracellular pH was analysed by recording BCECF fluorescence at intervals of 3 
seconds. Cells were perfused with modified Krebs, followed by NH4 Krebs, followed by 
NMDG-Cr Krebs (indicated by N), and finally returned to modified Krebs for the 
duration of the experiment (Table 2-15). Data are expressed as mean fluorescence 
ratio at 490 and 440 nm. B) NHE activity was recorded as the rate of change in pH back 
to steady state following an acid load which occurs following removal of NH4 (n = 10; 
paired t-test; * *  p < 0.01 com pared  to  contro l) (c.f. Section  2-10). As a positive 
control, cells were treated with EIPA (25 jjJVI) to inhibit NHE activity (n = 2).
Having shown that hydroxylase inhibition attenuates NHE activity, we next
wished to investigate whether NHE inhibition, using the NHE-specific inhibitor
EIPA, alters epithelial secretory responses. Since chronic exposure to
hydroxylase inhibitors exerts antisecretory effects in T84 cells, we hypothesised
that chronic exposure to the NHE inhibitor, EIPA, might have similar effects.
However, we found that Cl" secretory responses from T84 cells treated with EIPA
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(25 |j,M; 24 hours; bilateral) alone were unaltered compared to controls (data 
not shown). Similarly, addition of EIPA (25 |iM) bilaterally to control T84 cells in 
Ussing chambers was without effect on Cl" secretion. However, co-treatment of 
T84 cells with EIPA (25 |aM; 24 hours; bilateral) and DMOG (1 mM; 24 hours; 
bilateral), reversed the antisecretory effects of the hydroxylase inhibitor (Figure
3-21). This effect was not seen upon addition of . EIPA (25 jaM) to DMOG- 
treated cells in Ussing chambers.
B
EIPA (25|iM) 
Acute 24 hours
EIPA (25jiM) 
Acute 24 hours
Figure 3-21 Chronic, but not acute, treatment of Tg4 cells with EIPA reversed the 
antisecretory effects of DMOG. T84 cells were grown as monolayers on permeable 
supports until /?te stabilised at plateau levels. Cells were treated bilaterally with DMOG 
(1 mM; 24 hours) in serum-free medium in the presence or absence of EIPA (25 fiM; 24 
hours). Cells were washed, mounted in Ussing chambers and bathed in Ringer's 
solution (Table 2-3). After an initial stabilisation period EIPA was added acutely to 
designated chambers. CC secretory responses to A) FSK (10 |iM) and B) CCh (100 |iM) 
were measured (n = 3; ANOVA; ** p < 0.01, *** p < 0.001 compared to DMOG-only).
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3 - 4  D i s c u s s i o n
In the present study we confirmed the expression of the HIF prolyl and 
asparaginyl hydroxylases in the Tg4 colonic epithelial cell model. Previous 
studies found that the expression of the HIF hydroxylases was regulated by 
induction of hypoxia, while in this study it was found that the expression of the 
hydroxylases was regulated by hydroxylase inhibitors, such as DMOG (Epstein e t  
aL , 2001; Berra e t  aL , 2003; Marxsen e t  aL , 2004). While hydroxylase inhibition 
by DMOG and hypoxia are not one in the same, previous studies in a breast 
cancer cell line, MCF-7, have found there to be striking concordance between 
patterns of gene expression induced by hypoxia and by DMOG (Elvidge e t  aL,
2006). While many of these genes are HIF-1 or HIF-2-dependent, not all of the 
hypoxia or DMOG-regulated genes were targets of HIF, highlighting the 
importance of non-HIF targets of hydroxylases (Elvidge e t  a !., 2006). More 
recent studies have highlighted the sensitivity of the hydroxylases to varying 
levels of hypoxia versus hydroxylase inhibitors (Tian e t  aL , 2011b). For example, 
while proline hydroxylation is inhibited by 1 % hypoxia, asparagine 
hydroxylation is relatively insensitive to 1 % hypoxia, but is almost completely 
inhibited by DMOG. In agreement with other studies we found that hydroxylase 
inhibition caused a robust accumulation of H IF-la  and HIF-2a (Asikainen e t  aL,
2005). It was noted that H IF-la  mRNA expression was significantly reduced 
following treatment with DMOG. Interestingly, it has recently been shown by 
our collaborator's group that a negative feedback loop exists in which 
microRNA-155 induced by H IF-la  transcriptionally represses H IF-la  expression, 
thereby quenching the response (Bruning e t  aL , 2011). While the mRNA 
expression of PHD1 remained unaltered, PHD2 and PHD3 were transcriptionally 
upregulated in response to hydroxylase inhibition/ potentially through the 
actions of HIF-1, as previously demonstrated (Marxsen e t  aL , 2004). 
Interestingly, PHD3 mRNA expression which was upregulated 1 hour after 
treatment with DMOG, was significantly reduced by 3 hours. This drop in PHD3 
mRNA is coincident with the onset of the antisecretory effect of DMOG. With
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this in mind one could speculate that PHD3 mediates the antisecretory effect of 
hydroxylase inhibition, with the discrepancy in the time course for mRNA 
expression and antisecretory actions being explained by the time it takes for 
PHD3 protein translation to occur. Further studies would be required to 
determine if this is indeed the case. FIH-1 expression remained unaltered at 
both the protein and mRNA levels, which was in accordance with previous 
studies showing FIH-1 is not regulated by hypoxia in human kidney cells 
(Schodel e t  aL , 2010).
The primary finding of this chapter is that hydroxylase inhibition by DMOG 
attenuates colonic epithelial responses to secretagogues (Figure 3-22). Upon 
stimulation with either the Ca2+ dependent secretagogue, CCh, or the cAMP 
dependent secretagogue, FSK, secretory responses were found to be 
significantly attenuated in DMOG-treated monolayers. The antisecretory effect 
of hydroxylase inhibition was recapitulated by the use of a more specific and 
potent inhibitor of PHDs, FG-4497, and these results are discussed in more 
detail in Chapter 4 of this thesis. The antisecretory effect of hydroxylase 
inhibition was slow in onset, occurring over several hours, and being half- 
maximal by approximately 8 hours after treatment. This slow onset of response 
suggests that alterations likely occur at the level of protein expression. The 
effects of hydroxylase inhibition by DMOG were also concentration-dependent, 
occurring at concentrations previously reported to inhibit PHDs and FIH-1 in 
other systems (Cummins e t  aL, 2008; Floyd e t  aL , 2007; Lando e t  aL , 2002b). 
Stabilisation of H IF-la by hydroxylase inhibition temporally preceded the 
antisecretory effects, suggesting that DMOG may be exerting its antisecretory 
effects through altering H IF-la expression. In support of this idea HIF-1 has 
previously been shown to transcriptionally down-regulate several of the 
transport proteins involved in the Cl' secretory pathway (Zheng e t  aL , 2009; Ibla 
e t  aL , 2006). Acriflavine, an inhibitor of H IF-la, was employed to investigate 
the role of H IF-la in mediating the actions of DMOG, however acriflavine (5 
|iM) was found to be ineffective in attenuating the induction of the HIF-1 target,
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PHD2. Acriflavine also had no effect on the antisecretory actions of DMOG. 
Thus, further studies would be required to determine if HIF-i mediates the 
antisecretory effects of DMOG. Such studies could include the use of siRNAs to 
knock-down expression of HIF-la.
Importantly, the anti-secretory effects of DMOG were not associated with 
cytotoxic actions in T84 cells, as evidenced by analysis of LDH release. In fact, 
Rte, a reliable measure of epithelial integrity was significantly increased 
following treatment of the cells with DMOG. This is supported by previous work 
showing that DMOG can exert anti-apoptotic effects in murine colonic epithelial 
cells, and therefore the drug may promote intestinal barrier function in this way 
(Cummins e t  ah , 2008). More recently our collaborators have identified that the 
mechanism by which PHD inhibition antagonises apoptosis is PHDl-dependent. 
In fact, histological analysis of the intestine of PHD1 knock-out mice showed an 
increase in epithelial cell density, which could have implications for intestinal 
transport function (Tambuwala e t  a/., 2010).
Pro-secretory second messenger production is stimulated by agonists, such as 
ACh and VIP, which bind to their cognate receptors, thereby raising levels of 
intracellular Ca2+ or cAMP, respectively. The current studies show that both 
Ca2+- and cAMP-dependent Cl" secretory responses are attenuated by 
hydroxylase inhibition. Reports of the effects of DMOG on intracellular second 
messenger levels are lacking, however, previous research in renal carcinoma 
cells showed that increased intracellular Ca2+ contributes to H IF-la  degradation, 
by a mechanism involving the calpain system (Zhou e t  a i ,  2006). In the present 
study, DMOG caused a robust accumulation of H IF-la, suggesting that Ca2+ 
levels were unaltered, which was indeed the case. In fact, neither agonist- 
induced release of intracellular Ca2+, nor basal or stimulated levels of cAMP, 
were altered by treatment of T^  cells with DMOG. Furthermore, stimulation of 
cells with thapsigargin, an agent which increases intracellular Ca2+ levels in a
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receptor-independent fashion, indicated that thé antisecretory effect of DMOG 
on Ca2+-stimulated responses occurs downstream of receptor activation.
Although T84 cells are an excellent tool for investigating mechanisms that 
regulate epithelial secretory function, they are ultimately a reductionist model, 
and findings may not be entirely translatable to in vivo  situations. Thus, 
whether hydroxylase inhibition was also efficacious in inhibiting Cl" secretion in  
vivo  was investigated. A mouse model (C57BL/6) was employed since this 
model has been successfully used by other researchers for studying the effects 
of HIF-1 activation on the development of intestinal disease (Cummins e t  a i ,  
2008; Robinson e t  a i ,  2008; Karhausen e t  a i ,  2004). We found that similar to 
its effects in cultured colonic epithelial cells in v itro , hydroxylase inhibition in 
mice significantly reduced Cl" secretory responses to both CCh and FSK across ex  
vivo  colonic epithelium. The experiments carried out in mice were performed 
using a dose of DMOG previously reported to stabilise H IF-la  and to ameliorate 
colitis in mice, and which was found to increase cellular H IF-la  levels in the 
present study (Cummins e t  a i., 2008). Interestingly, there also appeared to be 
m HIF-la present in control tissues, although this may not altogether be 
unexpected given the high turnover rate of H IF-la  and the presence of mild 
hypoxia in healthy colonic epithelium (Taylor and Colgan, 2007). However, the 
low levels of H IF-la present suggest that it may not have a significant 
physiological role. Translation of these ex  vivo  findings into a 
pathophysiological model of diarrhoea was carried out using an allergic model 
of diarrhoea (Brandt e t  a i., 2003). Allergic diarrhoeas are associated with 
significant changes in /sc and Cl" secretion, and previous research has shown that 
OVA-induced diarrhoea is predominantly due to mast-cell stimulation of Cl" 
secretion (Harari et a i ,  1987; Perdue e t  a i., 1991). A lower dose of DMOG was 
required in these experiments based on experiments performed by our 
collaborators, which identified 160 mg/kg DMOG as being efficacious in 
ameliorating diarrhoeal disease. Strikingly, only 20 % o f  O V A -sen s itised  animals 
that were pre-treated with DMOG and then exposed to oral OVA were
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diarrhoea-positive after 4 allergen challenges, whereas 100 % of animals treated 
with OVA-alone had diarrhoea. These data suggest that hydroxylase inhibition 
prevents secretory diarrhoea in vivo  and could be of use in treatment of other 
diarrhoeal diseases, such as those associated with IBD, diarrhoea-predominant 
IBS, iatrogenic diarrhoeas such as those induced by chemotherapy, microscopic 
colitis, and bile acid malabsorption (Carter e t  a l., 2004; Maroun e t  o f.t 2007; 
Oelkers et a/., 1997; Hofmann, 2009).
The intestine is predominantly an absorptive tissue, therefore investigation of 
potential therapies for diarrhoeal disease must include examination of their 
effects on absorptive processes. Fluid absorption follows Na+ absorption by 
osmosis, therefore we first examined potential effects of DMOG on electrogenic 
Na+ absorption. Since no cell culture models for ENaC-mediated absorption in 
the intestine exist, we adopted a previously employed approach (lordache and 
Duszyk, 2007), where treatment of T84 colonic epithelial cells with the short 
chain fatty acid 4-PBA induces the expression of an amiloride-sensitive current. 
Following induction of active ENaC in T84 monolayers, inhibition of hydroxylases 
with DMOG caused a reduction in the basai ENaC current and by inference, a 
reduction in ENaC activity. Given that the mouse colon does not exhibit ENaC- 
mediated currents, our in v itro  work was translated into a rat model, since it is 
known that the rectum of the rat exhibits a comparatively large amiloride- 
sensitive current (Inagaki e t  a/., 2004). In accordance with our in v itro  work, at 
concentrations previously shown to inhibit hydroxylases in rats (Zhao et a i., 
2010), DMOG caused a reduction in the amiloride-sensitive current in ex vivo  rat 
rectum. The molecular mechanisms underlying this reduction remain to be 
elucidated, but may involve a reduction in the activity of the Na+/K+-ATPase, 
which is necessary for all transport processes in epithelial cells. This is discussed 
in more detail in Chapter 4 of this thesis. Hydroxylase inhibition specifically 
downregulated large intestinal ENaC activity, while small intestinal SGLT-1 
activity remained unaltered. Contrary to this however, previous research has 
shown that acute hypoxia of 1 hour duration, inhibits SGLT-1 activity in rat
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jejunum (Kies and Tappenden, 2002). However, these previous studies were 
conducted with supra-physiological levels of nutrients (120 mM). Since SGLT-1 
is such an important transporter in the context of the jejunum, it is beneficial 
from the perspective of an antidiarrhoeal, that DMOG has no effect on its 
activity (Wright e t  a !., 2011). Finally, NHE activity in T84 cells was found to be 
attenuated by hydroxylase inhibition. We suspect that this is more likely to play 
a role in the regulation of intracellular pH (pHj) as opposed to Na+ absorption, 
since NHE3 has been reported to be absent from T84 cells (Beltran e t  a t., 2008). 
Interestingly, co-incubation of EIPA with DMOG reversed the antisecretory 
effect of DMOG. It has been reported that chronic hypoxia elevated pH] by 
activating Na+/H+ exchange in pulmonary arterial smooth muscle cells and that 
this effect was inhibited by EIPA (Rios e t  a l ,  2005). Although our results 
indicate an inhibition of NHE activity by DMOG, the possibility remains that 
hydroxylase inhibition alters steady-state pHj, thereby attenuating Cl" secretion. 
However, it should also be noted that EIPA-induced effects occurred only at 
doses >25 |iM, which may indicate that this effect is due to non-specific actions 
of the inhibitor.
3-5 Summary
In summary these studies demonstrate a novel role for HIF hydroxylases in 
regulating intestinal epithelial ion transport in v itro  and in vivo. Hydroxylase 
inhibition attenuates Cl" secretion, an effect that in vivo  would be expected to 
prevent fluid secretion into the intestine. These findings are important for our 
understanding of how epithelial transport function may be regulated in health 
and disease and suggest that hydroxylases, and their associated signalling 
mechanisms, may provide good targets for the development of new drugs to 
treat intestinal disorders associated with diarrhoea.
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Figure 3-22 Hydroxylase inhibition attenuates colonic epithelial secretory function in 
vitro  and in vivo. Upon treatment with the hydroxylase inhibitor, DMOG, the activity 
of HIF hydroxylases is blocked, leading to HIF-a stabilisation in the cell. Cl' secretory 
responses to both Ca2+- and cAMP-dependent agonists are significantly attenuated and 
this effect is not due to alterations in the abundance of these prosecretory second 
messengers. DMOG-induced inhibition of Cl" secretion prevents fluid secretion into the 
intestinal lumen, thereby preventing diarrhoea.
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4 - 1  I n t r o d u c t i o n
Fluid secretion in the intestine is driven by the luminal secretion of Cl" from 
epithelial cells. The Cl' secretory pathway is tightly regulated and is composed 
of several transport proteins that work in concert to drive Cl" from the 
epithelium into the lumen of the gut. In the previous chapter we found that 
hydroxylase inhibition attenuated agonist-stimulated secretory responses 
across colonic epithelial cells. Thus, our data expand on previous studies which 
demonstrate that intestinal secretion can be regulated by hypoxia and its 
associated signalling mechanisms, including production of mitochondrial 
reactive oxygen species (ROS), reductions in ATP generation, and stimulation of 
H IF-la  and HIF-2a accumulation. Although mechanisms by which hypoxia 
regulates epithelial secretion are not well understood, previous studies suggest 
that hypoxic targets within epithelial cells can include transport proteins that 
comprise the Cl' secretory pathway.
The driving force for apical Cl' secretion and indeed, all epithelial electrolyte 
transport processes, is the basolaterally-located Na+/K+“ATPase (Skou, 1998; 
Kaplan, 2002). Several studies have shown the Na+/K+-ATPase to be regulated 
by hypoxia (Planes et al., 1996; Mairbaurl et o/., 2002; Carpenter et a l., 2003; 
Dada e t  a l., 2003; Gusarova et a l., 2011). Initiai studies indicated that hypoxia 
attenuated the activity of lung epithelial Na+/K+-ATPase, without altering its 
expression (Planes et a l., 1996; Carpenter et a l., 2003). The mechanisms 
involved are complex and involve mitochondrial ROS, which are produced 
during hypoxia, which activate Ca2+/calmodulin-dependent kinase kinase ¡3 
(CaMKKp). Activated CaMKKp then phosphorylates adenosine monophosphate- 
activated protein kinase (AMPK), which in turn phosphorylates PKC Ç (Gusarova 
e t  a l., 2011; Gusarova e t  a l., 2009). PKC Ç translocates to the plasma membrane 
where it phosphorylates Ser-18 on Na+/K+-ATPase a i, culminating in clathrin- 
dependent pump endocytosis (Dada e t  a l., 2003; Chen e t  a !., 2006). This 
process was shown to require the ubiquitin-conjugating system and to be pVHL-
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dependent, but interestingly was HIF-independent (Cornelias e t  a i ,  2006; Dada 
e t  a i ,  2007; Zhou e t  a i ,  2008). The aforementioned research was carried out in 
renal and alveolar epithelial cells, which are exposed to a p02 of approximately 
20-50 torr and 100 torr (16 % O2), respectively (Johannes e t  a i ,  2006). These 
levels of 0 2 are considerably higher than those to which intestinal epithelial 
cells are exposed, which when examined in the mouse, ranged from 58 torr in 
the stomach, to 3 torr in the colon (He e t  a i ,  1999). Nevertheless, the fact that 
the mechanism of Na+/K+-ATPase inhibition by PKC C, is conserved across renal 
and alveolar tissues, suggests that it may also be present in intestinal epithelia. 
Na+/K+-ATPase regulation is multifaceted, and thus has potential to be exploited 
for therapeutic intervention.
The activity of Na+/K+-ATPase pumps create an electrochemical driving force for 
entry of Na+ through basolateral Na+ K+.2CI" co-transporters (NKCC1). NKCC 
facilitates the entry of Na+, K+, and 2 Cl' into epithelial cells and its function has 
been well characterised in the colon (Matthews e t  a i ,  1992; Matthews e t  a i ,  
1994; D’Andrea e t  a i ,  1996; Haas and Forbush, 2000; Del Castillo e t  a i ,  2005). 
NKCC1 has been identified as the isoform expressed by human intestinal 
epithelium (Payne e t  a i ,  1995). Although it is known to be regulated by 
hypoxia and specifically by HIF-1, there is still a paucity of studies on NKCC 
function under such conditions (Ibla e t  a i ,  2006). However, since NKCC1 is a 
rate-limiting step in intestinal epithelial Cl' secretion, it too is likely to be an 
important factor in the alterations of epithelial transport function that occur 
during hypoxia (Barrett and Keely, 2000).
K+ ions that enter epithelial cells through NKCC1 are recycled through 
basolateral cAMP-activated K+ channels, KCNQ1, and basolateral Ca2+-activated 
K+ channels KCNN4 (Schroeder e t  a i ,  2000; Flores e t  a i ,  2007). More recent 
research has also implicated apically located K+ channels as being involved in 
luminal secretion of anions in the intestine (Nanda Kumar e t  a i ,  2010). Recent 
studies have implicated AMPK as being important in regulation of KCNQ1 under
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conditions of metabolic stress in kidney cells (Alzamora e t  a l., 2010). While it is 
possible that such effects may also occur in hypoxia, this has not been 
demonstrated in intestinal epithelial cells. However, since AMPK is not 
activated by hydroxylase inhibitors, it is unlikely to play a major role in 
mediating actions of DMOG described in the current studies (Emerling e t  a l.,
2007). Research by other groups has shown that serum and glucocorticoid- 
responsive kinase-1 (SGK1) regulates KCNQ1/KCNE3 endocytosis (Seebohm et 
a l., 2007). SGK1 is known to be regulated by hypoxia in other systems (Aoyama 
et a l., 2005; Rusai et a l., 2009). Thus, previous studies suggest that KCNQ1 can 
be regulated under conditions of hypoxia, or by hydroxylase inhibitors, through 
activation of SGK1. However, studies on the role of hypoxia, or hydroxylase 
inhibitors, on KCNN4 function are scarce.
Cl" accumulates in epithelial cells above its electrochemical equilibrium by its 
entry through NKCC1, and upon stimulation of the ceils by agonists such as 
acetylcholine or VIP, accumulated Cl" exits across the apical membrane (Figure
4-1). Luminal Cl“ exit is facilitated by Cl" channels, such.as cAMP-activated CFTR 
channels, and the more recently identified Ca2+-activated apical Cl" channel, 
TMEM16A (Ousingsawat e t  a l., 2009; Almaca et a l., 2009). Previous studies 
have indicated that hypoxia represses mRNA expression of CFTR in the intestine 
and other tissues, and further studies in the intestinal epithelium showed that 
this occurs by a HIF-l-dependent mechanism (Guimbellot et a l., 2008; Zheng e t  
a l., 2009). In sinonasal respiratory epithelia, both CFTR and TMEM16A mRNA 
transcripts have been shown to be significantly attenuated in hypoxic cultures 
(Blount et a l., 2011). Thus, in light of the antisecretory actions of DMOG 
observed in the current studies, the effects of hydroxylase inhibition on Cl" 
channel function warrants further investigation.
Each of the transport proteins that comprise the Cl" secretory pathway has been 
the subject of extensive previous research and various protocols have been 
established by which their activities can be investigated in isolation. For
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example, using simple modifications of the Ussing chamber/voltage clamp 
technique, the activity of several of these transport proteins can be measured 
as changes in /sc. However, electrophysiological studies are only useful where 
the transport process under investigation results in a net charge moving across 
the epithelium. For electroneutral transporters, such as NKCC1, other 
techniques must be employed, such as rubidium flux assays or ratiometric 
imaging using fluorescent probes, such as BCECF (Reynolds e t  a/., 2007). In 
order to further our understanding of the antisecretory effects of hydroxylase 
inhibition in intestinal epithelial cells, we employed some of these techniques, 
along with biochemical and molecular approaches, to more closely analyse the 
effects of DMOG on the expression and activity of transport proteins involved in 
the secretory process.
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Figure 4-1 Schematic representation of the Cl' secretory pathway in cells. This 
rather simplistic representation of the Cl' secretory pathway of T84 cells highlights the 
main types of transporters that contribute to Cl' secretion in this model. The 
electrochemical driving force for Cl' secretion is provided by the Na+/K+-ATPase on the 
basolateral membrane. The removal of 3 Na+ from the cell against their 
electrochemical gradient creates a driving force fo r the entry of Na+, K+, and 2 CP via 
basolateral NKCC1. Cl' and K+ accumulate within the cell, and upon stimulation by 
agonists such as ACh and VIP, which raise intracellular second messenger levels, 
basolateral K+ channels and apical Cl* channels open and luminal efflux o f Cl' occurs. 
The electrical gradient created by Cl' efflux promotes paracellular Na+ transport 
through tight junction pores and water follows passively by osmosis.
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4 - 2  A i m
The overall goal of this chapter was to investigate the impact of hydroxylase 
inhibition on the activity and expression of individual transport proteins that 
constitute the Cl' secretory pathway. Specifically, the aims of the chapter were 
to:
1. Identify alterations in transport protein activity and expression in 
response to hydroxylase inhibition.
2. Investigate molecular regulation of the Na+/K+-ATPase by hydroxylase 
inhibitors.
3. Investigate the potential involvement of HIF in the antisecretory effect 
of hydroxylase inhibitors.
4-3.1 Hydroxylase inhibition attenuates CFTR expression
We first set out to investigate the effects of hydroxylase inhibition on the 
activity of apical CFTR channels. Using a previously established protocol 
(Rochwerger e t  a i ,  1994); T84 cells were treated with DMOG (1 mM; 24 hours) 
and mounted in Ussing chambers. An apical to basolateral Cl' gradient of 
119.8-4.8 mM was established across the monolayers and the basolateral 
membranes were permeabilised by nystatin (100 jxg/ml). Following stabilisation 
of the current, FSK (10 (iM; apical) stimulated Cl'-currents were measured. 
Control Cl’ currents were inhibited 77.8 ± 2.3 %  by the CFTR inhibitor, CFTRinhi72 
(10 juM) (n = 6; *** p < 0.001), implying that the apical Cl" current was
predominantly CFTR-mediated. However, it was found that there was no
i
difference in FSK-induced changes in current (A /sc) when control and DMOG- 
treated cells were compared (Figure 4-2). CFTRinhi72 attenuated the current in 
DMOG-treated cells to a similar extent as that in control cells (78.6 ± 7.7 %; n = 
3; p < 0.001), suggesting that Cl" currents in DMOG-treated cells are also 
predominantly mediated by CFTR.
4 - 3  R e s u l t s
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Figure 4-2 Hydroxylase inhibition does not alter apical Cl' currents in cells. Tg4 cells 
were grown as monolayers on permeable supports until Rte stabilised at plateau levels. 
Cells were treated bilaterally with DMOG (1 mM) in serum-free medium for 24 hours 
and were then washed and mounted in Ussing chambers. The apical chamber 
contained normal Ringer's solution (Table 2-3), whereas the basolateral chamber 
contained a low Cl' solution, in which Cl' was replaced with equimolar gluconate (Table
2-5). A) Following 30 minutes of permeabilisation by nystatin (100 jig/ml), FSK (10 
\xW\) was added apically and changes in /sc were measured. B) Maximal changes in 
current in control and DMOG-treated cells were plotted as A lsc (n = 10).
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To determine whether CFTR expression is altered in intestinal epithelial cells by 
inhibition of hydroxylases, cells were treated with DMOG (1 mM) for several 
time points up to 24 hours. After treatment, analysis of CFTR mRNA and protein 
was performed by semi-quantitative PCR and SDS-PAGE, respectively. We 
found that there was a dramatic reduction in both CFTR mRNA and protein 
expression following treatment with DMOG (Figure 4-3). This is consistent with 
previous work showing that HIF-1 transcriptionally represses CFTR (Zheng e t  a l., 
2009).
A B
DMOG 1mM (hours) DMOG 1mM (hours)
Figure 4-3 Hydroxylase inhibition attenuates CFTR expression in colonic epithelial 
cells. T84 cells were grown as monolayers on permeable supports until Rte stabilised at 
plateau levels. Cells were treated bilaterally with DMOG (X mM) in serum-free medium 
for various times. A) mRNA was isolated from the cells and semi-quantitative PCR 
analysis was performed with primers specific for CFTR. 18SrRNA was used as a loading 
control (n = 4; ANOVA, * p < 0.05 compared to control). B) Total protein was isolated 
from cells and CFTR protein expression was measured by western blot, p-actin was 
used as a loading control (n = 5; ANOVA, * p < 0.05 compared to control).
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The effects of hydroxylase inhibition on the recently identified Ca2+ activated Cl" 
transporter TMEM16A were next investigated. TMEM16A has been implicated 
in facilitating Cl" secretion across various epithelia in the Gl tract, including the 
colon (Ousingsawat e t  a l., 2009; Almaca e t  a l., 2009). Recent research from our 
laboratory has implicated TMEM16A in mediating Ca2+ activated Cl‘ currents 
from Tg4 cells (Mroz and Keely, 2011). However, analysis of TMEM16A mRNA 
expression revealed no significant change after treatment with DMOG (1 mM) 
over several time points (Figure 4-4).
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Figure 4-^ 4 Hydroxylase inhibition does not significantly alter TMEM16A mRNA 
expression in colonic epithelial cells. T84 cells were cultured as monolayers on 
permeable supports until Rte stabilised at plateau levels. Cells were treated bilaterally 
with DMOG (1 mM) in serum-free medium for several time points up to 24 hours. Total 
RNA was isolated from the cells, cDNA was created using reverse transcriptase, and 
semi-quantitative RT-PCR analysis was performed with primers specific for TMEM16A. 
18SrRNA was used as a loading control (n = 5).
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4-3.2 Hydroxylase inhibition attenuates NKCC1 expression
NKCC1 has previously been shown to be transcriptionally repressed by HIF-1, 
therefore NKCC1 activity was next investigated (Ibla e t  a l., 2006). Tg4 cells were 
cultured on glass petri-dishes and were treated with DMOG (1 mM) for 24 
hours. The cells were loaded with the pH sensitive dye BCECF and pHj was 
analysed by recording BCECF fluorescence. Cells were then perfused with a 
solution containing NH4CI. Addition of NH4+ led to an initial alkalinisation, 
corresponding to NH3 uptake. This was followed by an acidification, 
corresponding to NH4+ uptake. The plateau phase or rate of recovery following 
the acid load, is representative of the activity of the NKCC1 co-transporter 
transporting NH4+, a substrate for the co-transporter (Heitzmann e t  a l., 2000; 
Bachmann e t  a i ,  2003). The rate of recovery in cells treated with DMOG was 
similar to that of controls (Figure 4-5).
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Figure 4-5 Hydroxylase inhibition does not alter NKCC1 activity in T^ cells. T84 ceils 
were cultured on glass-bottomed petri-dishes until approximately 80 % confluent. Cells 
were treated with DMOG (1 mM; 24 hours) and then washed in modified Krebs 
solution (Table 2-15). Cells were loaded with BCECF-AM (5 |aM; 60 minutes), washed, 
and were then incubated in modified Krebs solution for a further 15 minutes to 
facilitate any passive leakage of the dye. A) pH was analysed by recording BCECF 
fluorescence at intervals of 3 seconds. Cells were perfused with modified Krebs 
solution, NH4-Krebs solution, or NMDG-CI' Krebs solution (indicated by N), and returned 
to modified Krebs solution for the remainder of the experiment. Data are expressed as 
mean fluorescence ratio at 490 and 440 nm. B) NKCC1 activity was recorded as the 
rate of change in pH, during the acidification(from t = 0, to t = 1) (NH4 uptake) stage (n =
3-10). Cells were treated with bumetanide (Bum) (100 |aM) to inhibit NKCC1 activity.
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The expression of NKCC1 mRNA and protein was next examined by semi- 
quantitative RT-PCR and western blotting, respectively. In agreement with 
published research showing that HIF-1 transcriptionally represses NKCC1, we 
found NKCC1 protein and mRNA expression to be significantly attenuated by 
hydroxylase inhibition following 24 hours treatment with DMOG (1 mM) (Figure
4-6) (Ibla e t  a l., 2006).
A B
DMOG 1mM (hours)
Figure 4-6 Hydroxylase inhibition attenuates NKCC1 expression in colonic epithelial 
cells Tg4 cells were cultured as monolayers on permeable supports until Rte stabilised at 
plateau levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free medium 
for various periods of time. A) Total RNA was isolated from the cells and semi- 
quantitative PCR analysis was performed with primers specific for NKCC1. 18SrRNA 
was used as a loading control (n = 5; ANOVA; * p < 0.05 compared to control). B) Total 
protein was isolated from cells, and CFTR protein expression was measured by western 
blotting, p-actin was used as a loading control (n = 8; paired t-test; ** p < 0.01).
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NKCC1 expression was further analysed by confocal microscopy. Cells were 
cultured on transparent permeable supports until Rte stabilised at plateau levels 
and were then treated with DMOG (1 mM) for 24 hours. Figure 4-7 shows that 
NKCC1 (green) is highly expressed on the basolateral side of Tgvcells and that 
there appears to be no alteration in trafficking of the protein to the plasma 
membrane upon treatment with DMOG. Visualisation of the rhodamine- 
phalloidin-stained (red) actin collar around the apical membrane, and the 
basolateral nuclei stained with DAPI (blue) allows for orientation of the cells.
Control DMOG
Figure 4—7 Hydroxylase inhibition does not aiter NKCC1 membrane localisation in Tm 
cells. T84 cells were cultured as monolayers on permeable supports until tfte stabilised 
at plateau levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free 
medium for 24 hours. Cells were then washed in PBS, fixed in 100 % methanol, 
permeabilised with Triton X-100, and stained with specific fluorophore-labelled 
antibodies as outlined in Section 2-24. Pseudo-colours were assigned to the various 
structures, with nuclei being represented in blue, f-actin in red and NKCC1 in green. 
Scale bars are 5 jim in length.
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4-3.3 Hydroxylase inhibition does not affect basolateral K+ 
channels, KCNN4 or KCNQ1
The basolateral K+ channel involved in Ca2+-activated Cl' secretion across colonic 
epithelial cells has been previously identified as the intermediate conductance 
K+ channel, KCNN4 (Flores e t  a l., 2007). The effect of hydroxylase inhibition on 
the activity of basolateral KCNN4 was next investigated using a previously 
established protocol (Kirk and Dawson, 1983). T^  cells were mounted in Ussing 
chambers and an apical to basolateral K+ gradient of 123.2-5.2 mM was 
established across the epithelium. Apical membranes were then permeabilised 
with amphotericin B (50 >iM) and after re-stabilisation of baseline current, 
basolateral K+ currents were stimulated by addition of basolateral CCh (100 
|aM). We found that basal state K+ currents were significantly increased in 
DMOG-treated cells, however, stimulated basolateral Ca2+-activated K+ currents 
were unaltered by hydroxylase inhibition (Figure 4-8).
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Figure 4-8 Hydroxylase inhibition does not alter Ca2+-stimulated K+ currents in T84 
cells. T84 cells were cultured as monolayers on permeable supports until Rte stabilised 
at plateau levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free 
medium for 24 hours, washed, and mounted in Ussing chambers. The apical Ringer's 
solution contained high [K+] (Table 2-6), whereas the basolateral bath contained 
normal (low [K+]) Ringer's solution (Table 2-3). A) After mounting in Ussing chambers, 
cells were allowed to equilibrate for 15 minutes, after which amphotericin B (50 jaM) 
was added to the apical bath. After an additional 25 minutes, ouabain (100 i^M) was 
added basolaterally to inhibit Na+/K+-ATPase activity. Basolateral CCh (100 i^M) was 
then added to stimulate Ca2+-activated K+ channels in the basolateral membrane. B) 
Maximal changes in K+ currents were plotted as A /sc (n = 4).
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In order to further analyse potential effects of hydroxylase inhibition on KCNN4, 
we investigated whether there was any change in the overall abundance of the 
transporter after treatment with DMOG. KCNN4 mRNA and protein expression 
were analysed by semi-quantitative RT-PCR and western blotting, respectively. 
Cells were treated with DMOG (1 mM) for several time points, and mRNA and 
proteins were isolated in the usual manner. As shown in Figure 4-9, there was 
no change ¡n either mRNA or protein expression of KCNN4 following 
hydroxylase inhibition.
DMOG 1mM (hrs)
Figure 4-9 KCNN4 expression is unaltered by hydroxylase inhibition in cells. Tg*
cells were cultured as monolayers on permeable supports until Rte stabilised at plateau 
levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free medium for 
various periods of time. A) mRNA was isolated from the cells and semi-quantitative RT- 
PCR analysis was performed with primers specific for KCNN4. 18SrRNA was used as a 
loading control (n = 5). B) Total protein was isolated from cells, and KCNN4 (40 kDa) 
protein expression was measured by western blotting, p-actin was used as a loading 
control (n = 4).
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As a logical progression of our studies, we next went on to investigate if 
hydroxylase inhibition alters the expression of the cAMP-regulated basolateral 
K+ channel, KCNQ1. Hydroxylases were inhibited with DM06 (1 mM) for 24 
hours and KCNQl expression was investigated at both the mRNA and protein 
levels by semi-quantitative RT-PCRand western blotting, respectively (Figure 4 - 
10). It was found that there were no alterations in the expression of either 
KCNQ1 mRNA or protein in DMOG-treated cells.
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Figure 4-10 KCNQl expression is not altered by hydroxylase inhibition in Ts4 cells. T84
cells were cultured as monolayers on permeable supports until Rte stabilised at plateau 
levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free medium for 
various periods of time. A) mRNA was isolated from the cells and semi-quantitative RT- 
PCR analysis was performed with primers specific for KCNQl. 18SrRNA was used as a 
loading control (n = 4). B) Total protein was isolated from cells, and KCNQl protein 
expression was measured by western blot, p-actin was used as a loading control (n = 
4).
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KCNQl expression was further analysed by confocal microscopy. Cells were 
cultured on transparent permeable supports and were treated with DMOG (1 
mM) for 24 hours. As shown in Figure 4-11, KCNQl (green) is highly expressed 
on the basolateral side of T84 cell monolayers. There was also quite an amount 
of cytosolic staining and some staining towards the apical membrane. 
Furthermore, we found that there was no alteration in the trafficking of KCNQl 
to the membrane in DMOG-treated cells. Visualisation of the rhodamine- 
phalloidin-stained (red) f-actin collar around the apical membrane allows for 
orientation of the cells. Although nuclei were also stained using DAPI, they 
were omitted from these images so that KCNQl expression could be fully 
appreciated.
Control DMOG
Figure 4^11 Hydroxylase inhibition does not alter KCNQl trafficking in J M cells. T^
cells w ere  cu ltured as m onolayers on perm eable supports un til f lte stabilised a t plateau  
levels. Cells w ere  trea ted  b ila tera lly  w ith  DMOG (1 m M ) in serum -free m edium  fo r 24 
hours. Cells w ere  then  washed in PBS, fixed in 100 % m ethano l, perm eabilised w ith  
Triton X-100, and stained w ith  specific fluorophore -labe lled  antibod ies, as outlined  in 
Section 2 -2 4 . Pseudo-colours w ere assigned to  the various proteins, w ith  f-actin  being  
represented in red and KCNQl in green.
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4-3.4 Hydroxylase inhibition attenuates Na+/K+-ATPase 
activity in colonic epithelial cells
Our attention next turned to Investigating DMOG effects on the basolateral 
Na+/K+-ATPase. The Na+/K*-ATPase creates the electrochemical driving force for 
establishing the ionic gradients that drive ion transport across the epithelium. 
We used a well-established protocol to measure Na+/K+-ATPase pump activity 
(DuVall e t  a i ,  1998; Gomes and Soares-Da-Silva, 2002; Lam e t  a i ,  2003). 
However, preliminary experiments were first carried out to optimise this 
protocol, in order to more closely mimic physiological conditions under which 
the pump normally operates. To this end Na+/K+-ATPase activity was measured 
using 3 different concentrations of Na+; 0, 25, and 140 mM. A correlation 
between [Na+] and Na+/«+-ATPase activity was observed (Figure 4-12). For 
subsequent experiments 25 mM Na+ was employed, since this is more 
physiological than the 140 mM concentration employed in previous studies.
[Na4] (mM)
Figure 4^12 Na+/K+-ATPase activity is dependent on the concentration of Na+ present 
in the buffering solution. T84 cells were cultured on permeable supports until /?te 
stabilised at plateau levels. Cells were then washed, mounted in Ussing chambers, and 
bathed in modified Ringer's solutions containing 0, 25, or 140 mM Na+. Cells were 
apically permeabilised with amphotericin B (SO fiM) and were then stimulated by the 
basolateral addition of CCh (100 |iM). Maximal changes in current are plotted as A  /sc 
and expressed as jxA/cm2 (n = 3).
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Using the conditions optimised in Figure 4-12, cells were next treated with 
DMOG (1 mM; 24 hours) and Na+/K+-ATPase activity was measured. Cells were 
mounted in Ussing chambers and apically permeabilised with amphotericin B 
(50 (iM). Under basal conditions there was a significant reduction in the basal 
activity of the Na+/K+-ATPase in DMOG-treated cells (Figure 4-13 C). Similarly, 
hydroxylase inhibition significantly attenuated activity of the Na+/K+-ATPase in 
response to stimulation by CCh (100 j iM) (Figure 4-13 A, B). Basolateral ouabain 
(100 juM) practically abolished pump activity (Figure 4-13 B).
Time (mins)
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Figure 4-13 Hydroxylase inhibition attenuates Na+/K+-ATPase activity in T  ^cells. T84 cells 
were cultured on permeable supports until Rte stabilised at plateau levels. Cells were treated 
with DMOG (1 mM; 24 hours), washed, mounted in Ussing chambers, and bathed in Ringer's 
solution containing 25 mM Na+ (Table 2-7). A) Cells were apically permeabilised with 
amphotericin B (50 ^iM) for 30 minutes until the current had stabilised. Basolateral ouabain 
(100 juM) was added to negative control cells, and basolateral CCh (100 (¿M) was added to  all 
cells to stimulate Na+/K+-ATPase activity. B) Maximal CCh-induced currents were plotted as A /sc 
(n = 5; ANOVA; * * *  p < 0.001). C) Basal /sc in control and DMOG-treated cells prior to addition of 
CCh was plotted as /sc (n = 5; ANOVA; **  p ^  0.01. * * *  p ^  0.001).
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Since the antisecretory effect of hydroxylase inhibition is slow in onset and 
occurs over several hours, we hypothesised that this effect is likely due to 
alterations in protein expression. Thus, Na+/K+-ATPase pump expression in the 
absence or presence of DMOG was next investigated in Tg4 cells. The catalytic 
Na+/K+-ATPase oti subunit was first investigated since this is the catalytic subunit 
that facilitates the transport of ions. However, we found that neither Na+/K+- 
ATPase a \  subunit mRNA or protein expression were significantly altered by 
hydroxylase inhibition over a period of 24 hours (Figure 4-14).
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Figure 4-14 Hydroxylase inhibition does not alter Na+/K +-ATPase oti subunit 
expression in TM cells. T^ cells were cultured as monolayers on permeable supports 
until /?te stabilised at plateau levels. Cells were treated bilaterally with DMOG (1 mM) 
in serum-free medium for various periods of time. A) mRNA was isolated from the cells 
and semi-quantitative RT-PCR analysis was performed with primers specific for the 
Na+/K+-ATPase <Xi subunit (labelled as oti in the upper panel). 18SrRNA was used as a 
loading control (n = 4). B) Total protein was isolated from cells, and Na+/K+-ATPase oti 
protein expression was measured by western blotting (labelled as oti in the upper 
panel), p-actin was used as a loading control (n = 4-7).
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Since Na+/K+-ATPase gci subunit protein expression is unaltered by hydroxylase 
inhibition, we next examined the possibility that altered trafficking to be plasma 
membrane might be involved. To this end, we first employed an 
immunohistochemical approach. Cells were cultured on transparent permeable 
supports and treated with DMOG (1 mM) for 24 hours. As shown in Figure 4-15 
Na+/K+-ATPase oti subunit is highly expressed on the basolateral side of T84 cells. 
However, using this approach we found that there was no alteration in 
membrane localisation of the Na+/K+-ATPase a i  subunit in DMOG-treated cells.
Control DMOG
Figure 4-15 Hydroxylase inhibition does not alter Na+/K+-ATPase oti subunit 
membrane localisation in TM cells. T84 cells were cultured as monolayers on permeable 
supports until Rte stabilised at plateau levels. Cells were treated bilaterally with DMOG 
(1 mM) in serum free medium for 24 hours. Cells were then washed in PBS, fixed in 
100 % methanol, permeabilised with Triton X-100, and stained with specific 
fluorophore-labelled antibodies, as outlined in Section 2-3. Pseudo-colours were 
assigned to the various proteins, with the Na+/K+-ATPase a x subunit being represented 
in green. This image is representative of 4 similar experiments.
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As an alternative approach, surface expression of the Na+/K+-ATPase cti subunit 
was next investigated by cell surface biotinylation. In agreement with our 
immunohistochemical findings, these experiments revealed there to be equal 
amounts of Na+/K+-ATPase oti subunit present in the basolateral membrane of 
control and DMOG-treated cells (Figure 4-16).
Figure 4-16 Hydroxylase inhibition does not alter surface expression of the Na+/K+- 
ATPase a x subunit in cells. T84 cells were grown as monolayers on permeable 
supports until flte stabilised at plateau levels. Cells were treated bilaterally with DMOG 
(1 mM) in serum-free medium for 24 hours. Cells were then biotinylated and lysed, 
and surface Na+/K+-ATPase oil subunit protein expression was expressed as a factor of 
total protein. Protein expression was measured by western blot, p-actin was used as a 
loading control (n = 4).
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4-3.5 Hydroxylase inhibition does not alter ATP levels in 
^84 cells
As described above, the Cl" secretory mechanism is a highly energy dependent 
process that derives its electrochemical driving force from Na+/K+-ATPase pump 
activity. Na+/K+-ATPase pumps are known to use large quantities of cellular ATP 
(Milligan and McBride, 1985). Interestingly, the catalytic subunit of ATP 
synthase, which is responsible for ATP synthesis, contains a putative prolyl 
hydroxylation motif, LXXLAP (Table 4-1). Therefore, with this in mind, we next 
investigated if alterations in ATP synthase or ATP generation might underlie the 
effects of DMOG on Na+/K+-ATPase pump activity.
Table 4-1 ATP synthase a  amino acid sequence contains a putative prolyl 
hydroxylation motif.
HUMAN ATP synthase subunit a
MLSVRVAAAWRALPRRAGLVSRNALGSSFIAARNFHASNTHLQKTGTAEMSSILEERILG
ADTSVDLEETGRVLSIGDGIARVHGLRNVQAEEMVEFSSGLKGMSLNLEPDNVGVWFG
NDKLIKEGDIVKRTGAIVDVPVGEELLGRVVDALGNAIDGKGPIGSKTRRRVGLKAPGIIPRI
SVREPMQTGIKAVDSLVPIGRGQRELIIGDRQTGKTSIAIDTIINQKRFNDGSDEKKKLYCIY
VA1GQKRSTVAQLVKRLTDADAMKYTIVVSATASDAAPLQVLAPYSGCSMGEYFRDNGK
HALIIYDDLSKQAVAYRQMSLLLRRPPGREAYPGDVFYLHSRLLERAAKMNDAFGGGSLTA
LPVIETQAGDVSAYIPTNVISITDGQIFLETELFYKGIRPAINVGLSVSRVGSAAQTRAMKQV
AGTMKLELAQYREVAAFAQFGSDLDAATQQLLSRGVRLTELLKQGQYSPMAIEEQVAVIY
AGVRGYLDKLEPSKITKFENAFLSHVVSQHQALLGTIRADGKISEQSDAKLKEIVTNFLAGFE
A
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First, protein expression of the ATP synthase a  subunit was investigated. T84 
cells were treated with DMOG (1 mM) for different periods of time up to 24 
hours. After cell lysis, proteins were resolved by SDS-PAGE, and probed for the 
ATP synthase a  subunit by western blotting. It was found that protein 
expression of ATP synthase a  was not significantly altered following hydroxylase 
inhibition with DMOG (Figure 4-17).
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Figure 4^17 Hydroxylase inhibition does not alter ATP synthase a  protein expression 
in Tg4 cells. T84 cells were cultured as monolayers on permeable supports until flte 
stabilised at plateau levels. Cells were treated bilaterally with DMOG (1 mM) in serum- 
free medium for various periods of time. Cells were then lysed and ATP synthase a 
protein expression was analysed by western blotting, p-actin was used as a loading 
control (n = 4).
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Hypoxia is known to reduce cellular ATP production due to a metabolic switch 
from oxidative phosphorylation to glycolysis (Semenza, 2007). Such effects can 
be detrimental if insufficient ATP is produced to meet the requirements of the 
cell. D-fructose has been shown to prevent hypoxic cell death in the liver by 
supplying ATP via glycolysis (Anundi e t  a l., 1987) Therefore, we carried out 
similar experiments to determine if supplementation of the culture medium 
with D-fructose altered the antisecretory effect of DMOG treatment in T84 cells. 
However, as shown in Figure 4-18, we found that pretreatment with D-fructose 
(20 mM) did not ameliorate the antisecretory effects of hydroxylase inhibition 
in Tg4 cells.
d m o g  + - +
Figure 4^18 D-fructose does not ameliorate the antisecretory effects of hydroxylase 
inhibition in TM cells. T84 cells were cultured as monolayers on permeable supports 
until Rte stabilised at plateau levels. 24 hours prior to treatment, cells were cultured in 
D-glucose-free, high D-fructose (20 mM), medium. Cells were then treated bilaterally 
with DMOG (1 mM) for 24 hours in serum-free medium containing D-fructose. 
Monolayers were washed, mounted in Ussing chambers and bathed in D-fructose 
Ringer's solution (Table 2 -4 ) . Subsequent secretory responses to CCh (100 |iM) and 
FSK (10 |iM) were recorded. Data are expressed as maximal changes in stimulated 
current {A /sc) (n = 3, ANOVA; * p < 0.05; ** p < 0.01; *** p < 0.001 compared to 
respective controls).
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Since Na+/K+-ATPase pumps use large quantities of cellular ATP, the ATP content 
of control and DMOG-treated cells was next investigated (Milligan and McBride, 
1985). Using a commercially available kit, ATP levels of Tg4 cells treated with 
DMOG (1 mM) for 1, 3, or 24 hours were found to be no different to those of 
control cells. D-fructose treatment was also without effect on cellular ATP 
levels (Figure 4-19).
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Figure 4-19 Hydroxylase inhibition does not alter ATP levels in TM cells. T^ cells were 
grown as monolayers on permeable supports until Rte stabilised at plateau levels. Cells 
were treated bilaterally with DMOG (1 mM) in serum-free medium for 0, 1, 3, and 24 
hours. D-fructose (20 mM) was substituted for D-glucose in one set of treatments. A) 
A standard curve of ATP concentration was generated using reagents supplied with the 
commercially available kit. B) Cells were lysed and the ATP content of DMOG- and D- 
fructose-treated cells was measured by extrapolation from the standard curve (n = 13).
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4-3.6 The PHD inhibitor, FG-4497, exerts anti-secretory
actions in T84 cells and inhibits Na+/K+-ATPase activity
FG-4497 is a hydroxylase inhibitor developed by FibroGen Inc. This small 
molecule inhibitor, specific for PHD e n zy m e s , was previously disclosed in a 
patent filing, US20040254215A1. However, unlike DMOG, which is a pan­
hydroxylase inhibitor, FG-4497 is reported to be specific for the HIF-prolyl 
hydroxylases. During the course of my PhD studies an opportunity to 
collaborate with FibroGen Inc. arose and we took this opportunity to employ 
FG-4497 to confirm our previous findings with DMOG. We first analysed the 
effects of FG-4497 on agonist-induced secretory responses and H IF-la levels 
(Figure 4-20).
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Figure 4-20 FG-4497 attenuates Cl' secretion, and causes H IF-la accumulation in a 
concentration-dependent manner in TM cells. cells were cultured as monolayers on 
permeable supports until Rte stabilised at plateau levels. Cells were treated bilaterally with 
various concentrations of FG-4497 for 24 hours. For protein expression analysis, cells were 
lysed and HIF-la expression was measured by western blotting. (3-actin was used as a loading 
control (n = 4; ANOVA, ### p < 0.001 compared to  0 \xM FG4497). For electrophysiological 
experiments, cells were mounted In Ussing chambers, bathed in Ringer's solution (Table 2-3), 
and stimulated with basolateral CCh (100 jaM), and apical FSK (10 ¿iM) (n = 4; ANOVA, * * *  p < 
0.001 compared to 0 fiM  FG4497).
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In collaboration with FibroGen Inc. we also measured HIFa levels by an 
alternative approach using an MSD assay developed in their laboratories; T84 
cells were cultured as monolayers on permeable supports, and were treated 
with FG-4497 at various concentrations for 24 hours. Hydroxylase inhibition by 
FG-4497 resulted in a robust accumulation of both HIFa isoforms. HIF-lot 
protein increased from 474.76 ± 149.84 ng/ml in controls to 1324.84 ± 397.96 
ng/ml in FG-4497 (50 jxM; 24 hours)-treated cells, while HIF-2a protein
r
increased from 19.06 ± 8.21 ng/ml in controls to 167.41 ± 34.48 ng/ml in FG- 
4497-treated cells (Figure 4-21).
[FG4497] (mM)
B
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Figure 4 -2 1  H ydroxylase in h ib it io n  by FG-4497 s tim u la te d  a ccum ula tion  o f H IF - la  
and H IF-2a in cells. T84 cells w ere  g row n as m onolayers on perm eable supports  
until /?te stabilised a t plateau levels. Cells w ere trea te d  b ila tera lly  w ith  various  
concentra tions o f  FG-4497 in serum  free m edium  fo r  24 hours. Proteins w ere  
extracted and MSD assays w ere  perfo rm ed  (Section 2 -19). Concentrations o f A) HIF- 
l a  and B) HIF-2a w ere  extrapo la ted  fro m  standard curves generated (n = 4; ANOVA, * 
p < 0.05; * *  p < 0.01; * * *  p < 0.001 com pared to  controls).
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Using the experimental conditions optimised in Figure 4-12, cells were next 
treated with FG-4497 (50 |aM; 24 hours) or DMOG (1 mM; 24 hours), and 
Na+/K+-ATPase activity was measured. Cells were mounted in Ussing chambers, 
apically permeabilised with amphotericin B (50 jiM) and stimulated with 
basolateral CCh (100 |iM). Similar to our previous observations with DMOG, we 
found that there was a significant attenuation of CCh-stimulated Na+/K+-ATPase 
activity in FG-4497-treated cells (Figure 4-22).
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Figure 4-22 Na+/K+-ATPase activity is significantly attenuated in FG-4497-treated J M 
cells. T84 cells were cultured on permeable supports until ffte stabilised at plateau 
levels. Cells were treated with FG-4497 (50 pJVI; 24 hours),or with DMOG (1 mM; 24 
hours), washed, mounted in Ussing chambers, and bathed in Ringer's solution 
containing 25 mM Na+ (Table 2-7). Cells were apically permeabilised with amphotericin 
B (50 |iM) for 30 minutes. Basolateral CCh (100 |iM) was then added to the cells to 
stimulate Na+/K+-ATPase activity. Maximal CCh-induced currents were plotted as A lsc 
(n = 5-6; ANOVA; *** p < 0.001 compared to control).
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4-3.7 CoCI2 stabilises H IF-la protein expression and 
attenuates Cl' secretion independently of Na+/K+-ATPase 
activity
In order to further define the mechanisms by which hydroxylase inhibition 
might regulate epithelial secretory responses, we employed C0CI2. C0CI2 causes 
FIH-l-ihdependent accumulation of H IF-la  (Tian ef aL, 2011b), but also inhibits 
H IF-la  degradation in a different manner to DMOG and FG4497. CoCI2 inhibits 
VHL-mediated degradation of H IF-la  by directly blocking the binding site of 
pVHL on H IF-la (Yuan e t  aL , 2003). Co2+ is also known to deplete the cell of 
ascorbate, an essential cofactor for hydroxylase activity (Salnikow e t  aL , 2004). 
In initial experiments we set out to determine appropriate CoCI2 concentrations 
to employ by examining its effects on LDH release and /?te as indices of toxicity. 
There was no increase in LDH release from T84 cells treated with C0CI2 at 
concentrations as high as 1 mM (Figure 4-23 A). Similarly, after treatment with 
CoCI2 at a concentration of SOO i^M, Rte did not significantly change compared to 
that of the cells prior to treatment (Figure 4-23 B).
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Figure 4^23 CoCI2 does not exert toxic effects on cells. T84 cells were cultured on 
permeable supports until /?te stabilised at plateau levels. A) Cells were treated 
bilaterally with varying concentrations of CoCI2 for 24 hours. Lysate cells were treated 
with lysis buffer for a minimum of 30 minutes prior to analysis. An equal aliquot of 
apical and basolateral culture medium was taken and LDH released into the culture 
medium was measured using a commercially available kit (Section 2-16) (n = 3-6; 
ANOVA; * p < 0.05; *** p < 0.001 compared to control). B) Cells were treated 
bilaterally with CoCI2 (500 |iM) for defined periods of time and subsequent ffte 
measurements were recorded using an epithelial voltohmeter (n = 4)
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We next examined the effects of CoCI2 on H IF-la  protein expression in Ts4 cells. 
Cells were treated with various concentrations of C0CI2 in order to determine an 
optimal concentration for CoCI2 -induced H IF-la stabilisation. As shown in 
Figure 4-24, H IF-la  robustly accumulates in T84 cells treated with 500 |iM CoCI2.
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Figure 4-24 CoCI2 stabilises HIF-la protein expression in J M cells. T84 cells were 
cultured on permeable supports until Rte stabilised at plateau levels. Cells were treated 
bilaterally with various concentrations of CoCI2 in serum-free medium for 24 hours, 
after which HIF-1 a  protein expression was measured by western blotting. P-actin was 
used as a loading control (n = 3; ANOVA, **p < 0.01 compared to control).
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The effects of CoCI2 on epithelial secretory function were next examined. 
Similar to DMOG, it was found that treatment of T84 monolayers with CoCI2 (500 
|iM) for 24 hours exerted a profound antisecretory effect on the cells. 
Secretory responses to CCh (100 |iM) and FSK (10 jaM) were attenuated to 
51.63 ± 8.12 % (n = 4; ** p < 0.01) and 53.03 ± 8.43 % (n = 4; ** p < 0.01) of
those in control cells, respectively (Figure 4-
A
Time (min)
■25).
B
Control CoCI2
Figure 4—25 CoCI2 attenuates agonist-induced Cl secretory responses in TM cells. T84
cells were cultured on permeable supports until Rte stabilised at plateau levels. Cells 
were treated bilaterally with CoCI2 (500 i^M) in serum-free medium for 24 hours. Cells 
were then washed, mounted in Ussing chambers, bathed in Ringer's solution (Table 2- 
3), and subsequent Cl' secretory responses to basolateral CCh (100 p,M) and apical FSK 
(10 |iM) were measured (n = 4; ANOVA; ** p < 0.01 compared to control). Panel A 
shows the time course of these experiments while Panel B shows maximal secretory 
responses, measured as A lsc, to CCh and FSK in the absence or presence of C0CI2.
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In further experiments the effects of CoCI2 on agonist-stimulated Cl" secretion 
were found to be concentration-dependent. When cells were treated with 
CoCI2 for 24 hours, antisecretory effects were maximal at a concentration of 500 
j iM (Figure 4-26 A). The effects of CoCI2 (500 jiM) were also time-dependent, 
being maximal at 24 hours for cAMP-mediated responses and between 6-24 
hours for Ca2+-dependent responses (Figure 4-26 B).
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Figure 4-26 The antisecretory effect of CoCI2 in T** cells is time- and concentration- 
dependent. T84 cells were cultured on permeable supports until Rte stabilised at 
plateau levels. A) Cells were treated bilaterally with DMOG (1 mM) in serum-free 
medium for various time points. * Cells were then washed, mounted in Ussing 
chambers, bathed in Ringer's solution (Table 2-3), and subsequent Cl' secretory 
responses to basolateral CCh (100 jiM) and apical FSK (10 jiM) were measured (n = 4 - 
8; ANOVA, * p < 0.05; *** p < 0.001 compared to control). B) Cells were treated 
bilaterally with CoCI2 (500 pM) in serum-free medium for various times up to 24 hours 
before responses to basolateral CCh (100 jiM) and apical FSK (10 p,M) were measured 
in Ussing chambers (n = 4; ANOVA, * p ^ 0.05; *** p < 0.001 compared to control).
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Potential mechanisms underlying the antisecretory effect of CoCI2 in cells 
were next investigated. Apical Cl" currents, measured as previously described 
(Rochwerger e t  a l., 1994), were first investigated since CoCI2 has previously 
been shown to inhibit Cl" secretion in T84 cells (Taylor e t  a l., 1998). Apical Cl' 
conductance was found to be significantly attenuated by CoCI2 treatment 
(Figure 4-27 A). However, in direct contrast to our observations with DMOG, 
Na+/K+-ATPase activity was unaffected by treatment with CoCI2 (Figure 4-27 B).
A B
Figure 4-27 CoCI2 attenuates apical Cl' currents but not Na+/K +-ATPase activity in T84 cells. Tg4
cells were cultured as monolayers on permeable supports until Rte stabilised at plateau levels. 
Cells were treated bilaterally with CoCI2 (500 fiM) in serum-free medium for 24 hours. Cells 
were washed and mounted in Ussing chambers. A) For apical Cl' conductance experiments the 
apical bath contained Ringer's solution (Table 2-3), whereas the basolateral bath contained a 
low [Cl ] solution (Table 2-5). Cells were permeabilised by basolateral nystatin (100 |ag/ml) after 
which apical FSK (10 ^M ) was added to stimulate Cl" currents. Maximal changes in current were 
plotted as A /sc (n = 3; unpaired t-test; * p < 0.05). B) For measurements o f Na+/K+~ATPase 
activity, cells were bathed bilaterally in Ringer's solution containing 25 mM Na+ (Table 2-7). 
Cells were apically permeabilised with amphotericin B (50 (iM) after which basolateral CCh (100 
¿iM) was added to stimulate Na+/K+-ATPase activity. Maximal changes in current were plotted 
as A /sc (n = 3-6; ANOVA; * * *  p < 0.001 compared to  control).
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4-3.8 EIPA reverses the inhibitory effect of DMOG on 
IMa+/K+-ATPase activity
Finally, having previously shown that chronic inhibition of NHEs by EIPA, in the 
presence of DMOG, reversed the antisecretory effect of DMOG, we wished to 
investigate whether this was due to a reversal of the inhibitory effect of DMOG 
on Na+/K+-ATPase activity. Indeed, chronic treatment of cells with EIPA (50 |j,M; 
24 hours) in the presence of DMOG, reversed the inhibitory effects on Na+/K+- 
ATPase pump activity (Figure 4-28),
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Figure 4-28 Chronic NHE inhibition by EIPA reverses inhibition of the Na+/K+-ATPase 
by DMOG. T84 cells were grown as monolayers on permeable supports until Rte 
stabilised at plateau levels. Cells were treated bilaterally with DMOG (1 mM; 24 hours) 
in serum free medium in the presence or absence of EIPA (5-50 jxM; 24 hours). Cells 
were washed, mounted in Ussing chambers and bathed in low [Na+] Ringer's solution 
(Table 2—7). After an initial stabilisation period EIPA was added to designated 
chambers. Cells were apically permeabilised with amphotericin B (50 jj,M) after which 
basolateral CCh (100 jiM) was added to stimulate Na+/K+-ATPase activity. Maximal 
changes in current were plotted as A /sc (n = 6; ANOVA, ** p < 0.01 compared to 0 |iM 
EIPA).
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The main aim of this chapter was to identify specific transport proteins that may 
be targets of hydroxylase inhibitors in colonic epithelial cells and that could 
mediate their anti-secretory actions. Since previous studies have shown that 
CFTR may be a target of hydroxylase inhibition, we initiated these studies with 
experiments to study the effects of DMOG on CFTR function (Zheng et at.,
2009). Initially, the activity of CFTR was assessed using a modification of the 
Ussing chamber/voltage clamp technique (Rochwerger et at., 1994). In these 
experiments the term apical Cl" current was equated to CFTR activity based on 
the fact that the CFTR-specific inhibitor, CFTRinhi72, inhibited the apical Cl" 
currents by approximately 78 % (Caci et at., 2008). However, it was found that 
apical Cl' currents in Tg4 cells treated with DMOG (1 mM) for 24 hours were no 
different to those of controls. These findings were initially perplexing since, 
consistent with previous reports, expression analysis of CFTR showed a robust 
down regulation in response to hydroxylase inhibition (Zheng et at., 2009). One 
possible explanation for this was that DMOG might induce the expression of 
another type of apical Cl" channel that compensates for loss of CFTR expression. 
However, this does not seem likely since it was found that, similar to its effects
in control cells, CFTRinhi 72 also attenuated apical Cl' currents in DMOG-treated
\
T84 cells by 78%. Furthermore, DMOG did not alter the expression of the Ca2+- 
dependent Cl" channel, TMEM16A, at least at the level of mRNA expression. 
However, an alternative explanation for these apparently conflicting data, that 
CFTR activity is unaffected while its expression is abated, could come from  
previous observations that only 20 % of normal CFTR expression is required to 
maintain cAMP-dependent secretory responses in epithelial cells (De Jonge,
2006). Thus, despite the impact of hydroxylase inhibition on CFTR expression, it 
does not seem likely that this is a predominant factor mediating attenuation of 
intestinal secretory responses by hydroxylase inhibition.
4 - 4  D i s c u s s i o n
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Having ruled out the potential Involvement of altered apical Cl‘ conductances in 
mediating antisecretory actions of hydroxylase inhibitors, we next turned our 
attention to basolateral K+ channels. Recent studies have highlighted the role 
that K+ channels play in luminal anion secretion in the intestine, while others 
have shown that they are important regulators of fluid homeostasis (Flores et 
al., 2007; O'Mahony et al., 2007). Isolation of basolateral K+ conductances was 
achieved by modification of a previously published protocol (Kirk and Dawson, 
1983). However, these experiments did not reveal any differences in K+ 
currents stimulated by the Ca2+-dependent secretagogue, CCh, between control 
and DMOG-treated cells. However, it should be noted that this protocol is 
somewhat limited for 2 main reasons. Firstly, it only allows for the isolation of 
K+ conductances through basolateral KCNN4, and therefore potential effects on 
apical KCNN4 cannot be ruled out. It may be possible to investigate this in 
future studies by reversing the K+ gradient and permeabilising the basolateral 
membrane. However, if such an action of hydroxylase inhibition on apical 
KCNN4 occurs, it is not likely to be as a consequence of altered protein 
expression, since the 37 kDa band that represents the apical isoform was 
unaltered following DMOG treatment. Secondly, this protocol only allows for 
isolation of Ca2+-activated K+ currents, whereas cAMP-activated currents 
through KCNQ1 are not detected in this activity assay. Potential effects of 
hydroxylase inhibition on KCNQ1 activity would require further analysis. 
Interestingly, we did observe a small, but significant, increase in the basal K+ 
currents in DMOG-treated cells. This phenomenon could be explained by an 
increase in KCNQ1 activity, however, this hypothesis was not supported by any 
alterations in the expression of either KCNN4 or KCNQ1 at mRNA or protein 
levels.
We next turned our attention to studying a role for hydroxylases in regulating 
the Na+/K+-ATPase pump. The Na+/K+-ATPase pump consists of 2 subunits, a 
regulatory p subunit and a catalytic a  subunit that pumps 3 Na+ Ions from the 
cell in exchange for 2 K+ ions with each cycle of ATP cleavage (Skou, 1998;
Kaplan, 2002). The normal Ringer's solution which has been used throughout 
this thesis in unpermeabilised cells contains 140 mM Na+. Such levels of Na+are 
normally used in studies of epithelial function, as they are similar to those 
present in the intestine in vivo. However, since intracellular [Na+] is normally 
considerably lower (approximately 25 mM) than 140 mM, we speculated that at 
such high concentrations intracellular Na+ would drive the Na+/K +-ATPase pump 
at its Vmax, potentially masking any effects of hydroxylase inhibition. Thus, we 
employed a bathing solution which contained 25 mM Na+. Upon measurement 
of Na+/K+“ATPase activity, it was found that hydroxylase inhibition significantly 
attenuated CCh-stimulated pump activity. Interestingly, basal pump activity 
was also significantly reduced in DMOG-treated cells. This suggests that the 
mechanisms underlying the antisecretory actions of hydroxylase inhibition 
affect the pump itself, and are not due to alterations in the signalling pathway 
that links the muscarinic M 3 receptor to pump activation.
The relatively slow kinetics for the onset of the antisecretory effects of 
hydroxylase inhibition suggest that alterations in expression of the Na+/K+- 
ATPase may be involved. However, this does not appear to be the case, since 
neither mRNA nor protein levels of the catalytic subunit were altered in DMOG- 
treated cells. Several studies suggest that Na+/K+-ATPase activity can also be 
regulated through altered trafficking of the a  subunit to the cell membrane 
(Chow and Forte, 1995). However, examination of Na+/K+-ATPase a i  subunit 
localisation by confocal microscopy and cell surface biotinylation revealed that 
this too was unaltered by hydroxylase inhibition.
As already mentioned, the Na+/K+-ATPase requires a significant quantity of 
cellular ATP for its functioning, and hypoxia is known to reduce mitochondrial 
ATP production, therefore limiting its availability for the pump (Milligan and 
McBride, 1985; Papandreou et aL, 2006). HIF also has the capacity to 
downregulate ATP synthesis in conditions of hypoxia, while MYC-associated 
factor X interactors (MXIs) have been shown to attenuate mitochondrial
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biogenesis in response to HIF, and therefore cause ATP depletion (Semenza, 
2007; Zhang et al., 2007). Other research has shown that cellular damage and 
reductions in ATP levels that occur as a consequence of hypoxia/reperfusion 
injury, can be reversed by forcing the cell into glycolytic metabolism (Anundi et 
al., 1987; Kim et al., 2003). In this manner, D-fructose is taken up by the cell 
through apical GLUTS transporters, thereby promoting an increase in glycolytic 
generation of ATP. Furthermore, ATP synthase, an important enzyme for 
production of cellular ATP, contains a putative prolyl hydroxylation motif in the 
catalytic a  subunit which may have an impact on its expression or function.
Therefore, the question arose as to whether hydroxylase inhibition could 
attenuate the activity of the Na+/K+-ATPase by reducing cellular ATP levels. 
However, we found that hydroxylase inhibition by DMOG did not alter ATP 
levels in T84 cells. This may be accounted for by the fact that 0 2 is not a limiting 
factor in the present studies, and therefore glycolysis is being promoted in 
aerobic conditions, as occurs with the Warburg effect (Warburg, 1956; Ferreira, 
2010; Koppenol et al., 2011). Our findings are consistent with a previous study 
showing that DMOG does not cause an increase in cellular ROS production, 
indicating no uncoupling of the electron transport chain and thus no reduction 
of mitochondrial ATP synthesis (Emerling et al., 2007). Furthermore, another 
study showed that pretreatment of cardiomyocytes with DMOG preserved 
cellular ATP levels, even though 0 2 consumption was reduced by approximately 
85 % and ATP turnover rate was inhibited by 75 % (Sridharan et al., 2008). 
Preservation of ATP levels was due to a shift in cellular metabolism, with ATP 
production from glycolysis increasing to 40 %. Such shifts can occur when the  
ratio of energy supply to demand decreases, as in chronic hypoxia, and cellular 
homeostatic mechanisms attempt to balance ATP production to utilization 
(Budinger et al., 1996; Budinger et al., 1998; Chandel et al., 1997; Papandreou 
et al., 2006; Wheaton and Chandel, 2011). Therefore, ATP concentration can 
remain relatively stable during hypoxia and it is therefore not the most sensitive 
index of cellular energy status. To promote the glycolytic pathway of ATP
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synthesis, cells were cultured with D-fructose; However, we found that T84 cells 
cultured in D-fructose, with or without DMOG, exhibited no alterations in ATP 
content, nor was there a reversal of the antisecretory effect of hydroxylase 
inhibition. However, firm conclusions cannot yet be drawn from these 
experiments, since additional studies are required to investigate whether T84 
cells even express functional GLUT5 transporters. Finally, we found by western 
blot analysis that expression of the ATP synthase a  subunit, which contains a 
putative prolyl hydroxylation motif, is not altered by DMOG treatment, further 
supporting the idea that hydroxylase inhibition does not alter ATP levels in T84 
cells.
As previously stated DMOG is a non-specific 4-prolyl hydroxylase inhibitor and is 
not specific for hydroxylases activated during hypoxia. Therefore, in 
collaboration with FibroGen Inc., we obtained the use of their proprietary 
compound, FG-4497, which blocks the active site of the HIF hydroxylases (Fraisl 
et a l, 2009). Importantly, for the current studies, we found that effects of 
hydroxylase inhibition with DMOG, which works by mimicking a-ketoglutarate, 
were recapitulated with FG-4497. Antisecretory effects of FG-4497 were slow in 
onset and were only present at relatively high concentrations, in excess of those 
which stabilise H IF -la  and HIF-2a. Furthermore, FG-4497, similar to DMOG, 
also potently inhibited Na+/K +-ATPase activity. Thus, our data suggest that the 
antisecretory effects of hydroxylase inhibitors are mediated by HIF- 
hydroxylases, but in a manner that is independent of HIF-1 activation.
In order to further define the mechanisms by which hydroxylase inhibition 
might regulate epithelial secretory responses, CoCI2 was employed to stabilise 
HIF-a, by mechanisms distinct from those of DMOG and FG4497. C0 CI2 is well 
documented as a hypoxia mimetic and as a H IF -la  stabiliser, although little is 
known of the mechanism involved. Researchers investigating the molecular 
mechanisms of the CoCh-mediated stabilisation of H IF -la  have reported that 
C0 CI2 inhibits VHL-mediated degradation of H IF -la  by directly binding to the 2
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PER-ARNT-SIM domains on the N-terminal region of H IF-la , thus blocking the 
binding site for VHL on H IF -la  (Kanaya and Kamitani, 2003; Yuan et al., 2003). 
More recent studies showed that Co2+ depleted cells of ascorbate, an essential 
cofactor of the HIF hydroxylases and it is now known that CoCI2 causes the 
stabilisation of H IF-la, but with no effect on FIH-1 activity (Salnikow et al., 
2004; Tian et al., 2011b). In initial experiments, conditions with which to use 
C0 CI2 were optimised. While there was no increase in LDH release due to CoCI2 
treatment at any concentration tested, /?te was completely obliterated at a 
concentration of 1 mM, and therefore lower concentrations were employed for 
these studies. We found that CoCI2 increased the accumulation of H IF -la  in a 
concentration-dependent manner at concentrations that were not toxic to the 
cells. We also found that not only does CoCI2 attenuate cAMP-mediated Cl' 
secretion in Tg4 cells, as previously shown (Taylor et al., 1998), but it also 
attenuates Ca2+-mediated Cl' secretion. Further Investigation into the 
mechanisms involved revealed that while apical Cl' conductances were 
attenuated by CoCI2, Na+/K+-ATPase activity was unaltered. This is in direct 
contrast to the mechanism elicited by DMOG, which inhibited Na+/K+-ATPase 
but not CFTR activity, suggesting that the antisecretory effects of hydroxylase 
inhibition by DMOG are likely to be FIH-l-dependent. However, further studies 
will be required to verify this.
Similar to its effects on CFTR, NKCC1 expression has previously been shown to 
be transcriptionally repressed by HIF-1 (Ibla et al., 2006). In the current study 
we found that there was also a significant reduction in expression of NKCC1, 
both at the mRNA and protein levels, in response to treatment with DMOG. 
However, investigations into the activity of NKCC1 revealed no appreciable 
difference following hydroxylase inhibition. Previous studies have shown Cl' 
secretion and NKCC1 expression to be more potently attenuated after longer 
periods of hypoxia (> 24 hours), therefore longer exposure to DMOG may yield 
similar results (Ibla et al., 2006). The repression of NKCCl may be an important 
factor in mediating the antisecretory effects of hydroxylase inhibition since
182
NKCC1 is the primary entry pathway for Cl" ions into epithelial cells. Further 
experiments to investigate the activity and the expression of the co-transporter 
at later time points would be required to prove this.
4 - 5  S u m m a r y
In summary, our data suggest that the antisecretory effects of hydroxylase 
inhibition in intestinal epithelial cells occur, at least in part, through inhibition of 
Na+/K+-ATPase activity (Figure 4-29). The effects of hydroxylase inhibition 
appear to occur in a HIF-independent manner, and are likely to involve FIH-1. 
Furthermore, the mechanism by which hydroxylase inhibitors attenuate Na+/K +- 
ATPase activity does not appear to involve alterations in cellular ATP or 
localisation of the protein. Interestingly, previous studies show that there are 
multiple potential mechanisms by which Na+/K+-ATPase pump activity can be 
regulated without altering its membrane localisation. For example, FXYD 
proteins are membrane-associated proteins that can regulate pump activity 
without altering its surface expression (Garty and Karlish, 2006). Similarly, 
intracellular regulatory proteins, such as translationally-controlled tumour 
protein (TCTP) and sorting nexin 6  (SNX 6 ), are emerging as important 
regulators of Na+/K+-ATPase activity (Jung et a!., 2004; Yoon et al., 2006). In the 
next section of this thesis a more detailed analysis of how hydroxylase inhibitors 
might regulate Na+/K+-ATPase activity to exert antisecretory actions on colonic 
epithelial cells was conducted.
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Figure 4-29 Hydroxylase inhibition specifically attenuates Na+/K+-ATPase activity in 
Tg4 cells. Hydroxylase inhibition attenuates luminal Cl' secretion by a mechanism that 
involves attenuation of Na+/K+-ATPase activity, without altering expression of the pump 
at the basolateral cell surface. Although hydroxylase inhibitors reduce expression of 
apical CFTR channels, this does not appear to be a major contributing factor to their 
antisecretory actions. Our data suggest that the effects of hydroxylase inhibition are 
likely to occur in a HIF-independent, but FIH-l-dependent manner.
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5 - 1  I n t r o d u c t i o n
In the previous chapter we revealed a novel role for hydroxylases in regulating 
intestinal epithelial Na+/K+-ATPase activity, an effect that is likely to be 
important in mediating the antisecretory actions of hydroxylase inhibitors. 
When considering the use of such drugs as therapeutics, it is important to 
understand the molecular mechanisms involved. Thus, we next turned our 
attention to studying potential mechanisms by which hydroxylase inhibitors 
regulate Na+/K+-ATPase activity.
Na+/K+-ATPase pumps exist as heterodimers in the plasma membrane, with one 
a  and one p subunit (Craig and Kyte, 1980). However, resolution of the crystal 
structure of the Na+/K+-ATPase in the recent past, also revealed the presence of 
Na+/K+-ATPase y subunits in renal extracts (Morth et a/., 2007). Furthermore, 
additional studies show that Na+/K+-ATPase pumps exist as a complex of 
different subunits, allowing for tissue-specific regulation (Garty and Karlish, 
2006; Yoon et al.t 2006). Thus, our knowledge of the structure of the Na+/K+- 
ATPase is constantly evolving, but remains incompletely understood. There are 
many mechanisms by which the Na+/K+-ATPase pump can be regulated, and 
some of these were investigated in Chapter 4 of this thesis. In our studies, we 
found that hydroxylase inhibition of pump activity was not due to alterations in 
its expression or localisation at the plasma membrane, nor was it due to an 
altered availability of ATP. However, another way by which hydroxylase 
inhibition could alter Na+/K+-ATPase function is by altering its interactions with 
regulatory proteins.
The field of molecular regulation of the Na+/K+-ATPase js very complex, a fact 
that is highlighted by the plethora of recently identified proteins that can 
associate with, and regulate, pump activity (Sweadner and Rael, 2000; Geering, 
2006; Yoon et at., 2006; Mao et a i, 2005; Gorokhova et at., 2007). The proteins 
and molecules selected for investigation in this chapter were selected based on
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published evidence of their involvement in pump regulation. For example, not 
only are endothelins known regulators of the Na+/K+-ATPase, they are also 
secreted from intestinal epithelial cells and are potently induced by hypoxia. 
Another example is FXYD3, which is known to be a negative regulator of the 
Na+/K+-ATPase and which is highly expressed in the colon. Several other 
proteins of interest are investigated in more detail throughout this chapter.
Endothelin (ET) 1, 2, and 3 are peptide hormones with potent vasoconstrictor 
properties which are synthesised and secreted predominantly by vascular 
endothelial cells (Rubanyi and Polokoff, 1994). One of the most potent inducers 
of ET-1 is hypoxia, and this is brought about by HIF-1 binding to the et-1 gene in 
conjunction with other transcription factors (Watanabe e t  a l., 1990; Tonnessen 
e t  a l., 1995; Yamashita e t  a l., 2001). More recent research has shown that 
hydroxylase inhibition by DMOG in rats can also induce ET-1 expression in vivo  
(Nagel e t  a l., 2011). ETs bind to ET receptors A (ETRA) and B (ETRB) and all 3 ETs 
and their receptors are expressed in the colonic epithelium (Takahashi e t  a l., 
1990; Takizawa e t  a l., 2005; Kalabis e t  a l., 2008; Egidy e t  a l., 2000). Several 
studies have revealed that ET-1 exerts pro-secretory actions in humans and rats, 
with its actions being mediated by cyclo-oxygenase products and enteric nerves 
via activation of ETRA (Kuhn e t  a l., 1997; Moummi e t  a l., 1992; Kiyohara e t  a l.,
1993). Interestingly, earlier studies conducted on renal tubular epithelial cells 
show that ET inhibits Na+/K+-ATPase activity, an effect that involves generation 
of prostaglandin E2 (PGE2) (Zeidel e t  a l., 1989). More recent studies 
demonstrate that activation of ETRB also inhibits Na+/K+-ATPase activity in renal 
proximal tubule cells (Liu e t  a l., 2009). Thus, since epithelial-derived ETs are 
known to have the capacity to acutely regulate Na+/K +-ATPase function, in the 
present studies their potential role in mediating the antisecretory actions of 
hydroxylase inhibition was investigated (Prasanna e t a l . ,  2001; Liu et a l., 2009).
Another mechanism by which Na+/K +-ATPase pump activity can be 
downregulated in epithelial cells is by its sequestration into lipid rafts. Lipid
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rafts are membrane microdomains that are rich in cholesterol and 
glycosphingolipids (Pike, 2009). They are of great interest in the context of this 
thesis for several reasons. First and foremost, lipid rafts are known to be 
regulated by hypoxia (Botto et al., 2008). Secondly, hypoxia regulates 
cholesterol biosynthesis, an important component of lipid rafts (Nguyen et al., 
2007). Thirdly Na+/K+-ATPase function, membrane cholesterol, and caveolin-1 
(an important constituent of caveolae), are inextricably linked at the molecular 
level (Chen et al., 2009; Chen et al., 2011; Cai et al., 2008). Finally, as much as > 
50 % of plasma membrane Na+/K+~ATPase can become sequestered into lipid 
rafts, where it is thought to function more as a signalling molecule than an ion 
transporter (Wang et al., 2004). Interestingly, Na+/K+-ATPase movement to and 
from lipid rafts is dynamic, and upon cholesterol or caveolin depletion, some of 
this non-pumping Na+/K+-ATPase can return to the pumping pool (Liang et al., 
2007). Thus, sequestration into lipid rafts causes reduced activity of the pump 
without alterations in its cellular expression, a phenomenon that could explain 
the effects of hydroxylase inhibitors observed in the current studies. In its 
capacity, as a signalling protein, the Na+/K+-ATPase has been shown to bind 
endogenous and exogenous cardiotonic steroids, such as ouabain, thereby 
evoking intracellular responses through interactions with downstream signalling 
proteins, such as Src (Liang et al., 2006). Importantly, Src is also known to be a 
regulator of intestinal epithelial Cl' secretion (Keely et al., 2000). Therefore, we 
investigated if lipid rafts or Src family kinases might have a role to play in 
mediating the effects of hydroxylase inhibition on Na+/K +-ATPase activity.
Another possible mechanism by which hydroxylases might regulate epithelial 
secretory function could involve NFkB. NFkB is a known target of HIF- 
hydroxylases and has been shown to regulate transport proteins, specifically 
CFTR, expression in airway epithelial cells in response to interleukin- 
1(3 (Brouillard et al., 2001). Indeed, interleukin-ip itself has been shown to be 
upregulated in macrophages by HIF-dependent mechanisms (Imtiyaz et al.,
2010). Thus, a potential role for NFk B in DMOG-induced downregulation of Cl‘
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secretion was investigated using BMS-345541, a highly selective inhibitor of IkB 
kinase (Burke et al., 2003).
There is a multitude of intracellular signalling pathways involved in regulating 
epithelial Cl' secretory responses, some of which directly regulate the activity of 
the Na+/K+-ATPase. One such signalling pathway protein is PKC, of which there 
are several isoforms, classified into different groups. The classical PKCs are a  
and pil; the novel PKCs consist of 5, 8 , 0, and rj; whereas the atypical PKCs are C, 
and X. PKC is a well characterised regulator of Cl‘ secretion via its regulation of 
CFTR and NKCC1, amongst others (Song et al., 2001; Matthews et al., 1994).
Interestingly, PKC 8  has also been shown to regulate Cl’ secretion across T84 cells
;
under conditions of chemically-induced ischemia, and as already mentioned in 
the introduction to Chapter 4, PKC C, is a known regulator of Na+/K +-ATPase 
function (Yoo et al., 2001). This PKC isoform translocates to the plasma 
membrane where it phosphorylates Ser-18 on Na+/K+-ATPase a i, culminating in 
clathrin-dependent pump endocytosis (Dada et al., 2003; Chen et al., 2006). 
Another protein kinase, PKA, is known to be regulated by hypoxia (Beitner- 
Johnson et al., 1998), and is an important regulator of epithelial Cl" secretion, 
being best known for its role in regulating CFTR gating (Singh et al., 1998; Forte 
et a i, 1992; Chappe et a i, 2005). Thus, we also investigated the potential 
involvement of PKC and PKA in mediating the antisecretory actions of 
hydroxylase inhibition.
In conditions of hypoxia, global transcriptional and translational processes are 
known to be dampened as a consequence of cellular energy conservation 
processes (Liu and Simon, 2004). Conversely the master regulator of hypoxia, 
HIF, becomes active during hypoxia and drives transcription of genes that aid in 
adaptive responses. Results from Chapter 4 indicated the antisecretory effects 
to be HIF-independent. However, given the profound transcriptionally- 
mediated effects of HIF during hypoxia, experiments were designed to more
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conclusively explore the role of HIF in mediating the antisecretory effects of 
hydroxylase inhibition.
The Na+/K+-ATPase p subunit is one of the most important regulators of Na+/K+- 
ATPase activity since the pump has been shown to be inactive when it is absent 
(Horowitz et a i, 1990). The P subunit spans the membrane only once and is 
thought to be important for the correct insertion of the ap heterodimer into 
the plasma membrane (Hasler et a i, 2001). More recent studies have shown 
that the polarised expression of Na+/K+-ATPase pumps in epithelia also depends 
on the association of p-subunits located in neighbouring ceils, thus highlighting 
the importance of each of the pump subunits in regulating its transport 
properties (Shoshani et a i, 2005; Padilla-Benavides et al.f 2010).
As previously mentioned, the Na+/K+-ATPase exists as a protein complex with 
several subunits, such as the p subunit and the y subunit (FXYD2) (Morth et al., 
2007). Another important family of proteins known to regulate Na+/K+-ATPase 
activity are the FXYD proteins. This family of 7 proteins are structurally 
characterised by an FXYD motif, 2 conserved glycines, and a serine residue 
(Sweadner and Rael, 2000). FXYD proteins are known to modify the transport 
properties of Na+/K+“ATPase pumps in a tissue-specific manner, without altering 
its expression (Delprat et al., 2006; Geering, 2006). More recent research also 
suggests that they contribute to stabilisation of the pump at the membrane 
(Mishra et a i, 2011). Previous studies have implicated FXYD3 in regulation of Cl" 
currents in Xenopus oocytes, although at the time it was not yet known to be a 
regulator of Na+/K+-ATPase activity (Morrison et al., 1995). Subsequent studies 
have found FXYD3 to be highly expressed in the colon (Crambert et a i, 2005), 
and studies conducted on intestinal epithelial cells have shown that it negatively 
regulates Na+/K+-ATPase activity (Crambert et a i, 2005; Bibert et a i, 2009).
A relatively recently identified protein known as Modulator of NaVK+-ATPase 
(MONaKA; PXK) is also of relevance to the current studies. This protein has been
shown to bind Na+/K+-ATPase p subunits and to negatively regulate pump 
activity (Mao et al., 2005). MONaKA has been proposed by one group to be a 
functional sorting nexin that is important in regulating cellular function via its 
interaction with the actin cytoskeleton (Takeuchi et al., 2010). Thus, we 
investigated if this protein might be involved in mediating the antisecretory 
effect of DMOG in colonic epithelial cells.
Finally, another possible mechanism by which hydroxylase inhibition 
downregulates secretory function involves FIH-1. Studies carried out in Chapter 
4 showed that both DMOG and FG-4497 exert antisecretory actions at high 
concentrations, in excess of those required to stabilise HIF-la. At such 
concentrations FIH-1 is also known to be inhibited, and in fact FIH-1 was found 
to be more sensitive to inhibition by DMOG than were the prolyl hydroxylases 
(Tian et al., 2011b). Furthermore, FIH-1 is known to hydroxylate ankyrin repeat- 
containing proteins, including the cytoskeletal ankyrin family (Linke et al., 2007; 
Cockman et al., 2009; Yang et al., 2011). The ankyrin repeat is one of the most 
common protein-protein interaction motifs found in nature and has been 
postulated as a molecular signal for protein recognition (Mosavi et al., 2004; Li 
et al., 2006). This is interesting considering the Na+/K+-ATPase oil subunit 
possesses 2 cytoplasmic ankyrin-binding domains, and that these ankyrin 
binding domains are important in the regulation of the pump via interactions 
with the spectrin cytoskeleton (Devarajan et al., 1994; Zhang et al., 1998; 
Woroniecki et al., 2003). Thus, the possibility that FIH-1 mediates the effects of 
hydroxylase inhibition on Na+/K+-ATPase pump activity was further investigated 
in this chapter.
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5 - 2  A i m
From the preceding Introduction it is clear that there are many potential 
mechanisms by which the activity of the Na+/K+-ATPase can be regulated. 
Therefore, the general aim of this chapter was to investigate molecular 
mechanisms underlying regulation of the Na+/K+-ATPase by hydroxylase 
inhibitors.
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As described in the introduction to this chapter, the Na+/K+-ATPase is an 
important protein that plays critical roles in regulating epithelial transport and 
signalling under the control of multiple intra- and extracellular factors, many of 
which can be altered in conditions of hypoxia. Thus, a rather broad approach 
was first taken to identify potential signalling mechanisms that underlie the 
effects of hydroxylase inhibition on Na+/K+-ATPase function.
5-3.1 The antisecretory effects of hydroxylase inhibition 
are not mediated by an acutely acting soluble factor
Endothelins, which can be potently induced under conditions of hypoxia, are 
secreted molecules known to have the capability to acutely regulate Na+/K+- 
ATPase activity. Therefore, the possibility that hydroxylase inhibition of pump 
activity is mediated by the release of a soluble factor, such as ET-1, was next 
investigated. Hydroxylases were inhibited in T84 cells by DMOG (1 mM; 24 
hours). The apical and basolateral conditioned medium was then aspirated and 
applied to naive T84 cells for various periods of time ranging from 15 minutes to 
1 hour. Although DMOG is still present in this conditioned medium, we would 
not expect to see direct effects of the inhibitor over such short periods of time, 
and any effects observed should be due to factors secreted into the medium. 
However, as shown in Figure 5-1, the application of conditioned medium to 
naive T84 cells had no impact on subsequent Cl' secretory responses to either 
basolateral CCh (100 jiM) or apical FSK (10 jaM).
5 - 3  R e s u l t s
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Figure 5-1 The antisecretory effects of hydroxylase inhibition are not mediated by an 
acutely acting soluble factor. T84 cells were cultured as monolayers on permeable 
supports until ffte stabilised at plateau levels. Cells were treated bilaterally with DMOG 
(1 mM) in serum-free medium for 24 hours. After 24 hours the conditioned medium 
from the apical side of DMOG-treated cells was aspirated and applied to the apical side 
of naive cells (AP-AP) for various periods of time from 15 to 60 minutes. Similarly, 
basolateral conditioned medium was applied to the basolateral side of naive cells (BL- 
BL). Naive Tg4 cells had been cultured in serum-free medium for 24 hours prior to 
treatment with conditioned medium. A) Maximal changes in current in response to 
basolateral CCh (100 |iM) in control and treated cells were plotted as A /sc (n = 3). B) 
Maximahchanges in current in response to apical FSK (10 |j,M) in control and treated 
cells were plotted as A /sc (n = 3).
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5-3.2 Disruption of lipid rafts does not reverse ISIa+/K+- 
ATPase inhibition by hydroxylase inhibition
Na+/K+-ATPase pumps can become sequestered into lipid rafts under certain 
conditions, where it then acts as a signalling protein rather than an ion 
transporter. Thus, the effect of lipid raft disruption on Na+/K+-ATPase activity in 
DMOG-treated T84 cells was next investigated. As proof of principle that MPCD 
is working, cells were treated with MPCD alone, which should release 
sequestered Na+/K+-ATPase, and increase its activity. Pump activity was 
increased and was approaching significance in the presence of MPCD alone. 
However, it was found that basolateral treatment of the cells with MPCD with 
concentrations previously shown to deplete cholesterol in T 84 cells (Wolf et oi, 
2002), did not reverse the inhibitory effect of DMOG (Figure 5-2).
DMOG (1 mM) + - +
Figure 5-2 MpCD disruption of lipid rafts does not affect Na+/K+-ATPase activity in 
DMOG-treated TM colonic epithelial cells. T^ cells were cultured as monolayers on 
permeable supports until flte stabilised at plateau levels. Cells were treated bilaterally 
with DMOG (1 mM; 24 hours) in the presence or absence of basolateral MpCD (4 mM) 
for the final hour of DMOG treatment. Cells were washed, mounted in Ussing 
chambers, and bathed in Ringer's solution (Table 2-3). Maximal changes in current in 
response to basolateral CCh (100 juM) and apical FSK (10 jxM) in control and treated 
cells were plotted as A /sc (n = 3; ANOVA, ** p < 0.01, compared to untreated control).
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5-3.3 Post-translational modifications facilitate 
antisecretory actions of hydroxylase inhibition
Having ruled out the involvement of lipid rafts or an acutely acting secreted 
autocrine factor, a broad Investigation of the possible contributions of several 
different signalling pathways was next performed. NFkB is a known non-HIF 
target of hydroxylases that has been previously shown to have the capacity to 
regulate transport protein function (Cummins et 61., 2006; Brouillard et al., 
2001). Therefore, a potential role for NFkB activation in mediating hydroxylase 
effects on Na+/K+-ATPase activity was investigated. We employed BMS-345541 
to pharmacologically inhibit NFkB, with experiments first being conducted to 
determine the efficacy of the inhibitor. Treatment of T ^  cells with DMOG (1 
mM; 30 minutes) caused phosphorylation of IkBcc, as previously demonstrated, 
which was inhibited by BMS-345541 (Figure 5-3 A) (Cummins et al.r 2006). Basal 
levels of phosphorylated hcB a persisted in the presence of the inhibitor, which 
may be due to basal phosphorylation of the protein by other kinases, such as 
PKC (Steffan et a/., 1995). Next, T 84 cells were cultured on permeable supports 
with BMS-345541 in the presence or absence of DMOG (1 mM) for 24 hours. 
Cells were then mounted in Ussing chambers and secretory responses to CCh 
(100 jiM) and FSK (10 ^iM) were measured. We found that BMS-345541 had no 
effect on basal /sc or Rte, nor did it ameliorate the antisecretory effect of 
hydroxylase inhibition (Figure 5 -3  B).
196
A B
160
140 i
_  120 I
100
\  80
3  60 i
<  40
***
I I
20 I
0
'i 1 i
n DMOG(lmM)
p-actin 42kDa
BMS (10 jiM; 60') 
DMOG (1 mM; iff)
CCh
FSK
***
X
Figure 5 -3  NFkB does n o t m e d ia te  th e  a n tis e c re to ry  e ffe c t o f  hyd roxy lase  in h ib it io n  in  TM 
co lon ic  e p ith e lia l cells. cells w e re  cu ltu red  as m onolayers on perm eable  suppo rts  u n til /?te 
s tab ilised a t p la teau levels. A) Cells w e re  tre a te d  w ith  DMOG (1 m M ; 30 m inu tes) to  induce 
phospho ry la tion  o f IkBcx. NFkB was in h ib ite d  by p re tre a tm e n t o f cells w ith  BM S-345541 (10 
(¿M) fo r  30 m inu tes p r io r  to  D M O G -trea tm en t and then  fo r  th e  d u ra tio n  o f  D M O G -trea tm en t. 
Cells w e re  then  lysed and p ro te ins  w ere  separa ted by SDS-PAGE and analysed by w este rn  
b lo tt in g  fo r  phopho-licB a  (n = 3; ANOVA; * * *  p <  0.05). B) Cells w e re  tre a te d  b ila te ra lly  w ith  
DMOG (1 m M ) in se rum -free  m ed ium  fo r  24 hours e ith e r in the  absence o r  presence o f  BMS- 
345541. Cells w e re  washed, m oun ted  in Ussing cham bers, and ba thed  in R inger's so lu tion  
(Table 2-3). M ax im al changes in /sc in response to  basolatera l CCh (100 ^ M ) and apical FSK (10 
in c o n tro l and tre a te d  cells w ere  p lo tte d  as A !sc (n = 5; ANOVA; * * *  p <  0.001, com pared to  
respective con tro ls).
Having shown that NFk B was not likely to be involved in mediating the 
antisecretory effect of hydroxylase inhibition, we next examined Src family 
kinases. These important signalling proteins are known to regulate epithelial 
transport function and can also be regulated in conditions of hypoxia (Keely e t  
a l., 2000; Knock e t  a l., 2008). A potential role for Src family kinases was 
examined using PP2 (Hanke e t  a l., 1996). PP2 potentiated CCh (100 jaM)-
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stimulated responses to 191.51 ± 42.52 % of controls, but reduced FSK (10 jliM )- 
stirriulated responses to 64.62 ± 5.54 % of control similar to previous results 
(Keely e t  a l. ; 2000; Bertelsen e t  a l., 2002). Treatment with PP2 did not reverse 
the antisecretory effect of DMOG on Ca2+~dependent responses. Interestingly, 
however, PP2 significantly attenuated the antisecretory effect of hydroxylase 
inhibition on cAMP-dependent responses. DMOG alone inhibited FSK- 
stimulated responses to 29.40 ± 2.92 %  of those in controls. However, in the 
presence of both PP2 and DMOG, responses to FSK were 45.52 ± 5.15 % of 
controls (n = 5; ns compared to control) (Table 5-1). It is worth noting that the 
inhibition of FSK-stimulated current by DMOG in this set of experiments was 
greater than that initially reported and shown in Table 5-1 , We attribute this 
variation to variation between experiments.
Similar to Src family kinases, PKC is a critical regulator of epithelial transport 
protein function. Therefore, we also examined its potential involvement in 
mediating the antisecretory actions of hydroxylase inhibition. A well-described 
general inhibitor of the classical and novel PKC isoforms, GF 109203X, was 
employed. However, it was found that 24 hours treatment with GF 109203X in 
the presence of DMOG did not significantly reverse the antisecretory effects of 
the hydroxylase inhibitor (Table 5-1).
PKA is also known to be an important regulator of epithelial Cl' secretion (Singh 
et a l,, 1998). However, upon its inhibition with the specific inhibitor, H89, there 
was no reversal of the antisecretory effect of hydroxylase inhibition (Table 5-1) 
(Davies e t  aJ., 2000; Chijiwa e t  a  I 1990).
Finally, acriflavine (5 |iM), which was employed as a HIF inhibitor was also 
without effect on the antisecretory actions of hydroxylase inhibition (Table 5-1) 
(Lee e t  a l., 2009).
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Table 5-1 Pharmacological Investigation of the involvement of various signalling pathways in 
mediating antisecretory actions of DMOG. cells were cultured as monolayers on permeable 
supports until Rte stabilised at plateau levels. Cells were treated bilaterally with DMOG (1 mM; 
24 hours) in the presence or absence of various pharmacological inhibitors (Table 2-2). Cells 
were washed, mounted in Ussing chambers, and bathed in Ringer's solution (Table 2-3). Cl* 
secretory responses to basolateral CCh (100 ^iM) and apical FSK (10 ^ M) were then measured. 
Maximal responses to CCh and FSK are represented as % of respective control A /„ responses 
analysed by ANOVA for each inhibitor.
Treatment Target
BMS-345541 NFkB 
Control
Ì B f K i S l
IBMSI3355m  
PP2 Control Src-family 
kinases
AcrifKavine 
Control
ìdW g^ I  
B ftr iflw ìn fI 
H89 Control PKA
Response to CCh
(% of respective 
control)
128.81120.88  
(n = 3; ns)
76.32 ±11.78  
(n -  5; ns)
^ 5 jJ g § 1 0 ! l  
191.51 ±42.52  
(n = 4; p < 0.05)
78.99 ± 6.02 
(n = 6; ns)
30.76 ±3.18  
(n = 4; p < 0.001) 
B jJlsW jb fegj 
i( n a ^ fpEvotouì)]
Response to FSK
(% of respective 
control)
64.62 ± 5.53 
(n = 4; ns)
q g n p
M S B
80.78 ± 2.75 
(n = 6; ns)
m m tm
42.39 ± 1.71 
(n = 4; p < 0.001)
A potential role for new protein translation in mediating the antisecretory effect 
of hydroxylase inhibition was next investigated by use of the protein translation 
inhibitor, CHX. In order to verify the efficacy of CHX, experiments were first 
carried out in which HIF-la protein expression was induced by treatment of Tg4 
cells with DMOG (1 mM; 24 hours), in the presence or absence of various
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concentrations of CHX (0 -5  |iM). CHX (5 |xM) inhibited H IF -la  accumulation by 
64 % compared to DMOG alone (n = 2) (Figure 5 -4  A), similar to results 
previously obtained in T 84 cells (McRoberts et al., 1990). Tg4 ceils were next 
cultured with CHX (5 jxM ) in the presence or absence of DMOG (1 mM; 24 
hours). Cells were mounted in Ussing chambers and upon stimulation with 
basolateral CCh (100 |iM) and apical FSK (10 jiM), we found there to be no 
reversal of the antisecretory effect of hydroxylase inhibition (Figure 5 -4  B).
[CHX] (nM) o 
DMOG (1 mM) -
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CHX (5 nM) 
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Figure 5 -4  C ycfohex im ide  does n o t a lte r  th e  a n tis e c re to ry  e ffec ts  o f  h yd roxy lase  in h ib it io n  in 
Tb4 co lon ic  e p ith e lia l cells. cells w e re  cu ltu red  as m onolayers on pe rm eab le  suppo rts  u n til 
ffte stab ilised a t p la teau levels. A) Cells w ere  tre a te d  b ila te ra lly  w ith  DMOG (1 m M ; 24 hours) to  
induce H IF - la , in th e  presence o r absence o f CHX a t various con cen tra tion s  fo r  24 hours. Cells 
w e re  lysed and p ro te ins  w ere  separated by SDS-PAGE and H IF - la  was de tec ted  by w e s te rn  b lo t. 
(3-actin was n o t used as a load ing con tro l in these experim ents  as its expression w o u ld  also be 
expected to  decrease due to  C H X -treatm ent (n = 2). B) Cells w e re  tre a te d  b ila te ra lly  w ith  
DMOG (1 m M ; 24 hours) in th e  presence o r absence o f CHX (5 ^ M ). Cells w e re  washed, 
m ou n ted  in Ussing cham bers, and ba thed  in R inger's so lu tio n  (Table 2 -3 ). M axim al changes in 
cu rre n t in response to  baso la tera l CCh (100 jiM )  and apical FSK (10 ^ M )  in c o n tro l and tre a te d  
cells w e re  p lo tte d  as A  (n = 4; ANOVA; * p <  0.05; * * *  p <  0.001, com pared to  th e ir  respective  
con tro ls).
200
The potential involvement of gene transcription in mediating the antisecretory 
effect of hydroxylase inhibition was also investigated using the transcriptional 
inhibitor, AD. Again, to test the efficacy of AD, cells were first treated bilaterally 
with AD (250 ng/ml) for 24 hours and 18SrRNA mRNA expression was 
determined by semi-quantitative RT-PCR. These experiments showed that AD 
inhibited transcription of 18SrRNA to 61.51 ± 7.18 % of that in control cells 
(Figure 5 -5  A). T 84 cells were next cultured with AD (250 ng/ml) in the presence 
or absence of DMOG (1 mM; 24 hours), mounted in Ussing chambers and 
stimulated with basolateral CCh (100 ^iM) and apical FSK (10 juM). AD reduced 
both the Ca2+ and cAMP-mediated Cl‘ secretory responses in control cells, but it 
was also clear that AD did not reverse the antisecretory effects of hydroxylase 
inhibition (Figure 5 -5  B).
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Figure 5-5 Actinomycin D does not attenuate the antisecretory effect of hydroxylase 
inhibition in TM colonic epithelial cells. T84 cells were cultured as monolayers on 
permeable supports until /?te stabilised at plateau levels. A) Cells were treated 
bilaterally with AD (250 ng/ml) for 24 hours. Total RNA was isolated and mRNA 
expression of 18SrRNA was analysed by semi-quantitative RT-PCR (n = 4; paired t-test; 
** p < 0.05). B) Cells were treated bilaterally with DMOG (1 mM) in serum-free 
medium for 24 hours in the presence or absence of AD (250 ng/ml). Cells were 
washed, mounted in Ussing chambers, and bathed in Ringer's solution (Table 2-3). Cl' 
secretory responses were then stimulated with basolateral CCh (100 |j.M) and apical 
FSK (10 juM). Maximal responses to CCh and FSK were plotted as A lsc responses (n = 6; 
ANOVA; ** p < 0.01; *** p < 0.001, compared to respective controls).
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5-3.4 Na+/K+-ATPase p1 protein expression is significantly 
increased by hydroxylase inhibition
Since it is insensitive to CHX and AD, our data suggested that the antisecretory 
effect of hydroxylase inhibition is likely mediated by a post-translational event. 
Thus, the expression of some known regulatory proteins of the Na+/K+-ATPase 
pump was next investigated. PKC as already discussed in the introduction to 
Chapter 4, was the first to be investigated. Hydroxylases were inhibited by 
DMOG (1 mM; 24 hours) and PKC £ protein expression was investigated by 
western blotting (Figure 5-6). No changes in the abundance of PKC ^ in DMOG- 
treated cells were observed.
Figure 5-6 Hydroxylase inhibition does not alter PKC C, expression in T^ colonic 
epithelial cells. T84 cells were cultured as monolayers on permeable supports until Rte 
stabilised at plateau levels. Cells were treated bilaterally with DMOG (1 mM) in serum- 
free medium for 24 hours. Cells were lysed, proteins were resolved by SDS-PAGE, and 
PKC C, expression was analysed by western blotting, p-actin was used as a loading 
control (n = 4).
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Another protein known the regulate NaVK+-ATPase pump activity in colonic 
epithelial cells is FXYD3. Expression of this regulatory protein was also 
investigated at the mRNA level. Hydroxylases were again inhibited by DMOG (1 
mM; 24 hours) and FXYD3 mRNA expression was investigated by semi- 
quantitative RT-PCR (Figure 5-7). However, there were no changes observed in 
FXYD3 mRNA expression in DMOG-treated cells.
C ontro l DMOG
Figure 5-7 FXYD3 mRNA expression is not altered by hydroxylase inhibition in T84 
colonic epithelial cells. cells were cultured as monolayers on permeable supports 
until rtte stabilised at plateau levels. Cells were treated bilaterally with DMOG (1 mM) 
in serum-free medium for 24 hours. mRNA was isolated from the cells and semi- 
quantitative RT-PCR analysis was performed. 18SrRNA was used as a loading control (n 
= 5).
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In further experiments, the expression of the regulatory subunit of the Na+/K+- 
ATPase heterodimer, Na+/K+-ATPase Pi, was also investigated. Hydroxylases 
were inhibited by DMOG (1 mM; 24 hours) and Na7K+-ATPase Pi expression 
was investigated at both the mRNA and protein levels by semi-quantitative RT- 
PCR and western blotting, respectively. Interestingly, we found that while there 
were no changes in mRNA expression (Figure 5-8 A), protein expression of the 
35 kDa Na+/K+-ATPase Pi subunit was significantly increased to 173.83 ± 17.27 % 
of that in control cells (Figure 5-8 B).
A B
DMOG 1mM (hours) Z  DMOG 1mM (hours)
Figure 5-8 Na+/K+-ATPase p1 protein expression is increased by hydroxylase inhibition  
in Tg4 colonic epithelial cells. T84 cells were cultured as monolayers on permeable 
supports until Rte stabilised at plateau levels. Cells were treated bilaterally with DMOG 
(1 mM) in serum-free medium for various periods of time. A) mRNA was isolated from 
the cells and semi-quantitative RT-PCR analysis was performed with primers specific for 
Na+/K+-ATPase pi (labelled as pi in the upper panel). 18SrRNA was used as a loading 
control (n = 5). B) Total protein was isolated from cells, and Na+/K+-ATPase p! protein 
expression was measured by western blotting (labelled as Pi in the upper panel), p- 
actin was used as a loading control (n = 3; ANOVA; * p < 0.05 compared to control).
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Having found that Na+/K+-ATPase pa subunit protein (35 kDa glycoprotein) 
expression is increased after treatment with DMOG, localisation of the protein 
at the plasma membrane in Tg4 cells was analysed by confocal microscopy. Cells 
were cultured on transparent permeable supports and treated with DMOG (1 
mM; 24 hours). As shown in Figure 5-9, Na+/K+-ATPase \s very specifically 
expressed basolaterally within one z-plane of T84 cells (indicated by arrows). In 
agreement with our western blot data, there also appeared to be an increase in 
the amount of Na+/K+~ATPase P i in the plasma membrane and cytosol of 
DMOG-treated cells.
Control DMOG
Figure 5-9 Na+/K+-ATPase pa expression in the plasma membrane is increased by 
hydroxylase inhibition in TM colonic epithelial cells. cells were cultured as 
monolayers on permeable supports until Rte stabilised at plateau levels. Cells were 
treated bilaterally with DMOG (1 mM) in serum-free medium for 24 hours. Cells were 
washed in PBS, fixed in 100 % methanol, permeabilised with Triton X-100, and stained 
with specific fluorophore-labelled antibodies as outlined in Section 2-23. Pseudo­
colours were assigned to the various proteins where Na+/K+-ATPase p: js represented in 
green. This image is representative of 3 similar experiments.
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5-3.5 MONaKA is expressed at the plasma membrane of 
intestinal epithelial cells, and is increased by hydroxylase 
inhibition
The results thus far show that while Na+/K+-ATPase pump activity is attenuated 
by hydroxylase inhibition, expression of the Pi subunit of the protein is 
augmented. Thus, in the next series of experiments, the expression of MONaKA 
was investigated in T 84 cells. MONaKA is known to be an Na+/K+-ATPase pi- 
binding protein that attenuates pump activity (Mao et a/., 2005). Hydroxylases 
were inhibited by DMOG (1 mM) and after various periods of time MONaKA 
mRNA and protein expression were analysed. It was found that expression of 
MONaKA mRNA was significantly attenuated after 24 hours treatment with 
DMOG to 52.52 ± 6.32 % of that in control cells (Figure 5 -1 0  A). However, in 
contrast, MONaKA protein expression was significantly increased following 
hydroxylase inhibition to 199.62 ± 25.92 % of that in controls (Figure 5 -1 0  B).
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Figure 5-10 Hydroxylase inhibition attenuates MONaKA mRNA levels but increases 
MONaKA protein expression in TM colonic epithelial cells. cells were cultured as 
monolayers on permeable supports until Rte stabilised at plateau levels. A) Cells were 
treated bilaterally with DMOG (1 mM) in serum-free medium for various periods of 
time. mRNA was isolated from cells and semi-quantitative RT-PCR analysis was 
performed with primers specific for MONaKA. 18SrRNA was used as a loading control 
(n = 4; ** p < 0.01). B) Cells were treated bilaterally with DMOG (1 mM) in serum-free 
medium for 24 hours. Total protein was isolated from cells, and MONaKA protein 
expression was measured by western blotting, p-actin was used as a loading control (n 
= 14; ANOVA; ** p < 0.01 compared to control).
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Since results from our previous experiments with CHX (Figure 5-4) suggest that 
the antisecretory effect of hydroxylase inhibition is independent of d e  novo  
protein synthesis, effects of CHX on MONaKA protein expression were also 
investigated. As shown in Figure 5-11, DMOG-induced expression of MONaKA 
was not altered in the presence of CHX and was 176.55 ± 18.13 % of that in 
untreated controls. This result of this experiment is somewhat limited however, 
by the omission of a CHX-only treated control with which to compare.
Figure 5-11 Hydroxylase inhibition increases MONaKA protein expression 
independently of de novo  protein synthesis. T84 cells were cultured as monolayers on 
permeable supports until Rte stabilised at plateau levels. Cells were treated bilaterally 
with DMOG (1 mM; 24 hours) in the presence or absence of CHX (5 fiM) for 24 hours. 
Cells were lysed, proteins were separated by SDS-PAGE, and MONaKA was detected by 
western blotting. (3-actin was not used as a loading control in these experiments as its 
expression would be expected to decrease due to CHX-treatment (n = 6-20; ANOVA; ** 
p < 0.01; *** p < 0.001 compared to control).
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Next, MONaKA localisation at the plasma membrane was investigated using an 
immunohistochemical approach. Cells were cultured on transparent permeable 
supports and were treated with DMOG (1 mM; 24 hours). As shown in Figure 
5-12 , and in agreement with previous reports (Mao et ai., 2005), MONaKA was 
found to be expressed in control cells, with predominant expression in the 
membrane, but also with expression in the cytosol. However, following 
hydroxylase inhibition by DMOG (1 mM; 24 hours), there was a dramatic 
translocation of MONaKA, specifically to the basolateral membrane (indicated 
by arrows).
Figure 5—12 MONaKA expression in the basolateral membrane is increased by 
hydroxylase inhibition in TM colonic epithelial cells. T84 cells were cultured as 
monolayers on permeable supports until flte stabilised at plateau levels. Cells were 
treated bilaterally with DMOG (1 mM) in serum-free medium for 24 hours. Cells were 
washed in PBS, fixed in 100 % methanol, permeabilised with Triton X-100, and stained 
with specific fluorophore-labelled antibodies as outlined in Section 2-23. Pseudo­
colours were assigned to the various proteins where MONaKA is represented in green. 
This image is representative of 3 similar experiments.
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Since our data suggest that MONaKA and Na+/K+-ATPase px subunits are both 
expressed basolaterally in Tw cells (Figures 5 -9  and 5-12), the possibility that 
MONaKA may co-localise with the pump was next investigated using confocal 
microscopy. As shown in Figure 5-13, MONaKA has a more pronounced 
membrane expression following hydroxylase inhibition. However, co­
localisation appears to be more specific with the Na+/K+-ATPase Pi subunit, and 
is slightly offset with the N a7K +-ATPase cti subunit.
A 04 MONaKA Merge
Control 
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Control 
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Figure 5-13 MONaKA co-localises with both the a x and pi subunit of the Na+/K+- 
ATPase pump in TM cells. T84 cells were cultured as monolayers on permeable 
supports until Rte stabilised at plateau levels. Cells were treated bilaterally with DMOG 
(1 mM) in serum-free medium for. 24 hours. Cells were washed in PBS, fixed in 100 % 
methanol, permeabilised with Triton X-100, and stained with specific fluorophore- 
labelled antibodies, as outlined in Section 2-23. Pseudo-colours were assigned to the 
various proteins where in A) Na+/K+-ATPase a* is represented in green and in B) Na+/K+- 
ATPase pi is represented in green. In both panels MONaKA is represented in magenta 
and the merge of the 2 colours is in white. This image is representative of 3 similar 
experiments. Scale bars are 5 |nm in length.
While confocal images suggest that MONaKA co-localises with both the Na+/K+- 
ATPase a i  and pi subunits, the spatial resolution of this approach is not 
sufficient the prove that protein-protein interactions are occurring. Thus, to 
further investigate potential interactions between MONaKA and the Na+/K+- 
ATPase, co-immunoprecipitations were carried out. As shown in Figure 5-14, 
MONaKA was found to co-immunoprecipitate with the Na+/K+-ATPase oti 
subunit. However, this experiment is somewhat limited by the omission of the 
IgG negative controls required to prove specificity of the protocol.
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Figure 5-14 MONaKA co-immunoprecipitates with Na+/K+-ATPase oti subunit in TM 
cells. Tg4 cells were cultured as monolayers on permeable supports until Rte stabilised 
at plateau levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free 
medium for 24 hours and Na+/K+-ATPase subunits were immunoprecipitated (IP). 
Immunoprecipitates were washed thrice, and bound proteins were eluted using a low 
pH elution buffer. Proteins were resolved by SDS-PAGE, and MONaKA and Na+/K+- 
ATPase a,i protein levels were measured by western blotting (IB) (n = 5).
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Next, to confirm our findings from T84 cells, MONaKA localisation in isolated 
colonic crypts was also analysed using an immunohistochemical approach. 
Colonic crypts were isolated from mouse, rat, and human tissue, stained for 
MONaKA, and imaged by confocal microscopy. As shown in Figure 5-15  A -D , 
MONaKA (green) is highly expressed in crypts isolated from each species. 
Furthermore, it is clear from Figure 5-15  B, where the apical domain is labelled 
with a red actin coWar, that MONaKA is predominantly localised to the 
basolateral membrane of crypt cells. Finally, but importantly, the pattern of 
expression of MONaKA appears to be conserved across the 3 species.
mouse B mouse
human
Figure 5-15 MONaKA is expressed basolaterally in mouse, rat, and human colonic 
crypts. Colonic tissue was isolated from vehicle-treated mice and rats, and human 
tissue was obtained from the Gastroenterology Department of Beaumont Hospital. 
Crypts were isolated using the protocol described in Section 2-21. Isolated crypts were 
then attached to chamber slides using Cell-Tak™ as described in Section 2-22. Crypts 
were washed in PBS, fixed in 100 % methanol, permeabilised with Triton X-100, and 
stained with specific fluorophore-labelled antibodies as outlined in Section 2-23. 
Pseudo-colours were assigned to the various structures, with nuclei being represented 
in blue, f-actin in red, and MONaKA in green (20 jim scale bars). Panel B shows the 
area defined by the square in panel A at higher magnification (5 i^m scale bar).
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Next, to further confirm in vitro observations in T84 cells, co-localisation of 
MONaKA and the Na+/K+-ATPase pump was investigated in human crypts, again 
using an immunocytochemical approach. As shown in Figure 5 -16  A, MONaKA 
co-localises with the Na+/K+-ATPase oil subunit in the basolateral membrane (as 
indicated by arrow). The same was also found to be true for the Na+/K+-ATPase 
pi subunit as shown in Figure 5-16  B.
A
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Figure 5-16 MONaKA co-localises w ith  Na+/K +-ATPase a ± and px subunits in human 
crypts. Resected human colonic tissue was obtained from the Gastroenterology 
Department of Beaumont Hospital. Crypts were isolated (Section 2-21) and were 
attached to chamber slides using Cell-Tak™ (Section 2-22). Crypts were washed in PBS, 
fixed in 100 % methanol, permeabilised with Triton X-100, and stained with specific 
fluorophore-labelled antibodies, as outlined in Section 2-23. Pseudo-colours were 
assigned to the various markers. In panel A) Na+/K+-ATPase oci (labelled a x) is 
represented in green and in panel B) Na+/K+-ATPase Pi (labelled Pi) is represented in 
green (20 jam scale bars). In both panels, nuclei are stained with DAPI and are 
represented in blue, MONaKA is represented in magenta, and the merge is in white. 
The lower panels of both A and B show the areas defined by squares at higher 
magnification (5 jim scale bars).
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Next, in order to directly investigate its role in regulating Na+/K+-ATPase 
function, a siRNA approach was attempted to knock down expression of 
MONaKA. Experiments were first carried out using 6 -carboxyfluorescein (FAM)- 
labelled negative control siRNA to determine an appropriate transfection 
protocol for T 84 cells. However, with the transient transfection methods 
employed, transfection efficiency was found to be very low. As shown in Figure 
5 -17  A, only 20 % of the cells displayed the expected perinuclear staining 
(indicated by arrow) of the FAM-labelled negative control siRNA, 24 hours 
following transfection. Using mRNA to quantify transfection efficiency, the 
manufacturers suggest that the siRNA should have an efficiency of 80 %. 
However, after 24 hours there was no knockdown of MONaKA mRNA as 
measured by semi-quantitative RT-PCR (data not shown). After 3 days (Figure 
5 -17  B) there was no distinct staining of the perinuclear space, although there 
was staining in the cytoplasm, and by 7 days (Figure 5 -17  C) the FAM signal was 
very diffuse. We believe that at these later time points, the FAM reporter may 
be still present in the cells, but the siRNA has been degraded.
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Figure 5-17 Transfection of TM cells with FAM-labelled siRNA. T84 cells were 
trypsinised and transfected with FAM-labelled negative control siRNA (30 nM) with 0.4 
% NeoFX transfection reagent from Ambion. Cells were cultured on permeable 
supports in serum-free medium for 24 hours post transfection. Cells were then stained 
with DAPI, and visualised by confocal microscopy. A) There was an approximately 20 % 
transfection efficiency after 24 hours (5 |um scale bar). B) Extra-nuclear cytoplasmic 
staining was present 3 days post-transfection (10 ¿im scale bar). C) Staining of the 
FAM-labelled negative control siRNA became very diffuse 7 days post-transfection (10 
^m scale bar).
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Similarly, attempts to use a siRNA approach to inhibit MONaKA expression in 
polarized T 84 monolayers were not successful, and work to optimise conditions 
for siRNA transfection into T 84 cell monolayers is continuing in the laboratory. 
Therefore, as an alternative, albeit indirect, approach to further investigate a 
potential role for MONaKA in mediating the antisecretory effects of hydroxylase 
inhibition, we investigated these effects after washout of DMOG from the 
culture medium. These experiments were carried out in order to temporally 
correlate changes in MONaKA expression with changes in Cl" secretion. In these 
experiments, cells were treated with DMOG (1 mM; 24 hours) to inhibit 
hydroxylases, increase MONaKA protein expression, and attenuate Cl' secretion. 
After 24, hours, the cells were washed of DMOG and then incubated for a 
further 24 hours in serum-free culture medium without the hydroxylase 
inhibitor. After this time, cells were mounted in Ussing chambers and secretory 
responses to CCh (100 |iM) and FSK (10 juM) were measured. Although partially 
attenuated, the antisecretory effects of hydroxylase inhibition were still 
apparent 24 hours after removing DMOG from the culture medium (Figure 5-18  
A). In similar experiments, expression of MONaKA was investigated using the 
same protocol for DMOG-treatment. As shown in Figure 5 -18  B, 24 hours after 
removal of DMOG (wash), MONaKA expression remained elevated and was 
216.87 ± 41.33 % of that in control cells. This indicates that MONaKA is a very 
stable protein in vitro. It is possible that its stability is promoted by its 
interaction with the Na+/K+-ATPase, or by some other post translational 
modification.
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Figure 5-18 Antisecretory effects and increased MONaKA protein expression 
associated with hydroxylase inhibition are sustained after removal of inhibitor.
cells were cultured as monolayers on permeable supports until rtte stabilised at plateau 
levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free medium for 24 
hours, 48 hours, or for 24 hours in DMOG followed by a further 24 hours in serum-free 
medium without DMOG (indicated as 'wash' in panels A and B. A) Cells were mounted 
in Ussing chambers and stimulated with basolateral CCh (100 |xM) and apical FSK (10 
¿iM) (n = 3-4; ANOVA; ** p < 0.01; *** p < 0.001 compared to 24 hour no DMOG 
control). B) Cells were lysed, proteins resolved by SDS-PAGE, and MONaKA expression 
was analysed by western blotting, p-actin was used as a loading control (n = 4-5; 
ANOVA; * p < 0.05 compared to respective controls).
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5-3.6 Hydroxylase inhibition increases membrane 
expression of FIH-1 and its association with Na+/K+-ATPase
c t i
FIH-1 is known to hydroxylate ankyrin repeat domain-containing proteins and 
interestingly, the Na+/K+-ATPase a i  subunit contains 2 ankyrin-binding domains, 
suggesting FIH-1 may have an ability to interact with the pump. Earlier in these 
studies, FIH-1 expression In response to hydroxylase inhibition was investigated 
(Figure 3 -3) and was found to be unaltered at either the mRNA or protein level. 
Next, using an immunohistochemical approach, we investigated if FIH-1 
localisation might be altered in response to DMOG treatment. Cells were 
cultured on transparent permeable supports and treated with DMOG (1 mM; 24 
hours). As shown in Figure 5-19 , FIH-1 is specifically expressed basolaterally in 
untreated Tg4 cells. Furthermore, there was a clear increase in the abundance 
of FIH-1 in the basolateral membrane of DMOG-treated cells. Interestingly, 
there also appeared to be a translocation of the protein in the z plane, from a 
relatively dispersed state in control cells (indicated by arrow) to a more distinct 
location in DMOG-treated cells (indicated by arrow).
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Figure 5-19 Hydroxylase inhibition increases FIH-1 expression in the basolateral 
membrane of T84 colonic epithelial cells. T84 cells were cultured as monolayers on 
permeable supports until Rte stabilised at plateau levels. Cells were treated bilaterally 
with DMOG (1 mM) in serum-free medium for 24 hours. Cells were washed in PBS, 
fixed in 100 % methanol, permeabilised with Triton X-100, and stained with specific 
fluorophore-labelled antibodies as outlined in Section 2-23. Pseudo-colours were 
assigned to the various proteins where FIH-1 is represented in magenta. This image is 
representative of 3 similar experiments.
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Since FIH-1 appears to traffic to the membrane following hydroxylase inhibition, 
co-localisation of FIH-1 with the Na+/K+-ATPase subunits was next investigated 
in TS4 cells and in human crypts by confocal microscopy. As shown in Figure 5 -  
20 A there was a striking co-localisation of FIH-1 with the Na+/K+-ATPase oti 
subunit, displaying a more distinct membrane expression following hydroxylase 
inhibition. FIH-1 expression in human crypts appeared to be equally 
cytoplasmic and membranous (Figure 5 -2 0  B).
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Figure 5 -2 0  FIH-1 co-loca lises w ith  th e  Na+/K +-ATPase a t s u b u n it in  T34 cells and hum an  cryp ts .
T84 cells were cultured as monolayers on permeable supports until /?te stabilised at plateau 
levels. Cells were treated,bilaterally with DMOG (1 mM) in serum-free medium for 24 hours. 
Resected human colonic tissue was obtained from the Gastroenterology Department of 
Beaumont Hospital. Crypts were isolated (Section 2-21) and were then attached to chamber 
slides using Cell-Tak™ (Section 2-22). Cells and crypts were washed in PBS, fixed in 100 % 
methanol, permeabilised with Triton X-100, and stained with specific fluorophore-labelled 
antibodies, as outlined in Section 2-23. Pseudo-colours were assigned to the various proteins 
where Na+/K -ATPase ai is represented in green. In both panels FIH-1 is in magenta and the 
merge is in white (5 jam scale bar in panels A and B zoom, and 20 jam in upper panel B). This 
image is representative of 3 similar experiments
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To more directly demonstrate that that FIH-1 interacts with Na+/K+-ATPase 
pumps, co-immunoprecipitation experiments were carried o u t Using this 
approach whereby Na+/K+-ATPase a i  was immunoprecipitated, we found that 
there was increased levels of FIH-1 bound to Na+/K+-ATPase a i  in DMOG- 
treated cells (Figure 5-21). However, this experiment is somewhat limited by 
the omission of the IgG negative controls required to prove specificity of the 
protocol.
Na+/K +-ATPase ctj 112 kDa 
FIH-1 40 kDa
Control DMOG
Figure 5-21 Hydroxylase inhibition increases FIH-1 binding to Na+/K+-ATPase a x 
subunits in J M cells. T^ cells were cultured as monolayers on permeable supports until 
flte stabilised at plateau levels. Cells were treated bilaterally with DMOG (1 mM) in 
serum-free medium for 24 hours and Na+/K+-ATPase a i subunits were 
immunoprecipitated (IP). Immunoprecipitates were washed thrice, and bound proteins 
were eluted using a low pH elution buffer. Proteins were resolved by SDS-PAGE and 
FIH-1 and Na+/K+-ATPase protein levels were measured by western blotting (IB) (n = 
3; paired t-test; p = 0.075).
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Finally, to explore whether FIH-1 interacts with MONaKA, preliminary co- 
immunoprecipitation experiments were carried out. Using this approach 
whereby MONaKA was immunoprecipitated, we found that there were 
increased levels of FIH-1 bound to MONaKA in DMOG-treated cells (Figure 5 -  
22). However, this experiment is somewhat limited by the omission of the IgG 
negative controls required to prove specificity of the protocol.
Control DMOG
Figure 5-22 Hydroxylase inhibition increases FIH-1 binding to  MONaKA in cells.
Tg4 cells were cultured as monolayers on permeable supports until Rte stabilised at 
plateau levels. Cells were treated bilaterally with DMOG (1 mM) in serum-free medium 
for 24 hours and MONaKA was immunoprecipitated. Immunoprecipitates were 
washed thrice, and bound proteins were eluted using a low pH elution buffer. Proteins 
were resolved by SDS-PAGE and FIH-1 protein expression was measured by western 
blotting (IB) (n = 3).
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5 - 4  D i s c u s s i o n
Since our data from previous chapters suggested that hydroxylase inhibition 
does not alter membrane expression of the Na+/K+-ATPase or cellular ATP levels, 
in the current chapter we set out to investigate alternative mechanisms that do 
not involve altered pump expression or trafficking. Initially, we investigated the 
possibility that the effects of hydroxylase inhibition on Na+/K+-ATPase activity 
could be mediated by an epithelial-derived soluble factor, such as ET-1, acting in 
an autocrine fashion. Previous work has shown that ETs have the capacity to 
acutely regulate Na+/K+-ATPase function, via activation of ETB receptor, and 
subsequent increases in intracellular Ca2+ (Prasanna et al., 2001; Liu et al., 
2009). There are various other endogenous molecules that are known to 
attenuate pump activity, such as cardiatonic steroids, and the hypoxia- 
stimulated hypothalamic inhibitory factor (Schoner and Scheiner-Bobis, 2005; 
De Angelis and Haupert, 1998), although whether these molecules can be 
synthesised by the intestinal epithelium is not known. If a secreted molecule, 
such as ET-1, was responsible for attenuating pump activity, then one would 
expect that conditioned medium from DMOG-treated cells should mimic the 
antisecretory effects of the drug. However, we did not find this to be the case, 
implying that secreted endothelins, or indeed other acutely acting soluble 
mediators, are not involved in mediating the effects of hydroxylase inhibition. 
In future studies the inclusion of a positive control for these experiments, such 
as stimulation of cells with ET-1 itself, and inclusion of protease inhibitors in the 
conditioned culture medium would bolster these results.
We also investigated the possibility that increased sequestration of the Na+/K+- 
ATPase into lipid rafts could mediate the effects of hydroxylase inhibition. 
Previous studies have shown that regulation of the pump in this manner 
attenuates its transporting function and promotes its role as a signalling protein 
through increased coupling to Src family kinases (Liang et al., 2007). Thus, we 
investigated if chemical disruption of lipid rafts or inhibition of Src kinases could
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reverse the antisecretory effects of DMOG-treatment. However, when MPCD 
was employed to disrupt lipid rafts in the basolateral plasma membrane, 
antisecretory actions of DMOG were unaltered. This suggests that 
sequestration into lipid rafts is not a factor underlying inhibition of Na+/K+- 
ATPase activity by hydroxylase inhibitors. However, this cannot be fully ruled 
out because, although the activity of the Na+/K+-ATPase was increased in MPCD- 
alone treated cells in what was the positive control for this experiment, it was 
approaching but did not quite reach statistical significance. Similarly, we know 
that activation of Src kinases contribute to the attenuation of Cl" secretion, 
however, pharmacological inhibition of Src kinases with PP2 did not reverse the 
antisecretory effect of hydroxylase inhibition on Ca2+-dependent secretory 
responses (Keely et al., 2000). Interestingly however, upon Src inhibition with 
PP2, there was a partial reversal of the effect of DMOG on cAMP-dependent 
responses. These data may reflect a differential role for Src family kinases in 
mediating effects of hydroxylase inhibition on Ca2+ and cAMP-dependent 
secretory pathways. However, these data should be viewed cautiously since Src 
inhibition alone was noted to have profound effects on both Ca2+- and cAMP- 
induced responses (Bertelsen et al., 2002). A potential role for Src family 
kinases in mediating responses to hydroxylase inhibition could be further 
studied by investigating their phosphorylation and activation in response to 
DMOG treatment of colonic epithelial cells and by further investigating the 
effects of PP2 on DMOG-induced changes in transport protein function.
Several other signalling pathways were also investigated based on evidence 
indicating their potential for mediating the antisecretory effect of hydroxylase 
inhibition. PKC inhibition was found to be without effect on the antisecretory 
effects of DMOG. The PKC inhibitor, GF, has been reported to be a specific 
inhibitor of PKC that inhibits both classical and novel PKC isoforms (Toullec et 
al., 1991; Roberts et al., 2005). However, as with all chemical inhibitor data, 
one must be cautious in drawing conclusions, since other research has 
highlighted potential non-specific actions of the inhibitor (Alessi, 1997). PKA
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inhibition was also without effect on the anti-secretory actions of DMOG. 
However, although H89 is widely used as an inhibitor of PKA, it also inhibits 
other pathways and therefore should not be used as the single source of 
evidence of PKA involvement (Murray, 2008; Lochner and Moolman, 2006). 
Finally, and as previously mentioned in Chapter 3, acriflavine was employed as a 
HIF inhibitor and was also found to be without effect on the antisecretory 
actions of DMOG. However, this result must also be treated with caution, since 
acriflavine was also without effect on DMOG-induced induction of the HIF-1- 
target, PHD2 (data not shown). This suggests that either HIF-1 was still 
transcriptionally active in the presence of acriflavine, or that.PHD2 is under 
control of other transcription factors. Thus, our experiments using 
pharmacological inhibitors suggest that neither PKC, PKA, nor HIF are involved 
in mediating the antisecretory effects of hydroxylase inhibitors. However, these 
data should not be considered as conclusive since some of the inhibitors 
affected Cl" secretion themselves, and further studies are required to 
definitively exclude these signalling pathways from mediating antisecretory 
actions of hydroxylase inhibition.
Further experiments were carried out to determine whether the inhibitory 
effect of hydroxylase inhibitors on Na+/K+-ATPase activity could be 
translationally or transcriptionally-mediated. However, we found that neither 
AD nor CHX, which are well-described inhibitors of transcription and translation 
respectively, attenuated the antisecretory effects of DMOG. This suggests that 
the effects of hydroxylase inhibition are likely to be post-translationally- 
mediated. Interestingly, previous reports on the regulation of transport protein 
function by HIF-1 show these actions to be transcriptionally-mediated (Ibla et 
a!., 2006; Zheng et a/., 2009). Therefore, the current data support the idea that 
HIF is not involved in mediating the antisecretory effects of hydroxylase 
inhibition. Furthermore, these findings suggest that post-translational 
modifications, such as altered interactions with regulatory proteins, or 
phosphorylation of the pump itself, may be involved.
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To.test the hypothesis that altered interactions with regulatory proteins might 
be involved, we first carried out some preliminary investigations to determine 
the expression of Na+/K+-ATPase-modifying proteins in colonic epithelial cells. It 
was found that neither FXYD3 nor PKC £, expression was altered at either mRIMA 
or protein levels, respectively. Of course, these proteins could be investigated 
in more depth by, for example, analysing their association with the Na+/K+- 
ATPase by co-immunoprecipitations or employing siRNA to inhibit their 
expression. Interestingly, although the mRNA expression of Na+/K+-ATPase fa 
subunit remained unaltered, Na+/K+-ATPase Pi protein expression was 
significantly increased after 24 hours treatment with DMOG. Initially this result 
was perplexing, since the dogma has been that one Na+/K+-ATPase a  subunit 
binds to one Na+/K+-ATPase p subunit, and in our previous studies we showed 
a i  subunit expression to be unchanged by hydroxylase treatment. However, 
more recent studies investigating the ratio of Na+/K+-ATPase a  : p subunits have 
shown that the a  subunit can bind more than one p subunit, thereby offering an 
explanation for the observed increase in Pi, but not a i  subunits (Clifford and 
Kaplan, 2008). Confocal analysis revealed that the Na+/K+-ATPase Pi subunit 
appears to be specifically expressed within one z-plane in the basolateral 
membrane of T ^  cells and that it co-localises with the Na+/K+-ATPase a i  
subunit. Immunohistochemical analysis showed a higher expression of Na+/K+- 
ATPase P i in the cytoplasm after treatment with DMOG, but it could not be 
conclusively determined as to whether there was a higher proportion of the pi 
subunit in the membrane. Analysis of the expression of the Na+/K+-ATPase P i 
subunit at the protein level yielded interesting results, with only the lower 
molecular weight (35 kDa) band showing increased expression in response to 
hydroxylase inhibition. However, increased expression of this unglycosylated 
form of the protein does not appear to affect activity of the pump, as 
demonstrated in previous studies using site-directed mutagenesis (Beggah et 
al., 1997). Nor does glycosylation affect heterodimer formation or intracellular 
trafficking of the Na+/K+-ATPase (Tamkun and Fambrough, 1986). The
unglycosylated P i subunit is also associated with impairments in cell-cell 
junctions, decreased cell-cell contact, and increased migration, thereby causing 
an increase in paracellular permeability (Vagin et a!., 2007). However, our data 
do not support such a role for the Pi subunit in colonic epithelial cells, since 
hydroxylase inhibition promoted, rather than attenuated, transepithelial 
resistance. Further studies are required to elucidate the precise role that the 
unglycosylated P i subunit plays in the antisecretory effects of hydroxylase 
inhibition, but one possibility could be that it interacts with another regulatory 
protein to alter Na+/K+-ATPase pump function.
A search of the literature for proteins that interact with the Na+/K+-ATPase P i 
subunit to negatively regulate pump activity yielded MONaKA as a potential 
candidate. MONaKA was originally discovered as a regulator of the Na+/K+- 
ATPase in astrocytes and has been shown to be expressed in other tissues. 
MONaKA contains a kinase domain, however it is thought to be inactive, thus it 
is currently unknown how MONaKA might regulate Na+/K+-ATPase activity. 
Studies by other groups present conflicting data regarding the expression 
profile of this protein. One study investigates expression of several splice forms 
and notes their absence from the heart (Zou et al., 2005). However, a more 
recent study that investigated expression of one fragment of human MONaKA 
cDNA demonstrated its absence in the colon and presence in the heart 
(Takeuchi et al., 2010). This is in contrast to data accessed on the Human 
Protein Atlas (www.humanproteinatlas.org) which shows that it is expressed in 
all Gl tissues examined. The current studies revealed MONaKA to be expressed 
in colonic epithelial cells from a number of species, including humans. 
Furthermore, following hydroxylase inhibition its expression is increased almost 
200 % of that in control cells. This effect appears to be independent of de novo 
protein synthesis as demonstrated by our findings with the inhibitor of 
translation, CHX. Interestingly, in contrast to its effects on protein expression, it 
was found that mRNA expression of MONaKA was significantly reduced after 24 
hours treatment with DMOG. The mechanisms underlying these contrasting
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actions at the mRNA and protein levels are as yet unknown, but it is possible 
that this represents a negative feedback loop. Indeed, future experiments 
involving a micro RNA screen of hydroxylase inhibitor-treated colonic epithelial 
cells could yield some interesting results and new lines of inquiry.
We also found that trafficking of MONaKA to the plasma membrane was 
increased in DMOG-treated cells. Confocal imaging revealed that MONaKA co­
localised with Na+/K+-ATPase oti and P i subunits in human crypts. However, co­
localisation in T 84 cells was restricted to that of the P subunit. Co- 
immunoprecipitation experiments found MONaKA to associate with the Na+/K+- 
ATPase a i  subunit, although these results require confirmation with an IgG 
negative control. In further experiments it was found that 24 hours following 
removal of hydroxylase inhibitors, MONaKA expression remained elevated, 
indicating that it is a very stable protein in vitro. It is possible that such stability 
is promoted by its interaction with the Na+/K+-ATPase or by some other post 
translational modifications. .
Taken together the data presented here, along with what is already known 
regarding its inhibitory role in regulation of Na+/K+-ATPase pump activity, 
suggest that MONaKA plays an important role in mediating the antlsecretory 
effects of hydroxylase inhibition in colonic epithelial cells. Furthermore, since 
we found that the pattern of expression of MONaKA in colonic crypts appears to 
be conserved across several species, our data underscore the likely importance 
of this protein in regulating intestinal secretory function. These data suggest 
that MONaKA might represent a target for the development of new anti- 
diarrhoeal therapies. However, the ubiquitous expression of the Na+/K+-ATPase 
and wide expression of MONaKA, would necessitate local intestinal targeting of 
a drug that targets MONaKA for the treatment of diarrhoea.
Our studies show that hydroxylase inhibition not only leads to increased 
association with MONaKA but also of the Na+/K+-ATPase p i  subunit with FIH-1.
Interestingly, as shown in Chapter 3, the asparaginyl hydroxylase is not 
regulated by hydroxylase inhibition at the mRNA or protein levels. However, 
analysis of its localisation within the cell before and after hydroxylase inhibition 
revealed that its expression at the membrane was increased upon treatment 
with DMOG and that it co-localised with the Na+/K+-ATPase oti subunit. How 
such interactions might regulate pump activity are as yet unknown, but one 
could speculate that similar to MONaKA, FIH-1 is a negative regulator of the 
pump and that, upon DMOG-treatment, it is released from other binding 
partners, e.g., H IF -la , leaving it free to interact with the Na+/K+-ATPase (Mahon 
et ol., 2001). It has been shown that hydroxylation stabilises protein-protein 
interactions, therefore another possibility could be that via its ankyrin binding 
domain, the pump stably binds to a hydroxylated ankyrin partner, and that such 
an interaction facilitates its activity (Yang et ai, 2011). Such a mechanism has 
been previously shown to exist in the case of acetylated tubulin regulation of 
Na+/K+-ATPase activity (Casale et al.t 2003).
5-5 Summary
In summary, although there is still much work to be done, with the inclusion of 
more rigorous controls, the identification of MONaKA as a potential mediator of 
the antisecretory effects of hydroxylase inhibition in these studies is novel and 
intriguing. These data support existing evidence that the pump exists in a 
multimeric complex with several regulatory proteins, and suggest that both 
MONaKA and FIH are likely to have important roles to play in regulating pump 
activity in conditions of hypoxia (Figure 5-23). MONaKA is well known as a 
regulator of Na+/K+-ATPase pump function and our data suggest that it could act 
as a molecular switch that co-ordinates Na+/K+-ATPase pump activity with 
oxygen availability in epithelial cells. As such, MONaKA, and its associated 
regulatory proteins, represent good targets for the development of new anti- 
diarrhoeal drugs.
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Figure 5-23 Hydroxylase inhibition stimulates the formation of a multimene 
inhibitory complex at the Na+/K+-ATPase pump. Hydroxylase inhibition attenuates Cl' 
secretion by reducing of the activity of the Na+/K+-ATPase. We propose that this occurs 
through the stabilisation of MONaKA protein, independent of transcription or 
translation. MONaKA then binds to the Na+/K+-ATPase at the plasma membrane where 
it forms a complex with FIH-1 and inhibits the activity of the Na+/K+-ATPase, thereby 
inhibiting epithelial secretory responses.
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HIF hydroxylases, which include FIH-1 and PHDs, are cellular oxygen sensors 
that serve as gatekeepers of the hypoxic response. They utilise 0 2 as a co­
substrate and couple the hydroxylation of H IF -la  to the oxidative 
decarboxylation of a-ketoglutarate and C 0 2. They specifically hydroxylate 
target amino acids on H IF -la  and HIF-2a, IKK, and other proteins that contain 
consensus hydroxylation motifs. HIF hydroxylase regulation of cellular function 
is a rapidly expanding area of research as indicated by the number of 
publications on the topic in the recent past (Figure 1-4). One of the most 
prominent areas of HIF hydroxylase research is in the Gl tract where research is 
particularly focussed on the role of HIF hydroxylases in the pathogenesis of 
inflammation (Robinson et al., 2008; Cummins ef al., 2008; Tambuwala et al., 
2010; Hindryckx et al., 2010; Hart et a lt 2011), and cancer (Xue et al., 2010).
Cl’ secretion, an important physiological process in the intestine, is a highly 
energy-demanding process and depends on 0 2 for the generation of cellular 
energy in the form of ATP (Mandel and Balaban, 1981; Durand et al., 1988; 
Carra et al., 2011). ATP is utilised by Na+/K+-ATPase pumps to create the 
electrochemical driving force for Cl' secretion to occur. Previous studies have 
shown that hydroxylase inhibition ameliorates experimental colitis and prevents 
diarrhoea, thus this thesis was based on the overarching hypothesis that 
epithelial fluid and electrolyte transport may also be regulated by hydroxylase 
activity (Cummins et al., 2008; Robinson et al., 2008). The findings presented 
support this hypothesis by showing that hydroxylase inhibition significantly 
attenuates epithelial secretion both in vitro and in vivo. These findings make a 
significant contribution to our knowledge of the role of hydroxylases in 
intestinal physiology and suggest that these enzymes, and their associated 
signalling mechanisms, represent good targets for the development of new 
drugs to treat intestinal transport disorders. A schematic representation of our 
current understanding of how hydroxylase inhibition may downregulate 
epithelial secretion is shown in Figure 6-1.
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Figure 6-1 Hydroxylase inhibition attenuates colonic epithelial secretory function.
Hydroxylase inhibition causes robust stabilisation of HIF-la in colonic epithelia and also 
exerts profound antisecretory effects. Despite down-regulation of CFTR and NKCC1 
expression, the activities of these transporters were unaltered by hydroxylase 
inhibition. Neither Ca2+ nor cAMP levels in the cells were altered by hydroxylase 
inhibition. However, hydroxylase inhibition reduced the activity of basolateral Na+/K+- 
ATPase pumps. Hydroxylase inhibition did not alter the expression of the catalytic 
Na+/K+-ATPase oti subunit, but caused an increase in the expression of the Na+/K+- 
ATPase subunit and MONaKA. We show that the anti-secretory phenomenon occurs 
independently of transcription or translation, and we propose that MONaKA 
stabilisation may occur by inhibition of its proteasomal degradation. MONaKA and the 
Na+/K+-ATPase a x subunit associate at the plasma membrane where they form a 
complex with FIH-1. This complex behaves as a molecular switch, that inhibits the 
activity of the Na+/K+-ATPase, thereby attenuating luminal Cl' secretion.
Our investigations into regulation of ion transport by hydroxylase inhibition
were initially focussed on the transport process of Cl' secretion. In vitro studies
revealed that hydroxylase inhibition by DMOG was potently anti-secretory, an
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effect which was coincident with intracellular accumulation of H IF -la  and HIF- 
2a. Another inhibitor of HIF hydroxylases, FG-4497, which exerts its actions by 
directly blocking their active site, re-capitulated our findings with DMOG, re­
affirming the role of HIF hydroxylases in mediating this antisecretory action. 
Intracellular second messengers which activate the Cl' secretory pathway were 
not affected by hydroxylase inhibition which suggested that the antisecretory 
effect may be mediated by alterations in the transport proteins that constitute 
the Cl' secretory pathway. However, to first give our in vitro findings some 
physiological relevance we carried out experiments to translate them into a 
mouse model. Similar to its effects in cultured epithelia, treatment of mice with 
DMOG significantly blunted agonist-stimulated colonic /sc responses to CCh and 
FSK, which are known to be predominantly due to Cl' secretion (Cuthbert et ai,
1994). Since previous studies have demonstrated that Cl' secretion is the 
primary driving force underlying diarrhoea in anaphylactic models, we 
investigated the effect of hydroxylase inhibition in a mouse model of allergic 
diarrhoea (Perdue et a l 1991; Brandt et al., 2003). Diarrhoea in OVA-sensitised 
mice treated with DMOG was dramatically delayed and less severe compared to 
controls. These data clearly point to a potential role for drugs which target 
hydroxylase-dependent signalling mechanisms for treatment of diarrhoeal 
diseases.
While hydroxylase inhibition clearly exerts antisecretory actions in the colon, it 
is important to bear in mind that the intestine is primarily an absorptive organ. 
Approximately 9 litres of fluid enter the proximal small intestine each day and 
normally only approximately 200 ml are lost in the stool. With this in mind, 
when considering the development of new drugs for diarrhoea, their effects on 
absorptive processes must also be considered. SGLT- 1  is one of the main 
pathways for intestinal fluid absorption and is also the primary transporter 
involved in oral rehydration therapy. Interestingly, we found that absorption 
through small intestinal SGLT1 was not affected by hydroxylase inhibition. Since 
most fluid absorption occurs in the small intestine, this is a very important
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finding for consideration when using hydroxylase inhibitors for treatment of 
secretory diarrhoeas. In contrast with this, we found that the activity of 
another important intestinal epithelial Na+ transporter, ENaC, was significantly 
reduced following treatment with DMOG. This could be a particularly important 
consideration for people with pseudohypoaldosteronism (PHA), where there is 
already urinary loss of Na+ from the body (Kuhnle, 1997; Hummler and 
Horisberger, 1999). It has however, been suggested that under normal 
conditions there is a certain degree of redundancy in colonic ENaC function with 
regard to whole-body fluid and electrolyte homeostasis and therefore, specific 
targeting of hydroxylase inhibitors to the colon may be sufficient to overcome 
potential complications arising from renal effects of these drugs (Hummler and 
Horisberger, 1999).
NHEs are also important transport proteins that mediate absorption in the 
intestine and should also be considered when developing any new therapeutics 
that target epithelial transport function. Interestingly, it has been reported that 
chronic hypoxia elevated pHj by activating Na+/H+ exchange in pulmonary 
arterial smooth muscle cells, an effect which was inhibited by exposure to EIPA 
(Rios et ai, 2005). Using fluorescent imaging techniques we were able to 
determine that the activity of NHEs was blunted by DMOG-treatment in T ^  
cells. However, the studies described here cannot discriminate which NHE 
isoform might be involved, therefore, it is difficult to draw detailed conclusions. 
This is further compounded by the fact that there is a lack of selective inhibitors 
available for the various NHE isoforms, and because NHE3 is not expressed in 
our Tjj4 cell model of the colonic epithelium (Beltran et al., 2008). NHE3 is 
expressed apically throughout the intestine and plays a major role in Na+ 
absorption (Ikuma et al., 1999; Zachos et al., 2005; Schultheis et al., 1998). 
Studies have shown that at high concentrations (>25 |iM), EIPA inhibits NHE1 
and 2, but also inhibits the EIPA-resistant NHE4 isoform (Beltran et al., 2008). 
Since lower concentrations of EIPA (which inhibit NHE1 and 2, but not NHE4) did 
not affect Cl' secretion, the reversal of the inhibitory effect of DMOG by
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concentrations of EIPA > 25 fiM suggest it is ah NHE4-mediated effect. NHE4 is 
expressed basolaterally in epithelia of several tissues and has been shown to be 
important in the regulation of intracellular pH (Pizzonia et al., 1998; Beltran et 
al., 2008). Given their important role in mediating fluid and electrolyte 
absorption in the intestine, the role of hydroxylase inhibitors in regulation of 
NHE function is a subject that requires further investigation. Future studies 
could investigate the expression of the various NHE isoforms in DMOG-treated 
cells, employ 22Na isotopic flux assays for measurements of their activity, and 
siRNA approaches along with the use of more specific pharmacological 
inhibitors to elucidate the roles of individual isoforms.
Another intriguing aspect of NHE function that was not investigated in this study 
relates to its role in regulating inflammation. NHE inhibition has previously 
been shown to attenuate enterocyte inflammatory responses and to ameliorate 
the course of IBD in DSS-treated mice. This could have some bearing on 
previous findings by Cummins et al in the DSS model of colitis, where DMOG 
was shown to ameliorate colitis, attenuate apoptosis, and abrogate interleukin 
production (Cummins et ai, 2008). Previous studies have shown that NHE 
inhibition attenuates IL-8  production in endothelial and epithelial cells, while it 
inhibits apoptosis in colonic epithelial cells and other models (Nemeth et al., 
2002a; Nemeth et al., 2002b; Rebillard et al., 2007; Chakrabarti et al., 1997). 
NHE-1 is expressed on the basolateral membrane of colonic epithelial cells and 
is thought to function in a house-keeping role by maintaining pHj (Ikuma et al., 
1999). NHE1  and NHE3 are known to be induced in models.of colitis, including 
TNBS-induced colitis (Khan et al., 1998; Khan and Ali, 1999). Further studies 
have shown that inhibition of NHE1 ameliorates experimental colitis and 
reverses the colitis-induced reduction in contractility of colonic smooth muscle 
(Khan et al., 2005). Interestingly, Robinson et al have shown that hydroxylase 
inhibition by FG-4497 in a TNBS-induced mouse model of colitis, enhanced 
fibroblast contraction in collagen gels (Robinson et al., 2008). With this in mind, 
one could speculate that hydroxylase inhibition of NHE activity could be a
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unifying mechanism that enhances contractility, attenuates interleukin 
production, and prevents apoptosis in colitis. Thus, further investigations of 
hydroxylase regulation of NHEs could yield some important results as to their 
roles in regulating both ion transport and inflammation.
In order to determine the mechanisms underlying the antisecretory effect of 
hydroxylase inhibition in intestinal epithelial cells, the activities of various 
components of the Cl" secretory pathway were examined. No changes in apical 
CFTR currents following hydroxylase inhibition were observed. This was initially 
surprising, given that in agreement with previous studies, expression of CFTR 
was reduced in DMOG-treated cells (Zheng et a i , 2009). However, previous 
studies have shown that only small amounts of CFTR are required in the apical 
membrane for functionality which, in conjunction with studies of ion transport 
in the intestine of CF-mice, underscores the critical role that the channel plays 
in the lubrication of the intestinal lumen (De Jonge, 2006; Cuthbert et ai, 1994). 
In the current studies, an investigation of the effects of hydroxylase inhibition 
on expression of the Ca2+-dependent Cl' conductance, TMEM16A, indicated that 
there was a tendency towards an increase in expression of the protein at the 
mRNA level. Although this effect did not reach statistical significance in these 
studies, such a response in vivo could have important physiological significance 
where induction of Cl' channels, such as TMEM16A, could be a mechanism to 
compensate for the repression of CFTR by HIF-1.
H IF -la  is a primary target of the HIF-hydroxylases and HIF-1 has previously been 
shown to be an important regulator of transport proteins that comprise the Cl" 
secretory pathway (Ibla et ai, 2006; Zheng et ai, 2009). Since DMOG-induced 
stabilisation of HIF-1 was coincidental to the antisecretory actions of 
hydroxylase inhibition in the current studies, we carried out experiments to 
ascertain whether HIF-1 was involved in mediating this effect. Interestingly, we 
found that neither a HIF inhibitor (acriflavine) nor inhibition of transcription, or 
translation, reversed the antisecretory effects of hydroxylase inhibition. These
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data suggest, therefore, that the antisecretory effects of hydroxylase inhibition 
occur by a HIF-independent mechanism. Furthermore, findings indicate that 
while CoCI2 potently stabilised HIF, in contrast to DMOG it attenuated Cl' 
secretion by inhibiting CFTR activity, without altering Na+/K+-ATPase activity. 
DMOG and CoCI2 behave quite differently in terms of inhibition of HIF 
hydroxylases. C0CI2 does not inhibit asparaginyl hydroxylation, whereas DMOG 
potently inhibits asparaginyl hydroxylation (Tian et al., 2011b). This suggests 
that the antisecretory effects of DMOG may occur by a mechanism that involves 
inhibition of asparaginyl hydroxylation, but that is independent of HIF.
Since our data suggest that the antisecretory effect of hydroxylase inhibition is 
asparaginyl-hydroxylase-mediated, we explored the possibility that the 
asparaginyl hydroxylase, FIH-1, might be involved. Interestingly, FIH-1 
translocated to the basolateral membrane where it bound to the Na+/K+-ATPase 
ai subunit following DMOG-treatment. This suggests that FIH-1 in conjunction 
with MONaKA and Na+/K+-ATPase binds the pump to form a negative 
regulatory complex. The role that FIH-1 plays in this complex is unknown but 
one could speculate that FIH-1 is a negative regulator of the pump and that, 
DMOG-treatment results in a dissociation from HIF-la, leaving it free to interact 
with the Na+/K+-ATPase. It has been shown that hydroxylation stabilises 
protein-protein interactions, therefore another possibility could be that via its 
ankyrin binding domain, the pump stably binds to a hydroxylated ankyrin 
partner, and that such an interaction facilitates its activity (Yang et al., 2011). 
Such a mechanism has been shown to exist as evidenced by regulation of the 
Na+/K+-ATPase pump by acetylated tubulin (Casale et al., 2003).
While each of the transport proteins that comprise the Cl' secretory pathway 
are interlinked and are dependent on each other for function, the activity of 
Na+/K+-ATPase pumps is the energy-dependent step of the process. 
Interestingly, although we found that hydroxylase inhibition dramatically 
attenuated activity of the pump, expression of the catalytic ai subunit remained
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unaltered, as did levels of cellular ATP. This is in contrast to other research 
showing hypoxia attenuated pump expression as well as activity (Planes et al., 
1996; Mairbaurl et al., 2002; Carpenter et al., 2003; Dada et al., 2003; Gusarova 
et al., 2011). The mechanisms involved are complex and involve mitochondrial 
ROS, which is produced during hypoxia, but not by treatment with DMOG 
(Gusarova et al., 2011; Emerling et al., 2007). Therefore, we would not expect 
DMOG and hypoxia to have the same effects on the pump. We therefore 
investigated alternative mechanisms, and molecular regulation of the pump by 
proteins such as PKA, PKC, FXYD family members, Na+/K+-ATPase Pi, and 
MONaKA, amongst others. After an initial screen of these signalling pathways, 
an exploration of the expression of regulatory proteins was carried out, and the 
Na+/K+-ATPase Pi subunit provided a target for further study. Hydroxylase 
inhibition caused an increase in Na+/K+-ATPase pa protein expression. 
Incidentally, increases in Na+/K+-ATPase subunit expression have been 
previously shown to enhance /?te. This is due to the n-glycan branching of the 
Na+/K+-ATPase Pi subunit binding to other subunits on neighbouring cells, 
thereby increasing Rte (Vagin et al., 2008). This might, at least in part, explain 
the increase in Rte we observed in response to hydroxylase inhibition in these 
studies. However, since the Na+/K+-ATPase pi subunit is known to facilitate 
pump activity, it seemed unlikely that increases in its expression would inhibit 
the pump after treatment with DMOG (Shoshani et al., 2005; Padilla-Benavides 
et al., 2010). Therefore, Na+/K+-ATPase pr interacting proteins that are known 
to inhibit pump activity were explored (Mao et al., 2005; Gorokhova et al.,
2007). Investigation of one of these proteins, MONaKA, revealed it to be 
significantly upregulated by hydroxylase inhibition.
MONaKA exists as at least two splice variants, with the splicing conserved 
perfectly between mouse and human, suggesting that it serves an important 
function (Mao et al., 2005). Following DMOG-treatment, MONaKA translocated 
to the basolateral membrane where interestingly, its expression is also 
conserved across mouse, rat, and human colonic crypts, again accentuating its
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potential physiological importance in regulating basolateral transporters in 
intestinal epithelia. Although MONaKA protein expression was increased, 
mRNA expression was reduced by DMOG-treatment This could be as a result of 
a post-translational modification of MONaKA leading to its stabilisation, or due 
to a negative feedback loop to regulate MONaKA expression, perhaps mediated 
by an miRNA-mediated mechanism. The importance of miRNA in mediating 
responses to hypoxia has recently been highlighted by our collaborators who 
showed regulation of HIF-la by miRNA155 (Bruning et ai, 2011). Further 
studies to investigate the potential role for miRNAs in mediating hydroxylase 
actions on epithelial transport function are required.
In addition to MONaKA and the Na+/K+-ATPase (3i subunit, there are several 
other proteins known to be important in regulating Na+/K+-ATPase pump 
expression, including TCTP, Na+/K+-ATPase-interacting (NKAIN), and FXYD family 
members. Due to time constraints, these proteins were not investigated in the 
current studies but do warrant some discussion. TCTP was initially identified as 
a protein that binds to the third cytoplasmic domain of Na+/K+-ATPase ai, the 
expression of which was found to repress pump activity by a mechanism not yet 
fully understood (Jung et al., 2004). Further research by the same group 
showed that another cytosolic protein, SNX6, reversed this repression by 
binding to, and sequestering, TCTP. However, there is a paucity of information 
on the physiological roles of TCTP and SNX6 in the intestine, and future studies 
into the effects of hydroxylase inhibition on their expression and association 
with the Na+/K+-ATPase pump could yield some interesting findings. FXYD 
family members are membrane-associated proteins that are known to modify 
the transport properties of Na+/K+-ATPase pumps in a tissue-specific manner, 
without altering its expression (Garty and Karlish, 2006; Delprat et al., 2006; 
Geering, 2006). More recent research also suggests that they contribute to 
stabilisation of the pump at the membrane (Mishra et ai, 2011). Thus, this 
family of proteins could play an important role in mediating the effects of 1 
hydroxylases on pump activity in intestinal epithelial cells. Preliminary studies
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showed that treatment of cells with DMOG did not alter FXYD3 mRNÁ. We 
cannot however, rule out the possibility that FXYD3 expression might be 
regulated by post-translational mechanisms and this could be a topic for future 
studies. FXYD5 is also a candidate for future research as its over-expression has 
been shown to increase pump activity in Xenopus oocytes (Lubarski et al., 
2005). Finally, NKAINs are of great relevance to the current studies as they have 
been recently identified as Na+/K+-ATPase Pi interacting proteins that must also 
form complexes with MONaKA in order to be activated (Gorokhova et al., 2007).
Overall, the data presented in this thesis provide important new insights into 
how intestinal fluid and electrolyte transport may be regulated in health and 
disease. The discovery that hydroxylases play a key role in the regulation of 
intestinal secretion suggests that under conditions of intestinal stress, such as 
hypoxia associated with inflammation or fibrosis, downregulation of Na+/K+- 
ATPase activity may serve as a physiological switch that attenuates epithelial 
transport processes, thereby conserving cellular energy. Under such conditions, 
reductions in ATP consumption by the pump may allow for the redistribution of 
cellular energy from costly transport processes into tissue restitution and repair. 
Such actions may, at least in part, underlie the protective effects of hydroxylase 
inhibitors observed in mouse models of IBD (Robinson et al., 2008; Cummins et 
al., 2008). In fact, decreased Na+/K+-ATPase activity has been recorded in the 
intestines of patients with IBD (Ejderhamn et al., 1989). However, the current 
studies may have even more broad implications for our understanding of how 
intestinal physiology is regulated under normal conditions. Given the harsh 
environment in which the intestinal epithelium exists, between the richly 
perfused vasculature of the serosa and the anoxic lumen of the gut, 02 levels 
are constantly fluctuating. These fluctuations are amplified by the dynamic 
nature of the splanchnic circulation, with post-prandial increases and exercise- 
associated decreases in blood flow (Musch et al., 1987; Matheson et al., 2000). 
Thus, a molecular switch, such as that potentially mediated by MONaKA/FIH-l, 
to regulate ATP consumption by the Na+/K+-ATPase would be beneficial in that it
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could serve to co-ordinate epithelial transport with 02 availability. For example, 
between meals, intestinal blood flow and 02 availability are low and under 
these conditions, hydroxylases would be inactive. Under such conditions, we 
would expect Na+/K+-ATPase activity to be attenuated, thereby limiting energy 
expenditure on epithelial transport processes when they are not required. On 
the other hand, upon feeding, epithelial fluid and electrolyte secretion are 
required to provide a fluid environment for the mixing of food particles with 
digestive enzymes, and for lubrication of the food bolus as it moves through the 
lower intestine. Under these conditions, intestinal blood flow and 02 
availability increase, hydroxylases are activated, and pump activity increases, 
thereby allowing expenditure of cellular energy on transport processes. Our 
data suggest that MONaKA, the Na+/K+-ATPase px subunit, and FIH-1 potentially 
play key roles in these processes by forming multimeric complexes with the 
Na+/K+-ATPase ai subunit in a hydroxylase-sensitive manner. It would be 
interesting to test this hypothesis in future studies by examining association of 
MONaKA and FIH-1 with the pump under fasting and non-fasting conditions.
In conclusion, from a clinical perspective our data suggest that by virtue of their 
ability to act as a molecular switch to regulate epithelial secretion, hydroxylases 
represent good targets for development of new anti-diarrhoeal drugs. 
However, our studies also reveal that the anti-diarrhoeal effects of hydroxylase 
inhibitors are mediated by inhibition of Na+/K+-ATPase activity, by a mechanism 
that likely involves MONaKA. Since these proteins are expressed throughout 
the body, there is the possibility that side effects may occur upon anti- 
diarrhoeal treatment with hydroxylase inhibitors. While it is encouraging that in 
our own in vivo studies we did not observe significant toxicity to DMOG at 
concentrations that prevent diarrhoea, future studies should focus on the 
potential for using targeted drug formulations to enhance the delivery of 
hydroxylase inhibitors to the intestine. Such technologies have received much 
attention and are already in use to treat a variety of intestinal disorders (Yang et
243
ai, 2002; Haddish-Berhane et ai, 2007; Pràkash and Malgorzata Urbanska,
2008).
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DNA deoxyribonucleic acid
DRA down regulated in adenoma
DTT dithiothriol
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EGF epidermal growth factor
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MONaKA modulator of Na+/K+-ATPase
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SGK1 serum and glucocorticoid-responsive kinase-1
SGLT1 sodium glucose co-transporter 1
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TCTP translationally-controlled tumour protein
TMEM16A transmembrane protein 16A
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